Progress in Inflammation Research
Series Editor Prof. Michael J. Parnham PhD Director of Preclinical Discovery Centre of Excellence in Macrolide Drug Discovery GlaxoSmithKline Research Centre Zagreb Ltd. Prilaz baruna Filipovic´a 29 HR-10000 Zagreb Croatia Advisory Board G. Z. Feuerstein (Wyeth Research, Collegeville, PA, USA) M. Pairet (Boehringer Ingelheim Pharma KG, Biberach a. d. Riss, Germany) W. van Eden (Universiteit Utrecht, Utrecht, The Netherlands)
Forthcoming titles: New Therapeutic Targets in Rheumatoid Arthritis, P.-P. Tak (Editor), 2008 Inflammatory Cardiomyopathy (DCM) – Pathogenesis and Therapy, H.-P. Schultheiß, M. Noutsias (Editors), 2008 Matrix Metalloproteinases in Tissue Remodelling and Inflammation, V. Lagente, E. Boichot (Editors), 2008 Angiogenesis in Inflammation: Mechanisms and Clinical Correlates, M.P. Seed, D.A. Walsh (Editors), 2008 Microarrays in Inflammation, A. Bosio, B. Gerstmayer (Editors), 2008 Bone Morphogenetic Proteins: From Local to Systemic Therapeutics, S. Vukicevic, K.T. Sampath (Editors), 2008 Natural Products for Joint Health, M.J.S. Miller (Editor), 2008 (Already published titles see last page.)
The Resolution of Inflammation
Adriano G. Rossi Deborah A. Sawatzky Editors
Birkhäuser Basel · Boston · Berlin
Editors Dr Adriano G. Rossi Dr Deborah A. Sawatzky MRC Centre for Inflammation Research Queen’s Medical Research Institute University of Edinburgh 47 Little France Crescent Edinburgh, EH16 4TJ Scotland United Kingdom
Library of Congress Control Number: 2007934182
Bibliographic information published by Die Deutsche Bibliothek Die Deutsche Bibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data is available in the internet at http://dnb.ddb.de
ISBN 978-3-7643-7505-8 Birkhäuser Verlag AG, Basel – Boston – Berlin The publisher and editor can give no guarantee for the information on drug dosage and administration contained in this publication. The respective user must check its accuracy by consulting other sources of reference in each individual case. The use of registered names, trademarks etc. in this publication, even if not identified as such, does not imply that they are exempt from the relevant protective laws and regulations or free for general use. This work is subject to copyright. All rights are reserved, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, re-use of illustrations, recitation, broadcasting, reproduction on microfilms or in other ways, and storage in data banks. For any kind of use, permission of the copyright owner must be obtained. © 2008 Birkhäuser Verlag AG Basel · Boston · Berlin P.O. Box 133, CH-4010 Basel, Switzerland Part of Springer Science+Business Media Printed on acid-free paper produced from chlorine-free pulp. TCF ' Cover design: Markus Etterich, Basel Cover illustration: see page 126. With the friendly permission of Catherine Godson and Paola Maderna. Printed in Germany ISBN 978-3-7643-7505-8 e-ISBN 978-3-7643-7506-5 987654321
www.birkhauser.ch
Contents
List of contributors
.................................................................
vii
..............................................................................
xi
Derek Gilroy and Toby Lawrence The resolution of acute inflammation: A ‘tipping point’ in the development of chronic inflammatory diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1
Moira K.B. Whyte, Christopher Haslett and Edwin R. Chilvers Granulocyte apoptosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
19
Andrew Devitt and Christopher D. Gregory Innate immune mechanisms in the resolution of inflammation
..................
39
Ian Dransfield, Sandra Franz, Kim Wilkinson, Aisleen McColl, Martin Herrmann and Simon P. Hart Cell surface molecular changes associated with apoptosis . . . . . . . . . . . . . . . . . . . . . . .
57
Geoffrey J. Bellingan and Geoffrey J. Laurent Fate of macrophages once having ingested apoptotic cells: Lymphatic clearance or in situ apoptosis? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
75
Charles N. Serhan Novel lipid mediators in resolution and their aspirin triggered epimers: lipoxins, resolvins, and protectins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
93
Preface
Paola Maderna and Catherine Godson Beyond inflammation: Lipoxins; resolution of inflammation and regulation of fibrosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
Dalip J.S. Sirinathsinghji and Ray G. Hill Contents
Mauro Perretti and Roderick J. Flower Anti-inflammatory glucocorticoids and annexin 1
................................
141
Garry M. Walsh and Catherine M. McDougall The resolution of airway inflammation in asthma and chronic obstructive pulmonary disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159 David C. Kluth and Jeremy Hughes Resolution of glomerular inflammation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193 John L. Wallace and Philip M. Sherman Resolution of mucosal inflammation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 223 Index
vi
................................................................................
235
List of contributors
Geoffrey J. Bellingan, Centre for Respiratory Research, University College London, Rayne Institute, London, WC1E 6JJ, UK; e-mail:
[email protected] Edwin R. Chilvers, Respiratory Medicine Division, Department of Medicine, University of Cambridge, School of Clinical Medicine, Addenbrooke’s and Papworth Hospitals, Cambridge, CB2 2QQ, UK, e-mail:
[email protected] Andrew Devitt, School of Life & Health Sciences, Aston University, Aston Triangle, Birmingham, B4 7ET, UK; e-mail:
[email protected] Ian Dransfield, MRC Centre for Inflammation Research, University of Edinburgh Medical School, Teviot Place, Edinburgh EH8 9AG, UK; ¨ e-mail:
[email protected] Roderick J. Flower, William Harvey Research Institute, Bart’s and the London, Queen Mary School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK Sandra Franz, Institute for Immunology, FAU Erlangen-Nuremberg, Glückstrasse 4a, 91054 Erlangen, Germany Derek Gilroy, Rayne Institute, Centre for Clinical Pharmacology, University College London, 5 University Street, London WC1 6JJ, UK; e-mail:
[email protected] Catherine Godson, UCD School of Medicine and Medical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland; e-mail:
[email protected] Christopher D. Gregory, MRC Centre for Inflammation Research, The Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK
vii
List of contributors
Simon P. Hart, MRC Centre for Inflammation Research,University of Edinburgh Medical School, Teviot Place, Edinburgh EH8 9AG, UK Christopher Haslett, MRC Centre for Inflammation Research, Queen’s Medical Research Institute, University of Edinburgh Medical School, Edinburgh, EH16 4TJ, UK; e-mail:
[email protected] Martin Herrmann, Institute for Immunology, FAU Erlangen-Nuremberg, Glückstrasse 4a, 91054 Erlangen, Germany Jeremy Hughes, MRC Centre for Inflammation Research, University of Edinburgh, Queens Medical Research Centre, 47 Little France Crescent, Edinburgh EH16 4TJ, UK David C. Kluth, MRC Centre for Inflammation Research, University of Edinburgh, Queens Medical Research Centre, 47 Little France Crescent, Edinburgh EH16 4TJ, UK; e-mail:
[email protected] Geoffrey J. Laurent, Centre for Respiratory Research, University College London, Rayne Institute, London WC1E 6JJ, UK Toby Lawrence, Institute of Cancer, Centre for Translational Oncology, Bart’s and The London School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK; e-mail:
[email protected] Paola Maderna, UCD School of Medicine and Medical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland; e-mail:
[email protected] Aisleen McColl, MRC Centre for Inflammation Research,University of Edinburgh Medical School, Teviot Place, Edinburgh EH8 9AG, UK Catherine M. McDougall, School of Medicine, Institute of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen, UK Mauro Perretti, William Harvey Research Institute, Bart’s and the London, Queen Mary School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK; email:
[email protected] Charles N. Serhan, Center for Experimental Therapeutics and Reperfusion Injury, Brigham and Women’s Hospital and Harvard University, 75 Francis St., Thorn Building for Medical Research, Boston, MA 02115, USA
viii
List of contributors
Philip M. Sherman, Hospital for Sick Children and University of Toronto, 555 University Avenue, Toronto, Ontario, M5G 1X8, Canada John L. Wallace, Department of Pharmacology and Therapeutics, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, T2N 4N1, Canada; e-mail:
[email protected] Garry M. Walsh, School of Medicine, IMS Building, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK; e-mail:
[email protected] Moira K. B. Whyte, Academic Unit of Respiratory Medicine, School of Medicine and Biomedical Sciences, University of Sheffield, Royal Hallamshire Hospital, Sheffield S10 2JF, UK; e-mail:
[email protected] Kim Wilkinson, MRC Centre for Inflammation Research,University of Edinburgh Medical School, Teviot Place, Edinburgh EH8 9AG, UK
ix
Preface
It was with tremendous enthusiasm that we endeavoured to compile and edit this volume for Progress in Inflammation Research describing novel findings and developments pertaining to the processes governing the resolution of inflammation. It is perhaps surprising that this topic had, to our knowledge, not previously been covered as a separate subject area in a dedicated monograph given what now seems such an obvious thing to do. Historically, researchers have focussed and have made great advances on the initiation and propagation of inflammation. Little attention had been specifically devoted to elucidating the mechanisms orchestrating the resolution of inflammation, although a variety of mechanisms that limit the inflammatory response had been described (e.g., mediator dissipation and deactivation; exogenous mediator removal or reduction; receptor, cell and tissue desensitisation to mediators; identification of agents with anti-inflammatory potential such as IL-10, IL-1 receptor antagonists, TGF-`, etc). It is now believed that manipulation of more recently described processes, recognised as being actively involved in resolution, are therapeutically manipulatable for the treatment of inflammatory diseases. Indeed, patients with chronic inflammatory diseases are by necessity treated in order to reduce established and persistent inflammation with the added hope of preventing further progression of the inflammatory response. It has recently become evident that many of the anti-inflammatory agents currently used in the clinical setting influence inflammatory resolution. For example, glucocorticoids have been shown to influence processes now recognised as being important mechanisms allowing resolution to occur; namely glucocorticoids trigger apoptosis (programmed cell death) in most leukocytes (the neutrophil however is a notable exception) and augment apoptotic cell clearance by phagocytes. Similarly, aspirin, the most widely used NSAID, is involved in an unorthodox biosynthetic pathway yielding important lipid mediators (e.g., 15-epi-lipoxin A4 and 15-epi-lipoxin B4) actively involved in the resolution process. This volume contains major contributions from an international panel of experts who describe the basic processes regulating the resolution of inflammation including apoptosis, macrophage clearance of apoptotic cells and novel pro-resolution lipid
xi
Preface
mediators. In addition, there are sections that describe how existing anti-inflammatory drugs such as aspirin and glucocorticoids may influence these resolution processes. There are three chapters devoted to describing fine examples of clinically relevant inflammatory disease areas where much progress has been made in understanding resolution. We feel that we are at the beginning of a rapidly burgeoning and exciting area of inflammation research where new advances are being made in understanding the resolution of inflammation. It is without doubt that continued research will fully elucidate the mechanisms whereby existing anti-inflammatory drugs influence resolution. Furthermore, there is now emerging experimental in vivo evidence indicating that by pharmacologically and selectively inducing apoptosis of inflammatory cells, specifically enhancing non-phlogistic clearance of apoptotic cells by phagocytes, and administration of pro-resolution lipids (e.g., lipoxins, resolvins and protectins), inflammatory resolution is achievable. Consequently, we believe that better designed and novel classes of drugs that specifically target resolution processes will be forthcoming in the not too distant future. October 2007
xii
Adriano G. Rossi Deborah A. Sawatzky
The resolution of acute inflammation: A ‘tipping point’ in the development of chronic inflammatory diseases Derek Gilroy1 and Toby Lawrence2 1
Rayne Institute, Centre for Clinical Pharmacology, University College London, 5 University Street, London WC1 6JJ, UK; 2Institute of Cancer, Centre for Translational Oncology, Bart’s and The London School of Medicine and Dentistry, Charterhouse Square, London EC1M 6BQ, UK
The scope of this chapter Evolution has given us inflammation, a formidable ally in the constant battle against infection, cancer and tissue injury. It is a primordial response that protects against injury and restores damaged tissue to its normal physiological function. In fact, our well-being and survival depends upon its efficiency and carefully balanced control. In general, the innate inflammatory response initiates within minutes and, if all is well, resolves within hours. In contrast, chronic inflammation persists for weeks, months or even years. Here, we are going to discuss the key endogenous checkpoints necessary for mounting an effective, yet limited, inflammatory response and the crucial biochemical pathways necessary to prevent its persistence. Figure 1 depicts what we understand today about the endogenous soluble mediators that control the severity of inflammatory onset as well as its longevity. In doing so, we wish to underline the consequence to the host of failing to adequately control inflammatory resolution. Acute inflammation is characterised by leukocyte recruitment from the circulation, classically defined by the initial trafficking of polymorphonuclear granulocytes, followed by monocytes, which differentiate locally into macrophages [1]. Invariably, this response is triggered by tissue mast cells and resident macrophages, whose degranulation and activation sequentially release a battery of inflammatory mediators, including bioactive amines (histamine and 5-HT), cytokines, chemokines as well as lipid mediators that collectively recruit and activate inflammatory cells, which also results in oedema formation. While this system has an enormous capacity for synergy and redundancy, over the years it has served as the stable basis for the development of anti-inflammatory drug discovery, typified by the development of nonsteroidal anti-inflammatory inhibitors of eicosanoid synthesis beginning in the 1960s to more recent times with the inhibition of the actions of TNF-_. These early days of inflammation research that focused on elucidating the nature of soluble proinflammatory mediators have now given way to the view that inflammation is far more complex and sophisticated than originally appreciated, not least muddied by The Resolution of Inflammation, edited by Adriano G. Rossi and Deborah A. Sawatzky © 2008 Birkhäuser Verlag Basel/Switzerland
1
Derek Gilroy and Toby Lawrence
Figure 1 Schematic depicting the cellular and molecular components of resolving inflammation. Acute inflammation is characterised by the accumulation of neutrophils and oedema early in the response. Later, mononuclear cells and macrophages accumulate and help prepare the tissue for resolution. In both (A) and (B) we depict the role that specific molecular mediators play in these events. In (A), sequentially released pro-inflammatory mediators are released very early in response to injury/infection, which initiate and augment the acute-phase of the response (green lights). However, this is counterbalanced by endogenous anti- inflammatory signals such as corticosterone, which serve to temper the severity and limit the duration of this early onset phase. As inflammation progresses, certain „stop signals“ prevent further leukocyte traffic into tissue. These stop signals include the lipoxins, resolvins and prostaglandins (PGs) of the D series, and pave the way for monocyte migration and their differentiation to phagocytosing macrophages. These remove dead cells and then exit the site of inflammation. Stromal cells such as fibroblasts also contribute to the resolution of inflammation by the withdrawal of survival signals and the normalisation of chemokine gradients, thereby allowing infiltrating leukocytes to undergo apoptosis or leave the tissue through the draining lymphatics. This sequential set of responses leads to complete resolution and, importantly, the restoration of the inflamed tissue to its prior physiological functioning. This is the ideal sequence of events in physiological inflammation, which contrast to the situation in pathological inflammation (B), where some of the factors that initiate the resolution program lead to the inappropriate accumulation of leukocytes in the wrong place at the wrong time (from [69]).
2
The resolution of acute inflammation
the multiple protective and destructive roles the eicosanoids, for instance, that are now known to play in orchestrating the inflammatory response. Such clear diversity is not the preserve of lipid mediators but it extends to cytokines, chemokines and the expression of both activating and inhibitory receptors by inflammatory cells. On this theme of biological diversity, recent evidence suggests that alternative pattern recognition receptors of the scavenger receptor and C-type lectin families may play equally important roles in the recognition of microbes and the regulation of the host inflammatory response. Thus, the C-type lectin, Dectin-1 [2], was recently shown to act in concert with the Toll-like receptor (TLR)-2 to activate macrophages exposed to `-glucans from the yeast Candida albicans [3]. A number of these receptors also recognise endogenous inflammatory ligands including the scavenger receptors SRA and CD36, both of which have been described to mediate the phagocytosis of apoptotic cells, leading to a down-regulation of macrophage activation [4–6] (see the chapter by Dransfield et al.). Thus, many of the factors that drive inflammation also double-up in bringing about its resolution and it is this theme of inflammatory resolution that is going to be the focus of this chapter. In current day inflammation research, one of our objectives must be to understand whether known inflammatory mediators that ignite inflammation also trigger its resolution as well as highlighting resolution. In addition, resolution must be highlighted as a critical facet of the inflammatory response and, at the very least, to underline the importance of not altering its normal course of action when developing novel anti-inflammatory drugs. Ultimately, it is proposed here that resolution is controlled by endogenous pro-resolution factors, which may represent new possibilities for drug discovery in terms of designing modalities that mimic their mode of action or enhance their synthesis. In the course of doing so, we hope to argue that resolution is as active process, whose failure may predispose the host to chronic inflammatory diseases and autoimmunity, such as that typified by rheumatoid arthritis, inflammatory bowel disease, systemic lupus erythematosus and asthma.
Resolution of acute inflammation The receptors and signalling pathways that initiate and promote the inflammatory response have become increasingly well characterised; however, relatively little is known about how acute inflammation resolves to prevent chronic inflammatory diseases. We have discussed above the intracellular checkpoints that limit the activation of inflammatory cells either directly in response to infection or tissue injury or through paracrine activation by proinflammatory cytokines. If we were to define the fundamental requirements for the successful resolution of inflammation it is becoming increasingly clear that the most simple but absolutely critical determinant for the inflammatory response to switch off is the neutralisation and elimination of the injurious agents that initiated it. Failure to achieve this first step will invariably lead
3
Derek Gilroy and Toby Lawrence
to chronic inflammation, with the nature of the agent in question almost certainly dictating the aetiology of the developing chronic immune response. For example, chronic granulomatous disease is characterised by severe, protracted and often fatal infection, which results from a failure of the phagocytic NADPH oxidase enzyme system to produce superoxide and kill invading infections, leading to a predisposition to recurrent bacterial and fungal infections and the development of inflammatory granulomas [7]. Successfully dispensing with the inciting stimulus will signal a cessation to pro-inflammatory mediator synthesis (eicosanoids, chemokines, cytokines, cell adhesion molecules, etc.) and lead to their catabolism. This would halt further leukocyte recruitment and oedema formation. These are probably the very earliest determinants for the resolution of acute inflammation, the outcome of which signals the next stage of cell clearance. The clearance phase of resolution, be it innate immunity [polymorphonuclear leukocyte (PMN) or eosinophil driven] or adaptive immunity (lymphocyte mediated), also has a number of mutually dependent steps. The clearance routes available to inflammatory leukocytes include systemic recirculation [8] or local death of influxed PMNs, eosinophils or lymphocytes followed by their phagocytosis by recruited monocyte-derived macrophages [9]. Once phagocytosis is complete, macrophages can leave the inflamed site by lymphatic drainage [10] with evidence that a small population may die locally by apoptosis [11]. If all of these pathways are strictly followed then acute inflammation will resolve without causing excessive tissue damage and give little opportunity for the development of chronic, non-resolving inflammation. As with the onset phase of the acute inflammatory response, which is driven by a cohort of well-described endogenous factors, the resolution phase of the response is also highly coordinated and under the tight control of what may be called “pro-resolution” factors. In contrast to onset, however, these resolution phase factors are less well described.
Controlling the early phase of acute inflammation Inflammation is a reaction of the microcirculation that is characterised by the movement of serum proteins and leukocytes from the blood to the extravascular tissue with PMNs or eosinophils predominating at the early onset phase, giving way to phagocytosing macrophages leading to resolution. One well-described event in the transition towards resolution is the replacement of PMNs or eosinophils by monocytes and phagocytosing macrophages. However, until recently our understanding of the signals that control this cell profile switch was unclear. Studies addressing this issue of leukocyte infiltration in peritoneal inflammation have suggested that the interaction between interleukin (IL)-6 and its soluble receptor, sIL-6R, forms one of the major determinants of this switch from PMNs to monocytes [12, 13]. It was shown that sIL-6R, produced by the infiltrating PMNs, forms a complex with IL-6, which in turn, directly modulates CC and CXC chemokine expression. Thus, CXC
4
The resolution of acute inflammation
chemokine synthesis, induced by IL-1 and TNF-_, was suppressed, whereas the CC chemokine CCL2 (MCP-1) was promoted. This chemokine shift suppresses further neutrophil recruitment in favour of sustained mononuclear cell influx. In addition to chemokines, the eicosanoids also orchestrate the early transition to resolution in acute inflammation. Transcellular metabolism of arachidonic acid by lipoxygenase/lipoxygenase interaction pathways gives rise to the lipoxin (LX) family of eicosanoid metabolites [14]. LXs display selective actions on leukocytes that include inhibition of PMN chemotaxis [15], PMN adhesion to and transmigration through endothelial cells [16], as well as PMN-mediated increases in vascular leakage [17]. It is unclear at this point whether there is any cross-talk between the LXs and IL-6/sIL6R complex signalling in the control of leukocyte profile switching. Nonetheless, it seems that when acute inflammation needs to resolve the IL-6/sIL-6R, chemokines and LXs represent some of the earliest signals that control the switch from very early PMNs to monocyte/macrophage.
The transition to resolution Once PMNs and eosinophils have done their job and their help is no longer needed, what happens next? At this juncture it must be borne in mind that these are a formidable cell lineage and if left unchecked could do untold damage to an already inflamed site. After all, these cells are designed to combat infection by releasing hydrolytic and proteolytic enzymes as well as generating reactive oxygen species. Therefore, PMNs and eosinophils must be disposed of in a controlled and effective manner. To oversee this, nature has come up with an ingenious way of defusing such potentially explosive cells called programmed cell death or apoptosis. Apoptosis of inflammatory cells is a physiological process for the non-phlogistic removal of cells. During apoptosis, cells maintain an intact membrane and, therefore, do not release their potentially histotoxic agents. Necrosis of inflammatory leukocytes, on the other hand, involves a loss of membrane integrity, leading to the release of potentially toxic intracellular contents [9]. Moreover, apoptotic cells express a repertoire of surface molecules that allow their recognition and phagocytosis by macrophages [18]. Despite stating above that once the injurious agent has been neutralised PMNs and eosinophils are redundant, in fact, the way in which these cells die helps the resolution process enormously. Recognition of these apoptotic cells by macrophages does not liberate pro-inflammatory agents from the macrophages themselves but can release anti-inflammatory signals such as IL-10 and transforming growth factor` (TGF-`) [19]. Thus, not only is apoptosis a non-inflammatory way of disposing of cells, but this method has the added advantage of conferring upon macrophages an anti-inflammatory phenotype conducive to resolution. It is important to note that if not recognised and disposed of, apoptotic cells will eventually undergo secondary necrosis releasing damaging intracellular contents and amplifying the inflammatory
5
Derek Gilroy and Toby Lawrence
response. Therefore, increasing the rate of apoptosis, as a potentially anti-inflammatory strategy, must be matched by a mechanism that up-regulates macrophage phagocytic clearance capacity [20]. Thus, the removal process might also be susceptible to selective modulation by pharmacological agents for therapeutic gain. As mentioned above, the strategy of enhancing leukocyte apoptosis must also be paralleled with enhancing their phagocytosis by macrophages and other non-professional phagocytes. On this theme, there are an increasing number of factors that aid the phagocytic clearance of apoptotic granulocytes. Ligation of the matrix receptor CD44, for instance, results in the rapid and specific internalisation of apoptotic PMNs [21]. Besides controlling PMN trafficking, LXs also stimulate monocyte chemotaxis and adherence. Certainly, this may seem dangerous for inflammation as too many monocyte-derived macrophages can be a bad thing, but these LX-chemoattracted macrophages accelerate resolution by enhancing phagocytosis of apoptotic PMNs in a non-phlogistic manner [22]. In addition to a role in granulocyte apoptosis, glucocorticoids facilitate the phagocytic response. It was recently found that exposure of peripheral blood monocytes to glucocorticoids during the first 24 h of the 5-day culture period induced a highly phagocytic monocyte-derived macrophage phenotype [23]. Functional and morphological homogeneity was matched by cell surface phenotype, including specific induction of expression of the haemoglobin scavenger receptor, CD163 following glucocorticoid treatment. A potentially pro-resolution role for CD163 was demonstrated recently in both in vitro and in vivo models of resolving inflammation [24]. Here, the authors showed that human peripheral blood monocyte-derived macrophages either in culture medium or in resolving phase cantharidin-induced skin blisters express CD163. These authors also found elevated levels of CD163 on circulating monocytes in cardiac surgical patients during the resolution phase of the systemic inflammatory response to cardiopulmonary bypass surgery. In each case, binding of the haemoglobin–haptoglobin complex to CD163-bearing cells elicited potent IL-10 secretion, which in turn enhanced hemeoxygenase 1, widely shown to have anti-inflammatory and tissue protective properties. Such induction of hemeoxygenase 1 was observed in vivo 24–48 h after the onset of cardiopulmonary bypass surgery. This is coincident with the observations of Willis and colleagues [25], who showed that hemeoxygenase 1 was expressed during and essential for the resolution (24–48-h phase) of a rat carrageenin-induced pleurisy. Thus, apoptosis and the phagocytosis of apoptotic cells are crucial to the resolution process, failure of which may predispose, as mentioned earlier, to chronic inflammation and possibly autoimmunity. This has been proposed in the case of systemic lupus erythematosus (SLE); an autoimmune syndrome that is associated with the presence of autoantibodies to endogenous antigens exposed on dead or dying cells, which failed to be cleared and disposed of. Studies in mice, for instance, have established a role for the complement receptor C1q on macrophages in the development of this disease. C1q was discovered to be important for the phagocytic clearance of apoptotic cells; in the absence of this receptor mice devel-
6
The resolution of acute inflammation
oped a lupus-like syndrome [26]. The persistence of apoptotic cells and necrotic bodies led to the development of an inappropriate immune response to endogenous antigens. Evidence has also been established in human SLE patients for an association between C1q deficiency and disease [27]. The phagocytosis of apoptotic cells has been suggested to play an important role in the negative regulation of macrophage activation, apoptotic leukocytes may well fit into the category of endogenous anti-inflammatory mediators, therefore the mechanisms of apoptosis and the clearance of apoptotic cells may be critical in the development of chronic inflammation (as discussed further by Dransfield et al. in this book).
Soluble mediators of resolution: Opportunities for drug discovery Returning to eicosanoids, prostaglandin (PG) D2, a metabolite of the action of haematopoietic PGD2 synthase on COX-derived PGH2, has emerged recently as an eicosanoid with both pro- and anti-inflammatory properties. PGD2 undergoes dehydration in vivo and in vitro to yield biologically active PGs of the J2 series, including PGJ2, 612,14-PGJ2 and 15-deoxy-612,14-PGJ2 (15d-PGJ2). In addition to being a high-affinity natural ligand for anti-inflammatory peroxisome proliferators-activated receptor gamma (PPARa), 15d-PGJ2 also exerts its effects through PPARa-dependent as well as -independent mechanisms to suppress pro-inflammatory signalling pathways and the expression of genes that drive the inflammatory response. 15d-PGJ2 also preferentially inhibits monocyte rather than PMN trafficking through the differential regulation of cell-adhesion molecule and chemokine expression [28]. We have shown that COX 2-derived PGD2 metabolites contribute to the resolution of acute inflammation (pleuritis) through the preferential synthesis of PGD2 and 15d-PGJ2 [29], which, along with the alternative DNA-binding p50–p50 homodimers complexes of NF-gB [30] bring about resolution by inducing leukocyte apoptosis [11]. Recently, we extended these studies to examining the role of PGD2 metabolites in the resolution of adaptive immunity and lymphocyte function [31]. Indeed, there is an increasing body of evidence detailing the differential effects of PGD2 metabolites on leukocyte apoptosis as well as the signalling pathways involved [32, 33]. In addition to the well-known eicosanoids, there is a new generation of lipid mediators showing real promise as endogenous anti-inflammatories. Resolvins and docosatrienes are fatty acid metabolites of the COX/lipoxygenase pathways, where the omega-3 fatty-acid constituents of fish oils docosahexaenoic acid and eicosapentaneoic acid are the substrates and not arachidonic acid. These resolvins and docosatrienes were identified in inflammatory exudates during the resolving phase of acute inflammation and shown to be potent inhibitors of PMN transendothelial migration and microglial-cell cytokine expression, and to ameliorate experimental models of dermal inflammation and leukocyte accumulation in peritonitis at nano-
7
Derek Gilroy and Toby Lawrence
gram doses [34]. These studies on resolvin metabolism are uncovering surprising new avenues in anti-inflammation research, putting fatty acid metabolites right at the forefront of potential drug therapy. These studies are also challenging existing dogma that not all eicosanoids are detrimental to inflammation and are putting a balanced view of their role in pathophysiology. To add fuel this notion, a recent and very surprising paper has shown that eicosanoids of the LXs family, described above, are orally active in models of acute inflammation [35].
Signalling pathways that regulate inflammation The inflammatory response is characterised by coordinated activation of various signalling pathways that regulate expression of both pro- and anti-inflammatory mediators in resident tissue cells and recruited leukocytes (see Fig. 1). Currently most of our knowledge of signalling in inflammation is gained from studying members of IL-1 and TNF receptor families and the Toll-like microbial pattern recognition receptors (TLRs), which in fact belong to the IL-1R family. IL-1 and TNF-_ represent the archetypal pro-inflammatory cytokines that are rapidly released upon tissue injury or infection. TLRs recognise microbial molecular patterns, hence the term pattern-recognition receptor (PRR), and therefore TLRs represent a germlineencoded non-self recognition system that is hard-wired to trigger inflammation. However, there is some suggestion that endogenous ligands may trigger TLRs during tissue injury and certain disease states, which may act to promote inflammation in the absence of infection [36]. Although structurally different, these receptors use similar signal transduction mechanisms. Receptor engagement results in recruitment of adaptor proteins that possess either Toll–IL-1 receptor (TIR) domains in the case of TLRs and IL-1R or death domains (DD) in the case of the TNFR family, linked to the regulation of cell survival [37]. Once recruited these adaptors recruit further signalling proteins that belong to the TRAF family [38, 39] and various protein kinases, including IRAK1 and 4 in the case of TIR signalling [40] and RIP kinases in the case of TNFR signalling [41, 42]. These molecules activate several effector pathways, the most important of which lead to activation of mitogen-activated protein kinases (MAPK) [43, 44], including JNK [45] and p38 MAPK [46], as well as IgB kinases (IKK) [47]. The MAPKs lead to direct and indirect phosphorylation and activation of various transcription factors, especially those that belong to the bZIP family: AP-1 [48] and CREB [49], which bind to the promoters of pro-inflammatory genes. MAPKs also regulate pro-inflammatory gene expression through post-transcriptional mechanisms such as mRNA turnover, mRNA transport and translation [50–52]. The IKKs, which form a complex composed of two catalytic subunits-IKK_ and IKK` and a regulatory subunit IKKa/NEMO, are responsible for activation of the NF-gB transcription factor [47], which has emerged as a central regulator of inflammatory and immune responses [53, 54]. Target genes for the IKK
8
The resolution of acute inflammation
and MAPK pathways include IL-1 and TNF-_, generating a feed-forward mechanism to amplify the inflammatory response. The pro-inflammatory cytokines IL-6, IL-12 and type I interferons (IFNs), which are also target genes for IKK and MAPK regulation, signal via receptor-associated tyrosine kinases (RTKs) that belong to the JAK group, whose activation results in phosphorylation and nuclear translocation of STAT transcription factors [55]. Engagement of cytokine receptors, as well as TLRs, can also lead to activation of phosphoinositide-3-kinases (PI3K), which in turn activate other proteins kinases such as AKT [56]. Collectively, these proteins kinases coordinate the expression of a large number of pro-inflammatory mediators to initiate and maintain the inflammatory response.
Negative regulation of pro-inflammatory signalling All of the intracellular signalling pathways described above, which contribute to the onset of innate immunity and inflammation are also subject to negative regulation. PI3K signalling is inhibited by the PTEN phosphatase that belongs to the protein tyrosine phosphatase (PTP) family; some of its other members, for instance SHIP, SHP1/2 and CD45, are responsible for negative regulation of TK signalling [57]. MAPK kinase phosphatases (MKPs), which also belong to the PTP family, control the duration of MAPK activation as recently shown for TNF-_-mediated JNK activation [58]. Inducible suppressors of cytokine signalling (SOCS), which function as ubiquitin ligases, are responsible for the negative feedback control of JAK-STAT signalling [59]. A20 is another inducible ubiquitin ligase, which functions as a negative feedback regulator of TLR and TNFR signalling to IKK and NF-gB. A20 is also a direct target gene for the NF-gB pathway constituting a negative feedback loop for NF-gB activation [60]. Recently, a new pathway for negative regulation of IKK/NFgB was described from observations made in mice that harbour a variant of IKK_, IKK_AA, that can not be activated by upstream regulators. Although IKK_AA mice do not develop “spontaneous” inflammation, they develop an exaggerated inflammatory response when challenged with bacteria, fungal cell wall particles, or even immune complexes [61]. These studies established that, while IKK` catalytic activity is important for the activation of NF-gB through phosphorylation of endogenous inhibitory (IgB) proteins [62], IKK_ is required for termination of NF-gB activation through phosphorylation of the transcription factors RelA (p65) and c-Rel [61]. IKK-mediated phosphorylation results in polyubiquitination of the target protein, leading to its accelerated degradation via the 26S proteasome. However, while IgB degradation is essential for NF-gB activation and nuclear translocation, the accelerated degradation of nuclear Rel proteins via IKK_-mediated phosphorylation is important for controlling the duration of NF-gB activation. The evolution of two catalytic subunits in the IKK complex with opposing, yet complimentary, activity therefore ensures rapid and transient activation of NF-gB.
9
Derek Gilroy and Toby Lawrence
As discussed below, pro-inflammatory signalling pathways have the capacity of inducing the parallel expression of anti-inflammatory mediators, such as IL-10. Recent studies reveal that the signalling pathway used by TLRs to activate expression of pro- and anti-inflammatory cytokines diverges at the level of the adaptor proteins TRAF3 and TRAF6, such that TRAF3 is critical for induction of IL-10 expression and in its absence, expression of the TRAF6-dependent pro-inflammatory cytokines IL-6 and IL-12 is dramatically increased [63]. The balance between the TRAF3- and TRAF6- generated signals may therefore play an important role in controlling the inflammatory response and its perturbation may interfere with the proper resolution of inflammation. Some of these signalling pathways and their respective negative regulators are illustrated in Figure 2; a deficiency in any one of these negative regulators may result in either “spontaneous” chronic inflammation, perhaps reflecting host cell activation by PAMPs present in endogenous microflora, or an exaggerated inflammatory response to insult or injury that culminates in severe inflammation and damage to the host. Although all of these negative regulatory mechanisms affect different signalling pathways, genetic studies in mice have shown that even the absence of one negative regulator is sufficient to result in serious inflammatory disorders. Undoubtedly, aberrations in such negative regulatory pathways will be found to contribute to the development of chronic inflammatory diseases.
Resolution of T cell-driven inflammation Inflammation has an important role in instructing the adaptive immune response, in particular the maturation and migration of dendritic cells (DCs) from the site of inflammation, where they pick up antigens and traffic to the secondary lymphoid organs where they can prime antigen-specific immune responses. There have been major advances in the study of DC biology in the past few decades that clearly show that both pro-inflammatory cytokines, including TNF-_, and microbial products drive DC maturation and migration to draining lymphoid tissue. The immature DC at the site of inflammation has the capacity to efficiently take up and process antigens. Specific signals in the inflammatory environment trigger the expression of chemokines and receptors that promote the migration of antigen-loaded DCs to the local lymphoid organs where they can present their antigens to cells of the adaptive immune system. Although cross-talk between the innate and adaptive immune system is extensively reviewed elsewhere [64], it suffices to underline that the switch from an inflammatory response driven by short-lived granulocytes to a lymphocyteor macrophage-dominated event is classically associated with chronic inflammation. Various investigators have examined the resolution of lymphocyte-driven adaptive immune responses including Type III hypersensitivity (Arthus reaction) or Type IV delayed-type hypersensitivity (DTH) reactions, which are clinically relevant models
10
The resolution of acute inflammation
Figure 2 Schematic illustration of the co-ordinated activation of pro-inflammatory signalling pathways by TLR ligands and the pro-inflammatory cytokines TNF-_, IL-1 and IFN. Adaptor molecules (MyD88, TRADD, TRAF) and receptor associated kinases (RIP, IRAK, JAK) couple to downstream kinase cascades (MAPK; JNK, p38; TAB/TAK, IKK), which regulate the activation of transcription factors (AP-1, NF-gB, CREB, STAT) and the expression of proinflammatory genes. A number of negative regulatory mechanisms (broken lines) limit the activation of specific signalling pathways; SOCS targets JAK/STAT and TLR signalling; PTEN and SHIP phosphatases block PI3K; A20 and IKK_ negatively regulate the NF-gB pathway; the MAPK phosphatase MKP limits activation of JNK and p38.
of adaptive immune diseases. For instance, in a purified protein derivative-induced DTH response, it was shown that the induction and resolution of this response may depend on the expression of cytokines, such as IL-2 and IL-15, that regulate both proliferation and apoptosis in T cells [65]. Failure to control either of these phases of the reaction may contribute to the chronicity of T lymphocyte-mediated inflammatory reactions. In another important series of studies the endogenous factors that control the longevity of granulomatous autoimmune thyroiditis revealed that the ratio of CD4+/CD8+ T cells are critical determinants of its resolution. In this disease process, CD4+ T cells outnumber CD8+ T cells when lesions progress to
11
Derek Gilroy and Toby Lawrence
fibrosis, while CD8+ T cells outnumbered CD4+ T cells in thyroids that resolve [66]. Recently, we found that haematopoietic PGD2 synthase (hPGD2S) transgenic mice, bearing a DTH reaction, display an exaggerated inflammatory response that fails to resolve [67]. While hPGD2S-derived PGD2 and the cyclooxygenase-derived PGs possess potent but diverse biological roles in host defence, the suppressive effects of hPGD2S on T lymphocyte functioning appears to be mediated by 15d-PGJ2 and its inhibition of NF-gB DNA binding, with no contribution from PGD2 and its actions on either of its receptors namely DP1 or DP2/CRTH2. These findings suggest an important role for hPGD2S as a checkpoint controller in the progression from acute to resolving inflammation. Whether the absence of hPGD2S predisposes to chronic inflammation or autoimmunity has yet to be determined. Nonetheless, the clear lack of inflammation in animals that over-expressed hPGD2S further reinforces the critical role that this down-stream PGH2 metabolising enzyme plays in the aetiology of T lymphocyte-driven immune responses.
Unblocking the drains! The role of the lymphatic system in the context of the resolution of acute innate inflammation is enormously understudied given its essential function in draining inflammatory mediators and effete leukocytes away from the inflamed site [68]. We have already discussed the importance of PMN clearance to the resolution of acute inflammation, but it is equally important that phagocytosing inflammatory macrophages are cleared away from the inflamed site to prevent local macrophage-induced tissue damage, potential granuloma tissue damage and the development of chronic inflammation. However, despite the need to understand the endogenous control of macrophage clearance during acute inflammatory resolution, little is known about this field. There is increasing evidence that macrophage clearance from an inflamed site is a highly regulated event. Using an experimental model of acute resolving peritonitis, it was shown that macrophages adhere specifically to mesothelium overlying draining lymphatics and that their emigration rate is regulated by the state of macrophage activation [10, 68] providing the first evidence that macrophage emigration from the inflamed site is controlled by adhesion molecule regulation of macrophage–mesothelial interactions. This report highlights the importance of adhesion molecules controlling clearance of inflammatory macrophages into the draining lymphatic circulation, thus highlighting new pathways in the resolution of acute inflammation.
Conclusions In conclusion, it is clear the inflammatory response has a number of built-in checkpoint controls that limit the duration and magnitude of acute inflammation. Defects
12
The resolution of acute inflammation
in these endogenous anti-inflammatory pathways will undoubtedly predispose to the development of chronic inflammatory diseases. A further understanding and analysis of these pathways in the pathogenesis of chronic inflammation is required, this will allow the pursuit of therapeutic strategies to correct possible defects in these feedback control systems or manipulate these pathways to suppress inflammation. However, it is equally clear that the resolution of inflammation is driven by a complex set of pro-resolution mediators that regulate specific cellular events required to clear inflammatory cells from the site of injury or infection and restore tissue homeostasis. These endogenous anti-inflammatory and pro-resolution mechanisms are clearly intimately linked; however, the true goal in the treatment of chronic inflammatory diseases must be to inhibit persistent inflammation and restore tissue function. To achieve this goal we must improve our understanding of the resolution of inflammation and identify possible approaches to promote this process in combination with anti-inflammatory therapy. Perhaps the, as-yet-unidentified, antiresolution factors that may prevent the proper resolution of inflammation would represent appropriate targets to achieve this goal.
References 1 2 3
4 5 6 7 8
9
Majno G (1975) The healing hand: Man and wound in the ancient world. Harvard University Press, Cambridge, Massachusetts Brown GD, Gordon S (2005) Immune recognition of fungal beta-glucans. Cell Microbiol 7: 471–479 Gantner BN, Simmons RM, Canavera SJ, Akira S, Underhill DM (2003) Collaborative induction of inflammatory responses by dectin-1 and Toll-like receptor 2. J Exp Med 197: 1107–1117 Savill J, Dransfield I, Hogg N, Haslett C (1990) Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature 343: 170–173 Savill J, Gregory C, Haslett C (2003) Cell biology. Eat me or die. Science 302: 1516– 1517 Ren Y, Silverstein RL, Allen J, Savill J (1995) CD36 gene transfer confers capacity for phagocytosis of cells undergoing apoptosis. J Exp Med 181: 1857–1862 Goldblatt D, Thrasher AJ (2000) Chronic granulomatous disease. Clin Exp Immunol 122: 1–9 Hughes J, Johnson RJ, Mooney A, Hugo C, Gordon K, Savill J (1997) Neutrophil fate in experimental glomerular capillary injury in the rat. Emigration exceeds in situ clearance by apoptosis. Am J Pathol 150: 223–234 Heasman SJ, Giles KM, Ward C, Rossi AG, Haslett C, Dransfield I (2003) Glucocorticoid-mediated regulation of granulocyte apoptosis and macrophage phagocytosis of apoptotic cells: implications for the resolution of inflammation. J Endocrinol 178: 29–36
13
Derek Gilroy and Toby Lawrence
10
11
12
13
14
15
16
17
18 19
20
21
22
14
Bellingan GJ, Xu P, Cooksley H, Cauldwell H, Shock A, Bottoms S, Haslett C, Mutsaers SE, Laurent GJ (2002) Adhesion molecule-dependent mechanisms regulate the rate of macrophage clearance during the resolution of peritoneal inflammation. J Exp Med 196: 1515–1521 Gilroy DW, Colville-Nash PR, McMaster S, Sawatzky DA, Willoughby DA, Lawrence T (2003) Inducible cyclooxygenase-derived 15-deoxy(Delta)12-14PGJ2 brings about acute inflammatory resolution in rat pleurisy by inducing neutrophil and macrophage apoptosis. FASEB J 17: 2269–2271 McLoughlin RM, Witowski J, Robson RL, Wilkinson TS, Hurst SM, Williams AS, Williams JD, Rose-John S, Jones SA, Topley N (2003) Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J Clin Invest 112: 598–607 Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, RoseJohn S, Fuller GM, Topley N, Jones SA (2001) IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14: 705–714 Serhan CN (2002) Lipoxins and aspirin-triggered 15-epi-lipoxin biosynthesis: An update and role in anti-inflammation and pro-resolution. Prostaglandins Other Lipid Mediat 68–69: 433–455 Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN (2001) Lipid mediator class switching during acute inflammation: Signals in resolution. Nat Immunol 2: 612– 619 Papayianni A, Serhan CN, Brady HR (1996) Lipoxin A4 and B4 inhibit leukotrienestimulated interactions of human neutrophils and endothelial cells. J Immunol 156: 2264–2272 Serhan CN, Takano T, Clish CB, Gronert K, Petasis N (1999) Aspirin-triggered 15-epilipoxin A4 and novel lipoxin B4 stable analogs inhibit neutrophil-mediated changes in vascular permeability. Adv Exp Med Biol 469: 287–293 Fadok VA, Bratton DL, Henson PM (2001) Phagocyte receptors for apoptotic cells: recognition, uptake, and consequences. J Clin Invest 108: 957–962 Huynh ML, Fadok VA, Henson PM (2002) Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 109: 41–50 Ward C, Dransfield I, Chilvers ER, Haslett C, Rossi AG (1999) Pharmacological manipulation of granulocyte apoptosis: Potential therapeutic targets. Trends Pharmacol Sci 20: 503–509 McCutcheon JC, Hart SP, Canning M, Ross K, Humphries MJ, Dransfield I (1998) Regulation of macrophage phagocytosis of apoptotic neutrophils by adhesion to fibronectin. J Leukoc Biol 64: 600–607 Godson C, Mitchell S, Harvey K, Petasis NA, Hogg N, Brady HR (2000) Cutting edge: Lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol 164: 1663–1667
The resolution of acute inflammation
23
24
25 26
27 28 29
30 31
32
33
34
35
Giles KM, Ross K, Rossi AG, Hotchin NA, Haslett C, Dransfield I (2001) Glucocorticoid augmentation of macrophage capacity for phagocytosis of apoptotic cells is associated with reduced p130Cas expression, loss of paxillin/pyk2 phosphorylation, and high levels of active Rac. J Immunol 167: 976–986 Philippidis P, Mason JC, Evans BJ, Nadra I, Taylor KM, Haskard DO, Landis RC (2004) Hemoglobin scavenger receptor CD163 mediates interleukin-10 release and heme oxygenase-1 synthesis: Antiinflammatory monocyte-macrophage responses in vitro, in resolving skin blisters in vivo, and after cardiopulmonary bypass surgery. Circ Res 94: 119–126 Willis D, Moore AR, Frederick R, Willoughby DA (1996) Heme oxygenase: A novel target for the modulation of the inflammatory response. Nat Med 2: 87–90 Botto M, Dell’Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, Loos M, Pandolfi PP, Walport MJ (1998) Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 19: 56–59 Walport MJ, Davies KA, Botto M (1998) C1q and systemic lupus erythematosus. Immunobiology 199: 265–285 Gilroy DW, Lawrence T, Perretti M, Rossi AG (2004) Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov 3: 401–416 Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA (1999) Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 5: 698–701 Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA (2001) Possible new role for NF-kappaB in the resolution of inflammation. Nat Med 7: 1291–1297 Trivedi SG, Newson J, Rajakariar R, Jacques TS, Hannon R, Kanaoka Y, Eguchi N, Colville-Nash P, Gilroy DW (2006) Essential role for hematopoietic prostaglandin D2 synthase in the control of delayed type hypersensitivity. Proc Natl Acad Sci USA 103: 5179–5184 Ward C, Dransfield I, Murray J, Farrow SN, Haslett C, Rossi AG (2002) Prostaglandin D2 and its metabolites induce caspase-dependent granulocyte apoptosis that is mediated via inhibition of IkappaBalpha degradation using a peroxisome proliferatoractivated receptor-gamma-independent mechanism. J Immunol 168: 6232–6243 Rossi A, Kapahi P, Natoli G, Takahashi T, Chen Y, Karin M, Santoro MG (2000) Antiinflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. Nature 403: 103–108 Serhan CN (2004) A search for endogenous mechanisms of anti-inflammation uncovers novel chemical mediators: Missing links to resolution. Histochem Cell Biol 122: 305–321 Bannenberg G, Moussignac RL, Gronert K, Devchand PR, Schmidt BA, Guilford WJ, Bauman JG, Subramanyam B, Perez HD, Parkinson JF et al (2004) Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration. Br J Pharmacol 143: 43–52
15
Derek Gilroy and Toby Lawrence
36 37
38 39
40
41 42
43 44
45 46 47 48 49
50
51 52
16
Karin M, Lawrence T, Nizet V (2006) Innate immunity gone awry: Linking microbial infections to chronic inflammation and cancer. Cell 124: 823–835 Muppidi JR, Tschopp J, Siegel RM (2004) Life and death decisions: Secondary complexes and lipid rafts in TNF receptor family signal transduction. Immunity 21: 461–465 Baud V, Karin M (2001) Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 11: 372–377 Arch RH, Gedrich RW, Thompson CB (1998) Tumor necrosis factor receptor-associated factors (TRAFs) – A family of adapter proteins that regulates life and death. Genes Dev 12: 2821–2830 Suzuki N, Suzuki S, Duncan GS, Millar DG, Wada T, Mirtsos C, Takada H, Wakeham A, Itie A, Li S et al (2002) Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4. Nature 416: 750–756 Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder P (1998) The death domain kinase RIP mediates the TNF-induced NF-kappaB signal. Immunity 8: 297–303 Wertz IE, O’Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S, Wu P, Wiesmann C, Baker R, Boone DL et al (2004) De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature 430: 694–699 Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410: 37–40 Kyriakis JM, Avruch J (2001) Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81: 807– 869 Karin M, Gallagher E (2005) From JNK to pay dirt: jun kinases, their biochemistry, physiology and clinical importance. IUBMB Life 57: 283–295 Zarubin T, Han J (2005) Activation and signaling of the p38 MAP kinase pathway. Cell Res 15: 11–18 Ghosh S, Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109 (Suppl): S81–96 Karin M (1995) The regulation of AP-1 activity by mitogen-activated protein kinases. J Biol Chem 270: 16483–16486 Park JM, Greten FR, Wong A, Westrick RJ, Arthur JS, Otsu K, Hoffmann A, Montminy M, Karin M (2005) Signaling pathways and genes that inhibit pathogen-induced macrophage apoptosis – CREB and NF-kappaB as key regulators. Immunity 23: 319–329 Winzen R, Gowrishankar G, Bollig F, Redich N, Resch K, Holtmann H (2004) Distinct domains of AU-rich elements exert different functions in mRNA destabilization and stabilization by p38 mitogen-activated protein kinase or HuR. Mol Cell Biol 24: 4835–4847 Chen CY, Del Gatto-Konczak F, Wu Z, Karin M (1998) Stabilization of interleukin-2 mRNA by the c-Jun NH2-terminal kinase pathway. Science 280: 1945–1949 Dean JL, Sully G, Clark AR, Saklatvala J (2004) The involvement of AU-rich element-
The resolution of acute inflammation
53 54 55 56
57 58
59 60
61
62
63
64 65
66
67
binding proteins in p38 mitogen-activated protein kinase pathway-mediated mRNA stabilisation. Cell Signal 16: 1113–1121 Bonizzi G, Karin M (2004) The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25: 280–288 Li Q, Verma IM (2002) NF-kappaB regulation in the immune system. Nat Rev Immunol 2: 725–734 O’Shea JJ, Gadina M, Schreiber RD (2002) Cytokine signaling in 2002: New surprises in the Jak/Stat pathway. Cell 109 (Suppl): S121–131 Martin M, Schifferle RE, Cuesta N, Vogel SN, Katz J, Michalek SM (2003) Role of the phosphatidylinositol 3 kinase-Akt pathway in the regulation of IL-10 and IL-12 by Porphyromonas gingivalis lipopolysaccharide. J Immunol 171: 717–725 Neel BG, Gu H, Pao L (2003) The ‘Shp’ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem Sci 28: 284–293 Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M (2005) Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 120: 649–661 Alexander WS, Hilton DJ (2004) The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 22: 503–529 Boone DL, Turer EE, Lee EG, Ahmad RC, Wheeler MT, Tsui C, Hurley P, Chien M, Chai S, Hitotsumatsu O et al (2004) The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 5: 1052–1060 Lawrence T, Bebien M, Liu GY, Nizet V, Karin M (2005) IKKalpha limits macrophage NF-kappaB activation and contributes to the resolution of inflammation. Nature 434: 1138–1143 Maeda S, Chang L, Li ZW, Luo JL, Leffert H, Karin M (2003) IKKbeta is required for prevention of apoptosis mediated by cell-bound but not by circulating TNFalpha. Immunity 19: 725–737 Häcker H, Redecke V, Blagoev B, Kratchmarova I, Hsu LC, Wang GG, Kamps MP, Raz E, Wagner H, Häcker G et al (2006) Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439: 204–207 Janeway CA Jr, Medzhitov R (2002) Innate immune recognition. Annu Rev Immunol 20: 197–216 Orteu CH, Poulter LW, Rustin MH, Sabin CA, Salmon M, Akbar AN (1998) The role of apoptosis in the resolution of T cell-mediated cutaneous inflammation. J Immunol 161: 1619–1629 Chen K, Wei Y, Sharp GC, Braley-Mullen H (2003) Mechanisms of spontaneous resolution versus fibrosis in granulomatous experimental autoimmune thyroiditis. J Immunol 171: 6236–6243 Trivedi SG, Newson J, Rajakariar R, Jacques TS, Hannon R, Kanaoka Y, Eguchi N, Colville-Nash P, Gilroy DW (2006) Essential role for hematopoietic prostaglandin D2 synthase in the control of delayed type hypersensitivity. Proc Natl Acad Sci USA 103: 5179–5184
17
Derek Gilroy and Toby Lawrence
68
69
18
Bellingan GJ, Caldwell H, Howie SE, Dransfield I, Haslett C (1996) In vivo fate of the inflammatory macrophage during the resolution of inflammation: Inflammatory macrophages do not die locally, but emigrate to the draining lymph nodes. J Immunol 157: 2577–2585 Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O’Neill LA, Perretti M, Rossi AG, Wallace JL (2007) Resolution of inflammation: State of the art, definitions and terms. FASEB J 21: 325–332
Granulocyte apoptosis Moira K. B. Whyte1, Christopher Haslett2 and Edwin R. Chilvers3 1
Academic Unit of Respiratory Medicine, School of Medicine and Biomedical Sciences, University of Sheffield, Royal Hallamshire Hospital, Sheffield S10 2JF, UK; 2MRC Centre for Inflammation Research, Queen’s Medical Research Institute, University of Edinburgh Medical School, Edinburgh, EH16 4TJ, UK; 3Respiratory Medicine Division, Department of Medicine, University of Cambridge, School of Clinical Medicine, Addenbrooke’s and Papworth Hospitals, Cambridge, CB2 2QQ, UK
Introduction Neutrophil apoptosis (programmed cell death) is now recognised to play a fundamental role in the physiological resolution of innate immune responses. Early work by Metchnikoff correlated the ingestion of microphages (neutrophils) by macrophages with the resolution of acute inflammation, but nearly 100 years elapsed before the key role of apoptosis in determining the lifespan of granulocytes and their clearance from sites of inflammation was described [1]. Further work showed that apoptosis leads to down-regulation of neutrophil pro-inflammatory functions [2] and this, together with evidence that macrophage clearance of apoptotic granulocytes was anti-inflammatory [3], suggested that apoptosis induction could be a powerful therapeutic strategy to “turn off” neutrophilic inflammation [2]. By contrast, eosinophil clearance mechanisms appear to be more diverse and include primary cytolysis, migration to regional lymph nodes and transepithelial migration as well as apoptosis. Hence, allergen challenge in animals induces a rapid and highly co-ordinated exit of eosinophils into the airway lumen [4] and, once present in the lumen, these cells are expectorated and/or undergo apoptosis triggering; this latter event triggers phagocytic removal by alveolar or inflammatory macrophages, or bronchial epithelial cells [5]. While eosinophils are clearly capable of undergoing constitutive apoptosis both in vitro and in vivo [6, 7], studies conducted in a variety of models of allergic airways inflammation have shown little evidence of eosinophil apoptosis in the airway wall itself. It is possible that the highly efficient coupling of granulocyte apoptosis to macrophage recognition and removal may result in an underestimation of the true extent of eosinophil apoptosis in these circumstances; these data, however, support the concept that for the eosinophil, which serves little, if any, physiological function in the host, apoptosis may represent a relatively minor clearance mechanism from tissues [8]. The balance between neutrophil survival and apoptotic cell death is exquisitely regulated and involves multiple input signals, including both host-derived and The Resolution of Inflammation, edited by Adriano G. Rossi and Deborah A. Sawatzky © 2008 Birkhäuser Verlag Basel/Switzerland
19
Moira K. B. Whyte et al.
pathogen-derived molecules [9, 10]. Our current understanding of these events predicts that, in the setting of acute infection or inflammation, granulocyte apoptosis is delayed until essential host functions such as pathogen clearance are successfully performed, but thereafter proceeds promptly to avoid the tissue damage that could arise from a perpetuated response. Given the extent of co-ordinated granulocyte clearance that is occasionally required (e.g. in the context of lobar pneumonia or eosinophilic pneumonia) and the delicate balance between such pro-survival and pro-apoptotic signals, it is not surprising that there exists considerable potential for pathological perturbation of these physiological events. The cellular processes of apoptosis can also be dysregulated by certain pathogens as an immune evasion strategy, whereas delayed apoptosis and prolonged granulocyte survival is important in persistence of tissue inflammation.
External factors regulating granulocyte apoptosis It is now well established that the rate at which granulocytes undergo apoptosis, at least in vitro, can be modified by several extra-cellular stimuli. For the neutrophil these include certain cytokines and growth factors (e.g. GM-CSF, IL-1, IFN-a, C5a, IGF-1) [9–13], cell adhesion or interaction with particulate material, including bacteria and bacterial products (e.g. VCAM-1, LPS) [10, 14, 15] and various physicochemical perturbations (e.g. UV irradiation, hypoxia, acidosis, hyper-osmolarity) [16, 17]. A similar spectrum of apoptosis regulators has also been described in the eosinophil (see Tab. 1). In addition to such physiological and pathological stimuli, a wide array of pharmacological agents have been reported to modulate granulocyte apoptosis, the most classical being the pro-apoptotic effect of glucocorticosteroids in eosinophils [6] and protein synthesis inhibitors in neutrophils [18]. A few, as yet poorly defined modulators have also been reported including the capacity of a modified, largely tissue-bound form of C-reactive protein (CRP) and serum from trauma or septic patients to inhibit neutrophil apoptosis [19, 20] and peritoneal dialysis membranes and dialysate fluid to enhance neutrophil apoptosis [21]. Of more physiological relevance, a distinct population of circulating neutrophils that are CD54high, CXC chemokine receptor 1low has been detected recently, which are typical of cells that have undergone reverse endothelial transmigration, i.e. cells that have migrated from an inflamed site back into the systemic circulation; these cells appear to be relatively apoptosis resistant and in the presence of systemic inflammation can account for up to 2% of circulating neutrophils [22]. In general, the number of stimuli that induce granulocyte survival outnumber those that promote apoptosis, and stimuli that induce very transient cellular activation (e.g. the bacterial tripeptide fMLP or IL-8 in the neutrophil) appear to have a far more marginal effect on apoptosis compared to more sustained inputs (e.g.
20
Granulocyte apoptosis
Table 1 - Regulation of eosinophil apoptosis Apoptosis delaying factors Cytokines
Proposed mechanism
Ref(s)
IL-3, IL-5, GM-CSF
Receptors composed of unique alpha sub-unit and [96] common beta sub-unit (`c) [97] Ligand binding triggers recruitment of tyrosine [98] kinases lyn, syk, Jak2 and SHPTP-2
IL-9
Unknown, may be up-regulation of IL-5R expression
[99]
IL-13
Enhances synthesis/release of IL-3 and GM-CSF to act in autocrine fashion
[100]
TNF-_
Partly by p38 MAP kinase activation
[101]
Hormones
Leptin
May block mitochondrial release of cytochrome c
[102]
Bacterial endotoxin
LPS
Enhanced autocrine GM-CSF production
[103]
Interferons
IFN-a
Mediated by Jak2
[104]
Integrins
`2 Integrin
Enhanced paracrine/autocrine synthesis of cytokines, e.g. IL-5/GM-CSF through ICAM-1 and `2 integrin signalling
[105]
Fibronectin, laminin
Integrin-mediated interaction resulting in generation of survival cytokines
[106] [107]
Galectin
Ecalectin
Unknown, but independent of IL-3, IL-5 and GM-CSF
[108]
Prostaglandins
PGE2
Increasing cytosolic cAMP EP2R subtype expressed on eosinophils
[109]
Cysteinyl leukotrienes
LTB4, LTC4, LTD4
CysLTs produced by eosinophils, mast cells & Th2 lymphocytes Mediated by GM-CSF which increases CysLT production
[110]
Pharmacological Rolipram agents
Increasing cytosolic cAMP levels
[111]
CD antigens
CD40
Cross-linking CD40 enhances GM-CSF release
[112]
Gaseous compounds
Nitric oxide
Inhibits apoptosis by cyclic GMP driven process
[113]
Death receptors
Fas/APO-1/ CD95
Cross-linking with ligand (CD95L, FasL, APO-1L)
[114]
CD69
Ligation of CD69 in GM-CSF cultured eosinophils
[115]
21
Moira K. B. Whyte et al.
Table 1 - continued Apoptosis delaying factors Cytokines
Interleukins
Proposed mechanism
TGF-`
Inhibits IL-3-, IL-5-, GM-CSF- and IFN-a- [116] mediated survival
IL-4
Inhibits IL-3-, IL-5- and GM-CSF-mediated survival
[117]
IL-10
Inhibits LPS-induced GM-CSF release
[103]
Unknown, may inhibit of production of cytokines by other cells
[118]
Theophylline
Inhibits IL-5-mediated survival
[115]
Sodium channel-blockers, e.g. lidocaine
Inhibit survival-enhancing action of IL-5 and IFN-a
[119]
Ketotifen
Inhibit survival-enhancing action of IL-5
[120]
Potassium channelblockers, e.g. sulfonylureas
Inhibit cytokine-induced survival
[121]
Immunosuppressants, e.g. Cyclosporin A
Inhibit survival-enhancing action of IL-5
[120]
Gliotoxin
Inhibition of NF-gB
[77]
Orazipone
Inhibit survival-enhancing action of IL-5
[122]
Siglec-8
Production of ROS and mitochondrial cleavage and caspase cleavage
[123]
Pharmacological Glucocorticoids, e.g. agents dexamethasone
Antibody cross-linking
Ref(s)
GM-CSF, LPS, hypoxia). It is also evident that most agents that induce functional granulocyte priming, that is, enhance the magnitude of subsequent agonist-stimulated respiratory burst or degranulation responses, also prolong neutrophil survival, suggesting a functional and/or mechanistic link between these processes.
Stimuli for inducing apoptotic cell death in granulocytes The extracellular agents that promote neutrophil apoptosis divide into four main groups, particulate (e.g. E. coli, oil red micro-particles), death receptor ligands (including TNF-_, TNF-related apoptosis-inducing ligand or TRAIL and Fas-L) [23, 24], toxins (e.g. Staphylococcus aureus Panton-Valentine leukocidin, which is
22
Granulocyte apoptosis
a pore-forming toxin that targets neutrophil mitochondrial membranes) [25] and pharmacological agents (e.g. protein synthesis inhibitors, phorbol esters, zVADfmk, curcumin, sodium salicylate, etc.) [18, 26]. The former group underwrites the importance of phagocytosis-induced cell death (PICD) as being an important mechanism in driving neutrophil apoptosis and thereby inducing effective elimination of both the inciting particle and the phagocyte. Neutrophil apoptosis following phagocytosis of bacteria was first described for E. coli but subsequently for many other bacteria also [27, 28]; PICD can also be induced by latex beads, requires reactive oxygen species (ROS) production [28] and is regulated by differential expression of a large number of apoptosis regulators [29]. An important distinction needs to be made between the effects of cell adhesion and the interaction of neutrophils with extracellular matrix components such as fibronectin, which induce a `2-integrin-dependent survival response, and the phagocytic uptake of particles, including bacteria, which, while still `2-integrin dependent, triggers accelerated granulocyte apoptosis [30]. Likewise, the ability of TNF-_ to induce neutrophil and eosinophil apoptosis is highly dependent on the state of basal priming, the duration of agonist stimulation, and whether the cells are adherent or in suspension [31, 32]. These experiments underline the context-specific nature of many of the pro-apoptotic responses observed in granulocytes and help clarify some of the seemingly contradictory data that exist in the literature. In most studies, however, TNF-_ and FasL have both been shown to induce a modest increase in the rate of neutrophil apoptosis at early times, although notably TNF-_ has an overall survival effect if incubations are continued for longer periods (> 12 h) [31, 33]. Similar findings have also been reported for eosinophils, although the pro-apoptotic effect of TNF-_ and FasL in these cells appears to be more conditional and modest [34]. Of interest, the early pro-apoptotic effect of TNF-_ in neutrophils is dependent on co-ligation of both the TNF-RI and TNF-RII, a finding that has now been reported in other cell types and appears to relate to the capacity of TNF-RII, which has a higher affinity for TNF-_, to participate in ligand passing. TNF-_ can also ‘prime’ neutrophils for apoptotic induction by agents such as GM-CSF, LPS or the `2-integrin-activating antibody VIM12 [35]. Moreover, the pro-apoptotic efficacy of TNF-_ in neutrophils varies between individuals and this appears to relate to the level of cells surface CD13 or aminopeptidase N expression [36]. Another death ligand, TRAIL (TNF-related apoptosis-inducing ligand), can also regulate neutrophil apoptosis [24]. Neutrophils express TRAIL-receptor 2 (TRAILR2) and TRAIL-R3 at both mRNA and protein level with the latter thought to act as a decoy receptor for TRAIL [24]; the same study was unable to detect TRAIL-R1 or TRAIL-R4. Despite evidence from this and other studies that neutrophils can produce TRAIL, and that ligation of the TRAIL-R2 with a leucine zipper-tagged form of TRAIL induces apoptosis, no evidence could be found for TRAIL in auto-
23
Moira K. B. Whyte et al.
crine regulation of constitutive neutrophil apoptosis. TRAIL is, however, expressed on other immune cells such as T cells and macrophages and TRAIL-induced neutrophil apoptosis, mediated by autologous T cells, is a likely mechanism of neutropenia in systemic lupus erythematosus [37]. A similar complexity also exists regarding Fas/FasL interactions in the neutrophil. Hence, early reports suggested that human neutrophils expressed both FasL and its cognate receptor Fas [38]; while the latter is certainly true, independent examination has failed to identify FasL expression in neutrophils at either mRNA or protein level [23, 39]. As with His-tagged monomeric TRAIL, certain preparations of recombinant soluble FasL also appear unable to induce neutrophil apoptosis [40], whereas that produced by opsonised-zymozan stimulated or apoptotic neutrophil-fed macrophages is clearly pro-apoptotic [39]. These latter findings rather discount Fas/FasL-mediated fratricide as being important in neutrophils but support the capacity for FasL generated by other cells to induce neutrophil apoptosis.
Intracellular mechanisms mediating granulocyte apoptosis Granulocyte apoptosis can be initiated by activation of either the extrinsic or intrinsic pathways of cell death [41]. The extrinsic pathway is mediated through ligation of cell-surface death receptors, as described above, leading to formation of the DISC (death-inducing signalling complex) and cleavage of caspase-8 [42]. The intrinsic or “stress” pathway, typically initiated following oxidant damage, cytotoxic agents or UV radiation, leads to mitochondrial outer membrane permeabilisation (MOMP), release of small inter-membrane mitochondrial proteins, notably cytochrome C and apoptosis-inducing factor, and activation of both caspase-9-dependent and caspase-independent pathways [43, 44]. These two pathways can interact to enhance apoptosis: for example, the pro-apoptotic Bcl-2 protein Bid mediates cross-talk by actions of a Bid caspase-cleavage product on MOMP [45]. Both pathways culminate in a common executioner pathway, characterised by activation of caspase-3 and cleavage of DNA and chromatin [46]. Given the paucity of functional mitochondria in neutrophils [47], it has been debated whether the intrinsic, mitochondrial death pathway is important in granulocytes. There is now good evidence, however, for mitochondrial initiation of apoptosis [48, 49] and that neutrophils can achieve activation of the apoptosome and caspase-9 processing [50]. Mitochondrial membrane permeabilisation in neutrophils, as in other cell types, requires Bax translocation to the mitochondria prior to caspase-3 activation [51]. Caspases play key roles in the induction of granulocyte apoptosis, as in most cell types. Neutrophils express many of the known caspases, including the cytokineprocessing caspases-1, -4 and -5 [50, 52, 53], the upstream caspases-8, -9 and -10 [50, 54, 55] and the executioner caspases-3, -6 and -7 [50, 56]. Caspase-1 has an
24
Granulocyte apoptosis
important role in cytokine processing, particularly of pro-IL-1`, as a component of the inflammasome [53], but has an additional role as an upstream regulator of neutrophil apoptosis, since spontaneous apoptosis is delayed in caspase-1-deficient neutrophils [52]. Caspase-8 is activated following death receptor ligation [57], while caspase-10, in contrast, is activated in spontaneous but not death receptor-mediated neutrophil apoptosis [55]. Caspase-8 may also have a role in spontaneous neutrophil apoptosis, which is independent of death receptor ligation, with ROS causing aggregation of CD95 in lipid rafts to form a functional DISC and thus activate caspase-8 [58]. A role for caspase-8 in spontaneous or Fas-mediated eosinophil apoptosis is less clear [59]. Despite the very low levels of cytochrome C detected in neutrophils, there is good evidence for caspase-9 processing and apoptosome formation in neutrophils in both spontaneous and staurosporine-induced apoptosis [50]. Similarly, caspase-9 activation is a feature of eosinophil apoptosis [60]. The broader question of how susceptible neutrophils and eosinophils are to oxidant-mediated induction of apoptosis is more complex and the subject of some debate [61]. Certainly, the application of agents such as sodium arsenite and high concentrations of H2O2 and NO are capable of inducing granulocyte apoptosis and antioxidants can protect against various forms of PICD; likewise, neutrophils from patients with chronic granulomatous disease who lack a functional NADPH oxidase have been variably reported to display delayed spontaneous and Fas-mediated apoptosis [62] and TNF-_ fails to kill neutrophils under anoxic conditions [61]. In contrast, however, full-scale activation of the very substantial respiratory burst machinery in neutrophils using sequential incubation of cells with PAF followed by fMLP, or the addition of more physiologically relevant concentrations of pro-oxidants, has no effect on apoptotic thresholds. Likewise early TNF-_-induced neutrophil apoptosis, again reported to be oxidant-mediated, is preserved in the presence of a panel of antioxidants including trolox, superoxide dismutase, catalase, reduced glutathione and N-acetyl-l-cysteine [61]. Actinomycin A, which enhances mitochondrial ROS generation and augments TNF-_-induced apoptosis in several other cell types, fails to enhance the pro-apoptotic efficacy of TNF-_ in human neutrophils. Together, these data imply that neutrophils, as a physiologically important source of ROS are, in fact, relatively protected from the pro-apoptotic efficacy of these toxic intermediates. Intracellular acidification is an early feature of neutrophil apoptosis and stimulation of the vacuolar (H+) ATPase in cell membranes inhibits both apoptosis and intracellular acidification [63]. During phagocytosis of bacteria, intracellular alkalinisation can delay neutrophil apoptosis, while ingestion of larger numbers of bacteria leads to intracellular acidification and increased apoptosis [64]. Caspase-3 activation leads to cleavage of specific protein targets that result in cell death; some of these are generic such as actin [65], lamin B and fodrin [66] while others are potentially cell-type specific. In neutrophils, caspase-3 activation cleaves and activates protein kinase C (PKC)-b during spontaneous apoptosis [67],
25
Moira K. B. Whyte et al.
whereas in eosinophils, but not neutrophils, the mammalian sterile 20-like 1 and 2 (Mst1/Mst2) kinases are caspase substrates [68]. Proteases other than caspases have also been implicated in inducing granulocyte apoptosis: calpains have been shown to degrade XIAP but, in view of the low levels of XIAP found in neutrophils, the importance of this is uncertain [69]. Calpain-1 also plays a direct role in neutrophil apoptosis by enhancing the cleavage of Bax to an 18-kDa form that no longer interacts with Bcl-xL, thus “freeing up” this Bax isoform to induce MOMP and caspase-3 activation [70].
Intracellular mechanisms that delay granulocyte apoptosis The principal second-messenger cascades implicated in neutrophil and eosinophil survival are: (i) NF-gB [71], (ii) phosphoinositide 3-kinase (PI3K)/Akt [72], (iii) protein kinase-b (PKCb), (iv) adenylyl cyclase/cAMP/PKA [73, 74], (v) p42/44 and p38 MAPK [75, 76] and (vi) PHD/HIF-1_ pathways [16]. These have been well reviewed elsewhere and have major similarities to many other cell types. Hence observations largely by Rossi and co-workers have demonstrated that prostaglandin E1 (PGE1), PGE2, adenosine (working through the adenosine A2a receptor) and cAMP and its analogues are powerful suppressors of neutrophil (and eosinophil) apoptosis, preventing both loss of mitochondrial membrane potential and caspase activation via a protein kinase A-independent mechanism [73, 74, 77]. Likewise, the activation of one of the multiple PI3K isoforms expressed in myeloid cells [78] results in the conversion of phosphatidylinositol 4,5-bisphosphate to the lipid second messenger phosphatidylinositol 3,4,5-trisphosphate, which induces the phosphorylation and activation of Akt/protein kinase B. This targets a number of anti-apoptotic pathways including the BH3 only molecule Bad, Forkhead, caspase-9 and IKK_, although only the former has been confirmed in granulocytes. Activated Akt can also phosphorylate and release Hsp27. The NF-gB pathway has a well-defined pro-survival role in granulocytes and inhibitors such as glitoxin are powerful inducers of apoptosis and enhance TNF-_-killing; the enhanced survival of neutrophils under hypoxic conditions may also be mediated by a HIF-1_-mediated transcriptional up-regulation of this pathway. Of note, the late survival effect of TNF-_ appears to be driven by NF-gB-mediated release of IL-8, which then operates in an autocrine/paracrine manner to induce cell survival [79]. PKCb has also been reported to be important in mediating the survival effect of TNF-_ in adherent neutrophils through a positive regulation of RIP and TRAF2 assembly on TNF-RI (thereby enhancing NF-gB activation) and inhibition of TRADD association (thereby blocking the formation of the cytosolic FADD, TRADD2, RIP, caspase-8 complex II, which induces apoptosis) [32, 80].
26
Granulocyte apoptosis
Other major targets that mediate neutrophil longevity include Mcl-1 and A1 that, unlike Bcl-2, are both expressed to a significant degree in neutrophils [81–84]. Mcl-1, a member of the Bcl-2 family, is of particular interest given its short half-life of 2–3 h and its up-regulation by neutrophil-survival factors including GM-CSF, IL-1, TNF-_ and IL-15; it is regulated at both a transcriptional and proteosomal level and is a target for caspase-mediated cleavage. Moreover, gene expression profiling in neutrophils treated with GM-CSF showed additional up-regulation of the apoptosis inhibitor 5, Bcl-2-like 1, BNIP2, CFLAR, serum/glucocorticoid-regulated kinase (SGK), and TNF-_-induced protein 8 [85]. Inhibitors of apoptosis proteins (IAPs) are inhibitors of activated caspases and provide a further regulatory step in apoptosis pathways [86]. Their role in granulocyte apoptosis is, however, uncertain since several, including cIAP1, XIAP and survivin, are expressed at very low levels; however, G-CSF may up-regulate cIAP2 and this could contribute to its pro-survival effect in neutrophils. cIAP2 is also known to be over-expressed in chronic neutrophilic leukaemia [87].
Consequences of granulocyte apoptosis The requirement for a highly effective route of “physiological” granulocyte apoptosis and clearance is exemplified by pneumococcal pneumonia, where bacterial clearance is followed by complete resolution of the neutrophilic inflammatory infiltrate [88]. Since, as described previously, certain extracellular bacterial factors typically delay neutrophil apoptosis, whereas phagocytosis of bacteria induces apoptosis, the regulation of neutrophil apoptosis during infections is complex. These opposing effects can be integrated by a model of biphasic susceptibility, in which apoptosis is delayed until bacterial killing (associated with internalisation and ROS generation) is well advanced [28]. This model would allow for containment of infection and limit inflammatory tissue injury. These “physiological” host responses can, however, be subverted by pathogens as part of a strategy for immune evasion, as shown in a number of models of macrophage death [89]. Premature neutrophil apoptosis impairs bacterial killing and, if clearance mechanisms are overwhelmed and secondary necrosis occurs, could cause bystander tissue injury. Pseudomonas aeruginosa employs this strategy both in vitro and in vivo via the production of the phenazine metabolite pyocyanin [90, 91] and Streptococcus pyogenes induces apoptosis by altering the intrinsic programme of apoptosis at a transcriptional level [92]. Other organisms, notably Staphylococcus aureus, induce neutrophil necrosis [28], although the S. aureus Panton-Valentin leukocidin induces neutrophil apoptosis via activation of the mitochondrial pathway [25]. Other inducers of neutrophil necrosis include Burkholderia cenocepacia and the E. coli hemolysin [93–95].
27
Moira K. B. Whyte et al.
Conclusions Until very recently neutrophils and eosinophils have been stereotyped as largely short-lived and transcriptionally inert cells capable only of releasing set amounts of pre-formed mediators. In fact, these cells are remarkably versatile (and certainly synthetically active) and are involved in a number of biological processes aside from the orchestration and resolution of inflammation, including the facilitation of the specific immune response (e.g. through antigen processing), the regulation of angiogenesis, and modulation of tumour cell fate among others. While critical for host defence, the capacity for granulocytes to induce significant bystander organ damage dictates the need for powerful and safe clearance mechanisms for these cells, and constitutive and pathogen-induced apoptosis, coupled with efficient phagocytic recognition and disposal appears to afford one such mechanism. While many of the events that regulate inflammatory cell apoptosis are now understood, part of the future challenge is to establish how, where and when we can intervene to facilitate these processes in vivo and to determine the interplay with other non-apoptotic clearance mechanisms, for example those involved in the removal of circulating granulocytes by the spleen and bone marrow.
Acknowledgements The work in the authors’ laboratories is funded by the MRC, The Wellcome Trust, Asthma UK and the British Lung Foundation.
References 1
2 3
4 5
6
28
Savill JS, Henson PM, Haslett C (1989) Phagocytosis of aged human neutrophils by macrophages is mediated by a novel “charge-sensitive” recognition mechanism. J Clin Invest 84: 1518–1527 Whyte MK, Meagher LC, MacDermot J, Haslett C (1993) Impairment of function in aging neutrophils is associated with apoptosis. J Immunol 150: 5124–5134 Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM (1998) Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 101: 890–898 Erjefalt JS, Uller L, Malm-Erjefalt M, Persson CG (2004) Rapid and efficient clearance of airway tissue granulocytes through transepithelial migration. Thorax 59: 136–143 Walsh GM, Sexton DW, Blaylock MG, Convery CM (1999) Resting and cytokine-stimulated human small airway epithelial cells recognize and engulf apoptotic eosinophils. Blood 94: 2827–2835 Stern M, Meagher L, Savill J, Haslett C (1992) Apoptosis in human eosinophils. Pro-
Granulocyte apoptosis
7
8
9
10
11
12
13 14
15
16
17
18
grammed cell death in the eosinophil leads to phagocytosis by macrophages and is modulated by IL-5. J Immunol 148: 3543–3549 Simon H-U, Yousefi S, Schranz C, Schapowal A, Bachert C, Blaser K (1997) Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 158: 3902–3908 Farahi N, Cowburn AS, Rossi AG, Chilvers ER (2004) Eating their way out of trouble: Selective uptake of apoptotic eosinophils by bronchial epithelial cells. Clin Exp Allergy 34: 1503–1506 Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A (1992) Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood 80: 2012–2020 Lee A, Whyte MKB, Haslett C (1993) Prolongation of in vitro lifespan and functional longevity of neutrophils by inflammatory mediators acting through inhibition of apoptosis. J Leukoc Biol 54: 283–288 Begley CG, Lopez AF, Nicola NA, Warren DJ, Sanderson CJ, Metcalf D (1986) Purified colony-stimulating factors enhance the survival of human neutrophils and eosinophils in vitro: A rapid and sensitive microassay of colony-stimulating factors. Blood 68: 162–166 Lopez AF, Williamson DJ, Gamble JR, Begley CG, Harlan JM, Klebanoff SJ, Walterscorph A, Wong G, Clark SC, Vadas MA (1986) Recombinant human granulocytemacrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival. J Clin Invest 78: 1220–1228 Kooijman R, Coopens A, Hooghe-Peters E (2002) IGF-1 inhibits spontaneous apoptosis in human granulocytes. Endocrinology 143: 1206–1212 Ross EA, Douglas MR, Wong SH, Ross EJ, Curnow SJ, Nash GB, Rainger E, ScheelToellner D, Lord JM, Salmon M et al (2006) Interaction between integrin alpha9beta1 and vascular cell adhesion molecule-1 (VCAM-1) inhibits neutrophil apoptosis. Blood 107: 1178–1183 McGettrick HM, Lord JM, Wang KQ, Rainger GE, Buckley CD, Nash GB (2006) Chemokine- and adhesion-dependent survival of neutrophils after transmigration through cytokine-stimulated endothelium. J Leukoc Biol 79: 779–788 Walmsley SR, Print C, Farahi N, Peyssonnaux C, Johnson RS, Cramer T, Sobolewski A, Condliffe AM, Cowburn AS, Johnson N, Chilvers ER (2005) Hypoxia-induced neutrophil survival is mediated by HIF-1_-dependent NF-gB activity. J Exp Med 201: 105–115 Martinez D, Vermeulen M, Trevani A, Ceballos A, Sabatte J, Gamberale R, Alvarez ME, Salamone G, Tanos T, Coso OA et al (2006) Extracellular acidosis induces neutrophil activation by a mechanism dependent on activation of phosphatidylinositol 3-kinase/ Akt and ERK pathways. J Immunol 176: 1163–1171 Whyte MK, Savill J, Meagher LC, Lee A, Haslett C (1997) Coupling of neutrophil
29
Moira K. B. Whyte et al.
19 20
21
22
23
24
25
26
27 28 29
30 31
30
apoptosis to recognition by macrophages: coordinated acceleration by protein synthesis inhibitors. J Leukoc Biol 62: 195–202 Schwedler SB, Filep JG, Galle J, Wanner C, Potempa LA (2006) C-reactive protein: A family of proteins to regulate cardiovascular function. Am J Kidney Dis 47: 212–222 Ertel W, Keel M, Infanger M, Ungethum U, Steckholzer U, Trentz O (1998) Circulating mediators in serum of injured patients with septic complications inhibit neutrophil apoptosis through up-regulation of protein-tyrosine phosphorylation. J Trauma 44: 767–775 Cendoroglo M, Sundaram S, Groves C, Ucci AA, Jaber BL, Pereira BJ (1997) Necrosis and apoptosis of polymorphonuclear cells exposed to peritoneal dialysis fluids in vitro. Kidney Int 52: 1626–34 Buckley CD, Ross EA, McGettrick HM, Osborne CE, Haworth O, Schmutz C, Stone PC, Salmon M, Matharu NM, Vohra RK, Nash GB, Rainger GE (2006) Identification of a phenotypically and functionally distinct population of long-lived neutrophils in a model of reverse endothelial migration. J Leukoc Biol 79: 303–311 Renshaw SA, Timmons SJ, Eaton V, Usher LR, Akil M, Bingle CD, Whyte MK (2000) Inflammatory neutrophils retain susceptibility to apoptosis mediated via the Fas death receptor. J Leukoc Biol 67: 662–668 Renshaw SA, Parmar JS, Singleton V, Rowe SJ, Dockrell DH, Dower SK, Bingle CD, Chilvers ER, Whyte MKB (2003) Acceleration of human neutrophil apoptosis by TRAIL. J Immunol 170: 1027–1033 Genestier AL, Mchallet MC, Prevost G, Bellot G, Chalabreysse L, Peyrol S, Thivolet F, Etienne J, Lina G, Vallette FM et al (2005) Staphylococcus aureus Panton-Valentine leukocidin directly targets mitochondria and induces Bax-independent apoptosis of human neutrophils. J Clin Invest 115: 3117–3127 Cowburn AS, White JF, Deighton J, Walmsley SR, Chilvers ER (2005) z-VAD-fmk augmentation of TNF alpha-stimulated neutrophil apoptosis is compound specific and does not involve the generation of reactive oxygen species. Blood 105: 2970–2972 Watson RW, Redmond HP, Wang JH, Condron C, Bouchier-Hayes D (1996) Neutrophils undergo apoptosis following ingestion of Escherichia coli. J Immunol 156: 3986–3992 DeLeo FR (2004) Modulation of phagocyte apoptosis by bacterial pathogens. Apoptosis 9: 399–413 Kobayashi SD, Voyich JM, Buhl CL, Stahl RM, DeLeo FR (2002) Global changes in gene expression by human polymorphonuclear leukocytes during receptor-mediated phagocytosis: Cell fate is regulated at the level of gene expression. Proc Natl Acad Sci USA 99: 6901–6906 Mayadas TN, Cullere X (2005) Neutrophil `2 integrins: Moderators of life or death decisions. Trends Immunol 26: 388–395 Murray J, Barbara JA, Dunkley SA, Lopez A, van Ostade X, Condliffe AM, Dransfield I, Haslett C, Chilvers ER (1997) Regulation of neutrophil apoptosis by tumour necrosis factor-_: Requirement for TNFR-55 and TNFR-75 for induction of apoptosis in vitro. Blood 90: 2772–2783
Granulocyte apoptosis
32
33
34
35
36
37
38
39 40
41 42 43
44 45 46 47
Kilpatrick LE, Sun S, Korchak HM (2004) Selective regulation by delta-PKC and PI3kinase in the assembly of antiapoptotic TNFR-1 signaling complex in neutrophils. Am J Physiol Cell Physiol 287: C633-C642 Iwai K, Miyawaki T, Takizawa T, Konno A, Ohta K, Yachie A, Seki H, Taniguchi N (1994) Differential expression of bcl-2 and susceptibility to anti-Fas-mediated cell death in peripheral blood lymphocytes, monocytes and neutrophils. Blood 84: 1201–1208 Matsumoto K, Schleimer RP, Saito H, Iikura Y, Bochner BS (1995) Induction of apoptosis in human eosinophils by anti-Fas antibody treatment in vitro. Blood 86: 1437– 1443 Gardai S, Whitlock BB, Helgason C, Ambruso D, Fadok V, Bratton D, Henson PM (2002) Activation of SHIP by NADPH oxidase-stimulated Lyn leads to enhanced apoptosis in neutrophils. J Biol Chem 277: 5236–5246 Cowburn AS, Sobolewski A, Reed BJ, Deighton J, Murray J, Walmsley SR, Cadwallader KA, Chilvers ER (2006) Aminopeptidase N (CD13) regulates tumour necrosis factor-_induced apoptosis in human neutrophils. J Biol Chem 281: 12458–12467 Matsuyama W, Yamamoto M, Higashimoto I, Oonakahara K, Watanabe M, Machida K, Yoshimura T, Eiraku N, Kawabata M, Osame M, Arimura K (2004) TNF-related apoptosis-inducing ligand is involved in neutropenia of systemic lupus erythematosus. Blood 104: 184–191 Liles WC, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ (1996) Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: Implications for the regulation of apoptosis in neutrophils. J Exp Med 184: 429–440 Brown SB, Savill J (1999) Phagocytosis triggers macrophage release of Fas ligand and induces apoptosis of bystander leukocytes. J Immunol 162: 480–485 Ottonello L, Tortolina G, Amelotti M, Dallegri F (1999) Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J Immunol 162: 3601– 3606 Green DR (2000) Apoptotic pathways: Paper wraps stone blunts scissors. Cell 102: 1–4 Ashkenazi A, Dixit VM (1998) Death receptors: Signaling and modulation. Science 281: 1305–1308 Susin SA, Daugas E, Ravagnan L, Samejima K, Zamzami N, Loeffler M, Costantini P, Ferri KF, Irinopoulou T, Prevost MC et al (2000) Two distinct pathways leading to nuclear apoptosis. J Exp Med 192: 571–580 Green DR, Kroemer G (2004) The pathophysiology of mitochondrial cell death. Science 305: 626–629 Roy S, Nicholson DW (2000) Cross-talk in cell death signaling. J Exp Med 192: F21– 25 Thornberry NA, Lazebnik Y (1998). Caspases: Enemies within. Science 281: 1312– 1316 Bainton DF, Ullyot JL, Farquhar MG (1971) The development of neutrophilic polymorphonuclear leukocytes in human bone marrow. J Exp Med 134: 907–934
31
Moira K. B. Whyte et al.
48
49
50
51
52
53
54 55 56
57
58 59 60 61
62
32
Fossati G, Moulding DA, Spiller DG, Moots RJ, White MR, Edwards SW (2003) The mitochondrial network of human neutrophils: Role in chemotaxis, phagocytosis, respiratory burst activation, and commitment to apoptosis. J Immunol 170: 1964–1972 Martin MC, Dransfield I, Haslett C, Rossi AG (2001) Cyclic AMP regulation of neutrophil apoptosis occurs via a novel protein kinase A-independent signaling pathway. J Biol Chem 276: 45041–45050 Murphy BM, O’Neill AJ, Adrain C, Watson RW, Martin SJ (2003) The apoptosome pathway to caspase activation in primary human neutrophils exhibits dramatically reduced requirements for cytochrome C. J Exp Med 197: 625–632 Maianski NA, Mul FP, van Buul JD, Roos D, Kuijpers TW (2002) Granulocyte colonystimulating factor inhibits the mitochondria-dependent activation of caspase-3 in neutrophils. Blood 99: 672–679 Rowe SJ, Allen L, Ridger VC, Hellewell PG, Whyte MK (2002) Caspase-1-deficient mice have delayed neutrophil apoptosis and a prolonged inflammatory response to lipopolysaccharide-induced acute lung injury. J Immunol 169: 6401–6407 Martinon F, Burns K, Tschopp J (2002) The inflammasome: A molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 10: 417–426 Fadeel B, Ahlin A, Henter JI, Orrenius S, Hampton MB (1998) Involvement of caspases in neutrophil apoptosis: Regulation by reactive oxygen species. Blood 92: 4808–4818 Goepel F, Weinmann P, Schymeinsky J, Walzog B (2004) Identification of caspase-10 in human neutrophils and its role in spontaneous apoptosis. J Leukoc Biol 75: 836–843 Pryde JG, Walker A, Rossi AG, Hannah S, Haslett C (2000) Temperature-dependent arrest of neutrophil apoptosis. Failure of Bax insertion into mitochondria at 15°C prevents the release of cytochrome c. J Biol Chem 275: 33574–33584 Yamashita K, Takahashi A, Kobayashi A, Hirata H, Mesner PW Jr, Kaufmann SH, Yonehara S, Yamamoto K, Uchiyama T, Sasada M (1999) Caspases mediate tumour necrosis factor alpha induced neutrophil apoptosis and downregulation of reactive oxygen production. Blood 93: 674–685 Scheel-Toellner D, Wang K, Craddock R et al (2004) Reactive oxygen species limit neutrophil life span by activating death receptor signaling. Blood 104: 2557–2564 Daigle I, Simon HU (2001). Critical role for caspases 3 and 8 in neutrophil but not eosinophil apoptosis. Int Arch Allergy Immunol 126: 147–156 Simon HU (2001) Regulation of eosinophil and neutrophil apoptosis-similarities and differences. Immunol Rev 179: 156–162 Murray J, Walmsley SR, Mecklneburgh KI, Cowburn AS, White JF, Rossi AG, Chilvers ER (2003) Hypoxic regulation of neutrophil apoptosis: Role of reactive oxygen intermediates in constitutive and tumor necrosis factor _-induced cell death. Ann NY Acad Sci 1010: 417–425 Kasahara Y, Iwai K, Yachie A, et al (1997) Involvement of reactive oxygen intermediates in spontaneous and CD95 (Fas/APO-1)-mediated apoptosis of neutrophils. Blood 89: 1748–1753
Granulocyte apoptosis
63
64
65 66
67
68
69
70
71
72
73
74
75 76
Gottlieb RA, Giesing HA, Zhu JY, Engler RL, Babior BM (1995) Cell acidification in apoptosis: Granulocyte colony-stimulating factor delays programmed cell death in neutrophils by up-regulating the vacuolar H(+)-ATPase. Proc Natl Acad Sci USA 92: 5965–5968 Coakley RJ, Taggart C, McElvaney NG, O’Neill SJ (2002) Cytosolic pH and the inflammatory microenvironment modulate cell death in human neutrophils after phagocytosis. Blood 100: 3383–3391 Brown SB, Bailey K, Savill J (1997) Actin is cleaved during constitutive apoptosis. Biochem J 323: 233–237 Sanghavi DM, Thelen M, Thornberry NA, Casciola-Rosen L, Rosen A (1998) Caspase mediated proteolysis during apoptosis: Iinsights from apoptotic neutrophils. FEBS Lett 422: 179–184 Pongracz J, Webb P, Wang K, Deacon E, Lunn OJ, Lord JM (1999) Spontaneous neutrophil apoptosis involves caspase 3-mediated activation of protein kinase C-delta. J Biol Chem 274: 37329–37334 De Souza PM, Kankaanranta H, Michael A, Barnes PJ, Giembycz MA, Lindsay MA (2002) Caspase-catalyzed cleavage and activation of Mst1 correlates with eosinophil but not neutrophil apoptosis. Blood 99: 3432–3438 Kobayashi S, Yamashita K, Takeoka T, Ohtsuki T, Suzuki Y, Takahashi R, Yamamoto K, Kaufmann SH, Uchiyama T, Sasada M, Takahashi A (2002) Calpain-mediated X-linked inhibitor of apoptosis degradation in neutrophil apoptosis and its impairment in chronic neutrophilic leukemia. J Biol Chem 277: 33968–33977 Altznauer F, Conus S, Cavalli A, Folkers G, Simon HU (2004) Calpain-1 regulates Bax and subsequent Smac-dependent caspase-3 activation in neutrophil apoptosis. J Biol Chem 279: 5947–5957 Ward C, Chilvers ER, Lawson MF, Pryde JG, Fujihara S, Farrow SN, Haslett C, Rossi AG (1999) NF-kappaB activation is a critical regulator of human granulocyte apoptosis in vitro. J Biol Chem 274: 4309–4318 Cowburn AS, Cadwallader KA, Reed BJ, Farahi N, Chilvers ER (2002) Role of PI3kinase-dependent Bad phosphorylation and altered transcription in cytokine-mediated neutrophil survival. Blood 100: 2607–2616 Rossi AG, Cousin JM, Dransfield I, Lawson MF, Chilvers ER, Haslett C (1995) Agents that elevate cAMP inhibit human neutrophil apoptosis. Biochem Biophys Res Commun 217: 892–899 Teixeira MM, Rossi AG, Giembycz MA, Hellewell PG (1996) Effects of agents which elevate cyclic AMP on guinea-pig eosinophil homotypic aggregation. Br J Pharmacol 118: 2099–2106 Leuenroth SJ, Grutkoski PS, Ayala A, Simms HH (2000) Suppression of PMN apoptosis by hypoxia is dependent on Mcl-1 and MAPK activity. Surgery 128: 171–177 Aleman M, Schierloh P, de la Barrera SS, Musella RM, Saab MA, Baldini M, Abbate E, Sasiain MC (2004) Mycobacterium tuberculosis triggers apoptosis in peripheral neu-
33
Moira K. B. Whyte et al.
77 78
79
80 81
82
83
84
85
86 87
88 89 90
34
trophils involving Toll-like receptor 2 and p38 mitogen protein kinase in tuberculosis patients. Infect Immun 72: 5150–5158 Walker BA, Rocchini C, Boone RH, Ip S, Jacobson MA (1997) Adenosine A2a receptor activation delays apoptosis in human neutrophils. J Immunol 158: 2926–2931 Condliffe AM, Davidson K, Anderson KE, Ellson C, Crabbe T, Okkenhaug K, Vanhaesebroeck B, Turner M, Webb L, Wymann MP et al (2005) Priming of the neutrophil oxidase via temporal regulation of phosphoinositide 3-kinase activity. Blood 106: 1432–1440 Cowburn AS, Deighton J, Walmsley SR, Chilvers ER (2004) Independent roles of phosphoinositide 3-kinase and NF-kappa-B in the regulation of apoptotic thresholds in neutrophils. Eur J Immunol 34: 1733–1743 Micheau O, Tschopp J (2003) Induction of TNF receptor I-mediated apoptosis via two sequential signalling complexes. Cell 114: 148–150 Moulding DA, Quayle JA, Hart CA, Edwards SW (1998) Mcl-1 expression in human neutrophils: Regulation by cytokines and correlation with cell survival. Blood 92: 2495–2502 Moulding DA, Akgul C, Derouet M, White MR, Edwards SW (2001) BCL-2 family expression in human neutrophils during delayed and accelerated apoptosis. J Leukocyte Biol 70: 783–792 Orlofsky A, Somogyi RD, Weiss LM, Prystowsky MB (1999) The murine antiapoptotic protein A1 is induced in inflammatory macrophages and constitutively expressed in neutrophils. J Immunol 163: 412–419 Francois S, El Benna J, Dang PM, Pedruzzi E, Gougerot-Pocidalo MA, Elbim C (2005) Inhibition of neutrophil apoptosis by TLR agonists in whole blood: Involvement of the phosphoinositide 3-kinase/Akt and NF-kappaB signaling pathways, leading to increased levels of Mcl-1, A1, and phosphorylated Bad. J Immunol 174: 3633–3642 Kobayashi SD, Voyich JM, Whitney AR, DeLeo FR (2005) Spontaneous neutrophil apoptosis and regulation of cell survival by granulocyte macrophage-colony stimulating factor. J Leukoc Biol 78: 1408–1418 Chang HY, Yang X (2000) Proteases for cell suicide: Functions and regulation of caspases. Microbiol Mol Biol Rev 64: 821–846 Hasegawa T, Suzuki K, Sakamoto C, Ohta K, Nishiki S, Hino M, Tatsumi N, Kitagawa S (2003) Expression of the inhibitor of apoptosis (IAP) family members in human neutrophils: up-regulation of cIAP2 by granulocyte colony-stimulating factor and overexpression of cIAP2 in chronic neutrophilic leukemia. Blood 101: 1164–1171 Haslett C (1999) Granulocyte apoptosis and its role in the resolution and control of lung inflammation. Am J Respir Crit Care Med 160: S5–11 Zychlinsky A, Sansonetti P (1997) Perspectives series: host/pathogen interactions. Apoptosis in bacterial pathogenesis. J Clin Invest 100: 493–495 Usher LR, Lawson RA, Geary I, Taylor CJ, Bingle CD, Taylor GW, Whyte MK (2002) Induction of neutrophil apoptosis by the Pseudomonas aeruginosa exotoxin pyocyanin: A potential mechanism of persistent infection. J Immunol 168: 1861–1868
Granulocyte apoptosis
91
92
93
94
95
96
97
98
99 100
101
102 103
104
Allen L, Dockrell DH, Pattery T, Lee DG, Cornelis P, Hellewell PG, Whyte MK (2005) Pyocyanin production by Pseudomonas aeruginosa induces neutrophil apoptosis and impairs neutrophil-mediated host defenses in vivo. J Immunol 174: 3643–3649 Kobayashi SD, Braughton KR, Whitney AR, Voyich JM, Schwan TG, Musser JM, DeLeo FR (2003) Bacterial pathogens modulate an apoptosis differentiation program in human neutrophils. Proc Natl Acad Sci USA 100: 10948–10953 Bylund J, Campsall PA, Ma RC, Conway BA, Speert DP (2005) Burkholderia cenocepacia induces neutrophil necrosis in chronic granulomatous disease. J Immunol 174: 3562–3569 Hutchinson ML, Poxton IR, Govan JR (1998) Burkholderia cepacia produces a haemolysin that is capable of inducing apoptosis and degranulation of mammalian phagocytes. Infect Immun 66: 2033–2039 Russo TA, Davidson BA, Genagon SA, Warholic NM, Macdonald U, Pawlicki PD, Beanan JM, Olson R, Holm BA, Knight PR 3rd (2005) The E. coli virulence factor hemolysin induces neutrophil apoptosis and necrosis/lysis in vitro and necrosis/lysis and lung injury in a rat pneumonia model. Am J Physiol Lung Cell Mol Physiol 289: L207L216 Tai PC, Sun L, Spry CJ (1991) Effects of IL-5, granulocyte/macrophage colony-stimulating factor (GM-CSF) and IL-3 on the survival of human blood eosinophils in vitro. Clin Exp Immunol 85: 312–316 Rothenberg ME, Pomerantz JL, Owen W Jr, Avraham S, Soberman RJ, Austen KF, Stevens RL (1988) Characterization of a human eosinophil proteoglycan, and augmentation of its biosynthesis and size by interleukin 3, interleukin 5, and granulocyte/macrophage colony stimulating factor. J Biol Chem 263: 13901–13908 Yamaguchi Y, Suda T, Ohta S, Tominaga K, Minura Y, Kasahara T (1991) Analysis of the survival of mature human eosinophils: interleukin-5 prevents apoptosis in mature human eosinophils. Blood 78: 2542–2547 Gounni AS (2000) Interleukin-9 enhances interleukin-5 receptor expression, differentiation, and survival of human eosinophils. Blood 96: 2163–2171 Luttmann W, Knoechel B, Foerster M, Matthys H, Virchow J Jr, Kroegel C (1996) Activation of human eosinophils by IL-13. Induction of CD69 surface antigen, its relationship to messenger RNA expression, and promotion of cellular viability. J Immunol 157: 1678–1683 Tsukahara K, Nakao A, Hiraguri M, Miike S, Mamura M, Saito Y, Iwamoto I (1999) Tumor necrosis factor-alpha mediates antiapoptotic signals partially via p38 MAP kinase activation in human eosinophils. Int Arch Allergy Immunol 1: 54–59 Conus S, Bruno A, Simon HU (2005) Leptin is an eosinophil survival factor. J Allergy Clin Immunol 116: 1228–1234 Takanaski S, Nonaka R, Xing Z, O’Byrne P, Dolovich J, Jordana M (1994) Interleukin 10 inhibits lipopolysaccharide-induced survival and cytokine production by human peripheral blood eosinophils. J Exp Med 180: 711–715 Ochiai K, Kagami M, Matsumura R, Tomioka H (1997) IL-5 but not interferon-gamma
35
Moira K. B. Whyte et al.
105
106 107 108 109
110
111
112 113 114
115
116
117 118
119
36
(IFN-gamma) inhibits eosinophil apoptosis by up-regulation of bcl-2 expression. Clin Exp Immunol 107: 198–204 Chihara J, Kakazu T, Higashimoto I, Saito N, Honda K, Sannohe S, Kayaba H, Urayama O (2000) Signaling through the beta2 integrin prolongs eosinophil survival. J Allergy Clin Immunol 106: S99-S103 Tourkin A, Anderson T, LeRoy EC, Hoffman S (1993) Eosinophil adhesion and maturation is modulated by laminin. Cell Adhes Commun 1: 161–176 Anwar AR, Moqbel R, Walsh GM, Kay AB, Wardlaw AJ (1993) Adhesion to fibronectin prolongs eosinophil survival. J Exp Med 177: 839–843 Matsumoto R, Hirashima M, Kita H, Gleich GJ (2002) Biological activities of ecalectin: A novel eosinophil-activating factor. J Immunol 168: 1961–1967 Peacock CD, Misso NL, Watkins DN, Thompson PJ (1999) PGE 2 and dibutyryl cyclic adenosine monophosphate prolong eosinophil survival in vitro. J Allergy Clin Immunol 104: 153–162 Lee E, Robertson T, Smith J, Kilfeather S (2001) Leukotriene receptor antagonists and synthesis inhibitors reverse survival in eosinophils of asthmatic individuals. Am J Respir Crit Care Med 161: 1881–1886 Yasui K, Agematsu K, Shinozaki K, Hokibara S, Nagumo H, Yamada S, Kobayashi N, Komiyama A (2000) Effects of theophylline on human eosinophil functions: Comparative study with neutrophil functions. J Leukoc Biol 68: 194–200 Kim JT, Gleich GJ, Kita H (1997) Roles of CD molecules in survival and activation of human eosinophils. J Immunol 159: 926–933 Beauvais F, Joly F (1999) Effects of nitric oxide on the eosinophil survival in vitro. A role for nitrosyl-heme. FEBS Lett 443: 37–40 Tsuyuki S, Bertrand C, Erard F, Trifilieff A, Tsuyuki J, Wesp M, Anderson G, Coyle AJ (1995) Activation of the Fas receptor on lung eosinophils leads to apoptosis and the resolution of eosinophilic inflammation of the airways. J Clin Invest 96: 2924–2931 Yasui K, Hu B, Nakazawa T, Agematsu K, Komiyama A (1997) Theophylline accelerates human granulocyte apoptosis not via phosphodiesterase inhibition. J Clin Invest 100: 1677–1684 Alam R, Forsythe P, Stafford S, Fukuda Y (1994) Transforming growth factor beta abrogates the effects of hematopoietins on eosinophils and induces their apoptosis. J Exp Med 179: 1041–1045 Wedi B, Raap U, Lewrick H, Kapp A (1998) IL-4-induced apoptosis in peripheral blood eosinophils. J Allergy Clin Immunol 102: 1013–1020 Meagher LC, Cousin JM, Seckl JR, Haslett C (1996) Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 156: 4422–4428 Okada S, Hagan JB, Kato M, Bankers-Fulbright JL, Hunt LW, Gleich GJ, Kita H (1998) Lidocaine and its analogues inhibit IL-5-mediated survival and activation of human eosinophils. J Immunol 160: 4010–4017
Granulocyte apoptosis
120 Hossain M, Okubo Y, Sekiguchi M (1994) Eosinophil viability-enhancing activity in mite-sensitive bronchial asthma. Intern Med 33: 529–535 121 Bankers-Fulbright JL, Kephart GM, Loegering DA, Bradford AL, Okada S, Kita H, Gleich GJ (1998) Sulfonylureas inhibit cytokine-induced eosinophil survival and activation. J Immunol 160: 5546–5553 122 Kankaanranta H, Ilmarinen P, Zhang X, Nissinen E, Moilanen E (2006) Anti-eosinophilic activity of orazipone. Mol Pharmacol 69: 1861–1870 123 Nutku E, Hudson SA, Bochner BS (2005) Mechanism of Siglec-8-induced human eosinophil apoptosis: Role of caspases and mitochondrial injury. Biochem Biophys Res Commun 336: 918–924
37
Innate immune mechanisms in the resolution of inflammation Andrew Devitt1 and Christopher D. Gregory2 1
School of Life and Health Sciences, Aston University, Aston Triangle, Birmingham, B4 7ET, UK; MRC Centre for Inflammation Research, The Queen’s Medical Research Institute, 47 Little France Crescent, Edinburgh, EH16 4TJ, UK 2
Introduction The inflammatory response is a highly orchestrated and tightly controlled mechanism of defence characterised by infiltration of granulocytes and mononuclear cells. For this response to be beneficial it must deal with its initial inflammatory stimulus and then subside to allow the tissue to return to its pre-inflamed state. Such resolution requires cessation of inflammatory cell recruitment and, importantly, deletion of recruited cells in a safe and controlled fashion. Failure to delete cells appropriately may permit effete cells to undergo necrosis (lysis due to loss of plasma membrane integrity) with the generation of inflammatory and autoimmune consequences associated with leakage of intracellular contents [1]. Apoptosis constitutes a vital mechanism by which damaged, infected or unwanted cells (e.g. effete inflammatory cells) are removed from the body via a process that culminates in the efficient phagocytic removal of dying cells under carefully controlled conditions. This ultimate clearance process is used for both the removal of physiological cell death associated with normal tissue homeostasis and pathological cell death associated with inflammation and infection. Thus, deletion of cells in a resolving inflammatory situation is mediated through apoptosis and rapid phagocytosis of cell corpses by recruited and resident phagocytes. Importantly, especially in the context of innate immune system involvement in resolution of inflammation, this deletion and clearance must occur in a manner that itself does not generate or promote inflammatory responses. The mechanisms mediating non-phlogistic clearance of apoptotic cells are still poorly understood though the identities of many putative molecular players are known and include, perhaps counter-intuitively, components of the innate immune system. In this chapter we focus upon these molecules in the phagocytic clearance of apoptotic cells that is central to a resolving inflammatory response.
The Resolution of Inflammation, edited by Adriano G. Rossi and Deborah A. Sawatzky © 2008 Birkhäuser Verlag Basel/Switzerland
39
Andrew Devitt and Christopher D. Gregory
The innate immune system The innate immune system is a powerful (if often under-rated) system that constitutes an important early defence against pathogens. It comprises a series of factors that fall into groups including physical barriers to infection (e.g. skin), cellular factors (e.g. neutrophils, macrophages and their receptors) and humoral factors (e.g. complement) with the latter group containing induced innate factors (e.g. chemokines). In this chapter we seek to review the published role of innate immune components in the context of apoptotic cell clearance with a focus upon the resolution of inflammation.
Pattern recognition The concept of self/non-self recognition is central to immunology – how and why do we respond to some antigens and not others? Janeway [2] proposed that the innate immune system discriminated ‘non-self’ (‘infectious non-self’) from ‘self’ (‘noninfectious self’) at the point of recognition: the former being foreign and exposed patterns that are evolutionarily conserved (so-called pathogen-associated molecular patterns or PAMPs) and such PAMPs were proposed to be recognised by specialised receptors known as pattern recognition receptors (PRRs). The discovery that components of the innate immune system are involved in the recognition and removal of apoptotic cells (unwanted self) clearly raises questions of this view of immune recognition. The striking similarities in the recognition of bacteria and apoptotic cells led to the proposal that apoptotic cells themselves expose similar patterns for recognition termed ‘apoptotic cell-associated molecular patterns’ (ACAMPs) [3, 4]. These patterns which, by definition, closely resemble the three-dimensional structure of PAMPs may then also be recognised by PRRs. While the “infectious non-self” model proposed by Janeway does not allow for such similarities in self and nonself, one alternative theory that may does not rely upon non-self being foreign but on being injurious or dangerous [5]. This ‘danger hypothesis’ is supported by the involvement of innate immune system components in the recognition of apoptotic cells (non-infectious/non-dangerous self) and underlines a central point in immunology: it is not what the immune system recognises but how it responds. Whatever the underlying mechanisms that permit differential responses to self and non-self, it is clear that the innate immune system is firmly involved in both.
Clearance of apoptotic cells Over the past decade, the number of putative molecular players involved in the clearance of apoptotic cells has expanded significantly and these have been reviewed
40
Innate immune mechanisms in the resolution of inflammation
Figure 1. A cartoon to illustrate innate immune system components implicated in the clearance of apoptotic cells by phagocytes.
extensively elsewhere [6, 7]. Those molecules that play an important role in both innate immunity to pathogens and in the clearance of apoptotic cells are depicted schematically in Figure 1. These factors comprise cellular receptors and, increasingly, factors that act as opsonins for apoptotic cells, thereby bridging apoptotic cells to phagocytes [8]. While all receptors on macrophages and neutrophils might reasonably be considered innate immune molecules, a few candidates from Figure 1 stand-out as classical innate immune molecules being known primarily as antimicrobial effector molecules and fitting the description of PRRs. It was the discovery of CD14, the prototypic PRR, as an important apoptotic cell receptor that raised the suggestion that innate immune responses of phagocytes to microbes and apoptotic cells may share common components.
CD14 – The prototype PRR CD14 is the prototypical innate immune receptor. It was the first cloned in the late 1980s [9, 10] and identified as a glycosylphosphatidylinositol (GPI-)-anchored membrane glycoprotein [10, 11]. Its widely acknowledged role in the recognition of a wide range of molecular species from microbes (most notably LPS) and its media-
41
Andrew Devitt and Christopher D. Gregory
tion of an inflammatory response identify it clearly as a PRR. However, a large array of ligands from non-microbial origins have also been identified [12].
CD14 and recognition of apoptotic cells The identification of a role for CD14 in the recognition and clearance of apoptotic cells stems from the activity of a murine mAb (61D3) against human monocytes [13] was first established more than two decades ago. This mAb specifically and strongly stained human monocytes and, during screening for its ability to modulate the clearance of apoptotic cells by human macrophages, 61D3 was noted to block apoptotic cell clearance in vitro [14]. Formal identification of the antigen specified by 61D3 proved more difficult but finally an expression cloning approach using Cos cells transiently expressing a cDNA library generated from HL60 cells cloned the 61D3 cDNA [15]. Sequencing led to a surprising result, the antigen defined by 61D3 was the LPS receptor, CD14, a receptor renowned for its ability to elicit strong pro-inflammatory responses [16] and mediate endotoxic shock [17, 18]. At that time, relatively little was understood about the mechanisms and consequences of apoptotic cell clearance by macrophages, although one thing was certain – it was a non-phlogistic process. More striking still was the suggestion that mAb 61D3 defined both the apoptotic cell- and LPS-binding site on CD14 [15]. Following early antibody studies implicating CD14 in apoptotic cell clearance, it has taken a range of in vitro and in vivo studies to elucidate the role of CD14 in apoptotic cell clearance. Initially, over-expression of CD14 in Cos cells was shown to promote the ability of those cells to recognise and clear apoptotic cells in vitro in a manner inhibitable by 61D3 [15]. This role for CD14 was further dissected through the use of interaction assays between macrophages and apoptotic cells undertaken at temperatures non-permissive for phagocytosis revealing that, at least minimally, CD14 is a tethering receptor for apoptotic cells. This is further supported by the observation that soluble CD14 can bind apoptotic cells, suggesting CD14 is capable of interacting directly with apoptotic cells [19]. While in vitro studies provide an important and useful step in identifying candidate molecules implicated in a process, full biological significance is gained through assessment of the consequence of loss of their function in vivo. It is of note that a number of receptors and molecules implicated in the clearance of apoptotic cells through in vitro studies have proved rather disappointing when attentions were turned to in vivo studies in knockout animals [6]. For example the inability of SR-A-deficient mice to present a phenotype in line with the proposed role for SR-A in apoptotic cell clearance [20] has led to widespread acknowledgement of the possibility of redundancy in clearance mechanisms. In marked contrast, in vivo studies of the role of CD14 demonstrated a widespread phenotype with raised numbers of persistent apoptotic cell corpses being detectable in a range of tissues (including thymus, spleen, lung and
42
Innate immune mechanisms in the resolution of inflammation
liver) when CD14 was absent [19]. Further detailed studies indicated that this was due to defective clearance of apoptotic cells rather than increased cell death, with CD14–/– peritoneal macrophages being less competent to remove administered apoptotic cells and CD14–/– thymic phagocytes unable to cope with high loads of thymic cell death following dexamethasone administration. These observations indicate that CD14 plays an important role in apoptotic cell clearance during both physiological and pathological cell death and argue strongly that its role is non-redundant, at least in the context of the mouse strain and tissues investigated. A significant role for CD14 in the resolution of inflammation seems highly likely in light of its ability to remove apoptotic granulocytes [21] and the results described above. Studies are currently underway to address the consequence of CD14 deficiency in a range of inflammatory situations. The precise role for CD14 in the resolution of an inflammatory response is not clear but a key attribute for any molecule involved in resolution must be to function in such a way as not to induce or exacerbate inflammation. CD14 is thus suited to a resolving role, through the tethering and removal of apoptotic cells, as ligation of CD14 by apoptotic cells is not inflammatory [15, 19].
Phagocyte receptors: Scavenger receptors CD36, a class B scavenger receptor, was one of the first macrophage receptors to be implicated in the clearance of apoptotic cells. First identified through mAb inhibition studies [22] and further dissected through over-expression studies [23], CD36 appears to function in concert with the integrin _v`3 (CD51/CD61: the vitronectin receptor, implicated earlier in apoptotic cell clearance [24]) with thrombospondin acting as a molecular ‘bridge’ between the apoptotic neutrophil and the phagocyte [22]. The conservation of scavenger receptors (both presence and function) throughout evolution is highlighted by the discovery of Croquemort in Drosophila. Croquemort, a CD36 superfamily member, mediates clearance of apoptotic cells while playing little role in the clearance of bacteria – perhaps suggesting that evolution of receptors for the clearance of apoptotic cells, at least during development, was followed by a role in host defence [3]. Of particular relevance to this chapter, studies highlighting a role for CD36 in clearance of apoptotic cells were focussed upon the clearance of apoptotic neutrophilic granulocytes, strongly implicating a role for these molecules in resolution of inflammation. Additional scavenger receptors have also been identified as apoptotic cell receptors following in vitro studies, including Lox-1 [25, 26], SR-AI and II (CD204) [27, 28] and SRBI [29–32]. However, these studies focussed upon clearance of apoptotic cells other than inflammatory cells (e.g. thymocytes) and, while surface changes associated with apoptosis are suggested to be conserved [33], the role of these molecules in resolution of inflammation requires direct study. Furthermore, the role
43
Andrew Devitt and Christopher D. Gregory
of scavenger receptors for clearing apoptotic cells in vivo is unclear with knockout studies failing to report any cell clearance defect [20]. This is most likely due to significant redundancy in the function of scavenger receptors, a view that is supported by the observations that macrophages deficient in CD204 show an up-regulation of CD36 [34]. Studies to address the effect of multiple receptor knockouts on apoptotic cell clearance and resolution of inflammation are required to identify the in vivo roles of potentially redundant receptors.
Humoral factors: Complement The discovery of a role for complement components, collectins and pentraxins in the clearance of apoptotic cells emphasised the notion that pattern recognition is clearly more than recognition of PAMPs. It is now clear that molecules of the complement cascade that were previously thought of as defence molecules are also involved in removal of dead and dying cells. Deficiency in C1q is the most powerful genetic risk factor in the aetiology of the autoimmune disease systemic lupus erythematosus (SLE, a condition linked to the failure of apoptotic cell clearance) and in mice deficient in C1q a dramatic kidney defect is evident with persistent apoptotic cells and glomerulonephritis [35]. The role of C1q in clearance of apoptotic cells with particular reference to inflammation was highlighted through the work of Taylor et al. [36], which demonstrated that both resident and inflammatory peritoneal macrophages showed reduced competence for the removal of apoptotic cells in C1q–/– animals – a deficit that could be complemented through the addition of C1q-containing serum. Conflicting reports (from a range of experimental systems) exist as to the extent of activation of the complement cascade required for complement-dependent clearance of apoptotic cells with C1q possibly functioning as a simple opsonin without C3 involvement [36, 37]. Other reports support complement fixation [38] and C3 deposition as the major molecular mechanism underlying complement-dependent clearance of apoptotic cells [39–41]. Deposition of C3b on cell surfaces is rapidly followed by proteolytic cleavage to form iC3b and apoptotic cell-associated iC3b has been shown to promote apoptotic cell removal [42]. Despite any perceived differences in these reports, it is clear that complement components contribute to apoptotic cell removal and any conflicts between reports relating to complement activation may well be due to timing variation in the experimental systems. It is reasonable that following C1q opsonisation of apoptotic cells macrophages may bind and remove apoptotic cells but delay at this point may permit activation of complement to allow the involvement of other, downstream, complement components in the process. This progressive involvement of different factors is an attractive and economical model of apoptotic cell removal where additional factors only become involved in clearance once others have failed.
44
Innate immune mechanisms in the resolution of inflammation
If complement activation provides enhanced apoptotic cell clearance, the stimulus for activation must be addressed. A possible role for phosphatidylserine, exposed at the apoptotic cell surface, in the activation of complement (via the classical and alternative pathways) has been suggested as a mechanism leading to the deposition of iC3b on the apoptotic cell surface [39]. A more detailed mechanism for activation of complement by the classical pathway at the apoptotic cell surface has also been put forward where natural IgM antibodies opsonise the apoptotic cell [41, 40, 43] and initiate complement activation. Such involvement of IgM (while not essential for complement-mediated apoptotic cell removal) is thought to be required for the efficient removal of apoptotic cells in vivo [41] and natural IgM has been shown to be the major pathway leading to complement activation via the classical pathway. It is suggested that these natural antibodies opsonise apoptotic cells via the recognition of oxidised lipids at the apoptotic cell surface [44] or through recognition of altered phospholipids that arise during apoptosis as a result of the activation of phospholipase A2 during apoptosis [45]. Interestingly, this latter report further proposes that apoptotic cell opsonisation with IgM also activates non-classical pathways of activation, albeit to a lesser extent. It is of note that the serum acute-phase protein CRP (a member of the pentraxin family also implicated in apoptotic cell clearance, see below) is capable of binding to C1q and amplifying complement activation. It has been shown that CRP binds apoptotic cells, promoting activation of the classical pathway of complement activation and iC3b deposition, while preventing assembly of downstream complement factors (e.g. membrane attack complex) through the recruitment of factor H, a complement regulatory protein [46]. All of the effects of CRP are dependent upon C1q and, in inflammatory situations where CRP levels may increase many fold, this may provide an important mechanisms for promoting complement activation and apoptotic cell clearance. It is clear that there is significant research into the molecular mechanisms underlying complement-dependent opsonisation and clearance of apoptotic cells. So what of the receptors? CR3 (CD11a/CD18; _m`2) and CR4 (_d`2) have been implicated in the removal of iC3b-opsonised apoptotic cells through the use of antibody inhibition studies [42]. While CR3 and CR4 are attractive candidate iC3b receptors, a new candidate receptor, CRIg (complement receptor of the immunoglobulin superfamily), has been identified [47]. While CRIg is highly expressed on Kupffer cells and functions for removal of complement-opsonised circulating pathogens, it is notably expressed by a number of tissue resident macrophages (e.g. alveolar, synovial), although a formal role in the clearance of iC3b-opsonised apoptotic cells is yet to be addressed. Phagocyte receptors for C1q have been implicated in apoptotic cell clearance with calreticulin and CD91 binding the collagenous tails of C1q [37, 48]. Other receptors have been implicated but to date the involvement in apoptotic cell clearance remains unclear. For example, while CD93 (C1qRp) is involved in modulat-
45
Andrew Devitt and Christopher D. Gregory
ing phagocytic capacity [49] and contributes to apoptotic cell clearance in vivo, it appears, at least in mice, not to be required for C1q-dependent clearance [50].
Humoral factors: Collectins Additional humoral factors of the innate immune system, the collectins, have been implicated in the clearance of apoptotic cells. Collectins comprise a family of C-type lectins with complex structures based upon a monomer containing a globular head region with carbohydrate-recognition domain and a collagenous tail arranged into trimers and associated multimers [51, 52]. The lung collectin proteins surfactant protein A and D (SP-A and SP-D) and the circulating serum collectin mannose-binding lectin (MBL) [37, 48, 53, 54] have been shown to bind apoptotic cells and promote their clearance. This work has been supported by in vivo analyses to indicate that a deficiency in SP-D [48] can lead to an incompetence to clear apoptotic cells instilled into the lungs (while SP-A and C1q deficiency showed little effect) [48]. This work is in line with previous ex vivo studies indicating that SP-D and, to a lesser extent, SP-A promote apoptotic neutrophil clearance by alveolar macrophages, whereas MBL and C1q showed no effect [53]. Recent work in vivo, however, has shown that MBL-defective mice [55] fail to efficiently clear apoptotic cells injected into the peritoneal cavity and raises the possibility that variations in reports are the result of different experimental model systems or tissue-specific effects of individual molecules. This latter report supports the results of earlier work using CD14-deficient mice, which demonstrated for the first time that it is possible to have defective apoptotic cell clearance (with persistence of corpses) that does not lead inextricably to inflammation or autoimmunity. This suggests a non-redundant role for MBL in apoptotic cell clearance where large numbers of apoptotic cells may be required to be removed rapidly, as may occur at the site of inflammation, and has led to the suggestion that the mechanisms for tethering apoptotic cells and for induction of the anti-inflammatory effects of apoptotic cells can be uncoupled [19]. Collectin (and C1q) receptors have been implicated in apoptotic cell clearance. Calreticulin and CD91 are involved in C1q-, SP-A- and SP-D-dependent clearance of apoptotic cells in the lung through binding of the collagenous tails of the collectin family [37, 48]. While calreticulin was proposed to act with CD91 on the surface of the phagocyte as a “common collectin receptor complex” [48], it has recently been suggested that, through apoptosis-dependent redistribution of CD47, calreticulin on the apoptotic cell surface becomes reorganised such that it can interact with CD91 on the phagocyte (in trans) to promote clearance [56]. Interestingly, SIRP-_ on phagocytes has been shown to bind SP-A and SP-D via their globular head region [57], suggesting a possible mechanism for modulating the inflammatory environment. This binding is the reverse of the orientation previously suggested where the globular heads bind the apoptotic cell surface and collagenous tails mediate receptor
46
Innate immune mechanisms in the resolution of inflammation
binding. How this might, if at all, play a role in apoptotic cell clearance as a direct collectin receptor has not been addressed. CD14 has also been suggested to function in the binding of SP-A, SP-D [58, 59] and mannose-binding protein [60]. The role of collectins in modulating the inflammatory environment may be the major function of these molecules in the clearance of apoptotic cells [37, 57, 61].
Humoral factors: Pentraxins The pentraxins are another family of soluble innate immune factors that may be upregulated during the acute-phase response to infection and tissue damage. As their name suggests, they have a pentameric structure and are represented in short forms (e.g. CRP, SAP) and long forms (e.g. PTX3). These pentraxin members have been shown to bind apoptotic cells and, in the case of CRP, promote clearance through involvement of complement (see above [46]). SAP also binds to apoptotic cells, albeit late apoptotic cells, via phosphatidylethanolamine in blebs [62] and mediates their uptake by macrophages [63]. The long pentraxin PTX3, however, is somewhat different; it appears to bind apoptotic cells (lymphocytes and granulocytes) and, to a lesser extent, necrotic cells and prevents uptake by dendritic cells [64, 65]. This was suggested as a mechanism by which autoantigens are sequestered from antigen-presenting cells for the control of potential autoimmune reactions. This work has been followed up with similar results addressing uptake by macrophages and has been suggested as a causative factor in the appearance of persistent apoptotic neutrophils at the site of vasculitis [66]. Interestingly, the pentraxins, at least in part, appear to bind to similar sites on apoptotic cells by virtue of the ability of CRP and SAP to block binding of labelled PTX3. CRP, SAP and PTX3 are all capable of binding C1q to activate the classical complement cascade and, as such, the role for CRP in activating complement at the apoptotic cell surface (above) may be a family-wide characteristic [67–69]. How then does PTX3 differ in its effects upon apoptotic cell clearance? One possibility is that PTX3 binds and sequesters soluble C1q to limit its action in binding apoptotic cells and activating C3 [65]. The significant increase in circulating CRP levels during inflammation [70] makes this an attractive candidate that is pro-resolution from the onset of inflammation as has been suggested for other factors [71]. Multiple receptors for CRP were suggested from analyses that indicated the presence of a low-affinity receptor for CRP (identified as FcaRI [72]) and a high-affinity receptor for CRP (identified as FcaRII [73]). Further analyses using mice deficient in individual or combinations of FcaR were used to identify the receptors used for binding of pentraxin-opsonised apoptotic cells [74] and highlighted a requirement for FcR a chain. Interestingly, this report showed that only SAP (not CRP, the major induced acute-phase protein in humans) opsonised and promoted clearance of apoptotic neutrophils by human macrophages despite both SAP and CRP medi-
47
Andrew Devitt and Christopher D. Gregory
ating clearance of apoptotic Jurkat cells by the murine macrophage-like cell line J774. However, in this study, heat-inactivated serum was used and likely therefore removed the ability of complement to play a part in mediating CRP function. The pentraxins do appear, however, to use FcaRI and/or FcaRIII for the clearance of apoptotic cells.
Induced innate immune responses Although the innate immune response lacks the education and memory of the acquired immune system, the ability to induce certain components ad hoc provides an important level of control and refinement to the innate immune system. Chemokines are an important example of such induced innate immune responses and underlie the recruitment of inflammatory cells to sites of infection or of tissue damage from circulation. Such responses have been implicated in the recruitment of phagocytes to the site of cell death [6, 75] via release of apoptotic blebs [76], S19 ribosomal protein homodimers or lysophosphatidylcholine (LPC) from apoptotic cells [77]. The generation of LPC, like the generation of epitopes for the binding of natural IgM is dependent upon the cleavage of surface phospholipids during apoptosis [45, 77]. The large number of cell deaths by apoptosis at an acutely inflamed site makes it highly unlikely that resident phagocytes (“professional” or “amateur”) would be able to cope without recruited help. The extent to which apoptotic cellderived chemoattractants play a role in recruitment of phagocytes to sites of inflammation is still unknown and, as yet, no chemokines have been implicated in the attraction of phagocytes to apoptotic cells.
“Pyre prevention” As pattern recognition molecules of the innate immune system (e.g. CD14 and MBL) are implicated strongly in pathogen recognition and defence via inflammation, it is intriguing that they also mediate removal of apoptotic cells (a non-phlogistic process). The basis of such differing responses is a current challenge in this area of research and studies are underway to identify molecular mechanisms that underlie differing responses to PRR ligation by PAMPs and ACAMPs. A simple explanation of such a dichotomy may be that ACAMPs (as threedimensional structural analogues of PAMPs) do not actually exist and PRRs are ligated in a different and non-inflammatory manner by apoptotic cell-associated molecules (e.g. via ligation of different portions of the receptor). Indeed, formal identification of an ACAMP is yet to be reported; however, epitope mapping using anti-CD14 mAbs shows close similarity in the LPS and apoptotic cell binding sites on CD14 [15].
48
Innate immune mechanisms in the resolution of inflammation
The “infectious non-self” model of recognition proposed by Janeway (suggesting that the innate immune system discriminates ‘self’ from ‘infectious non-self’ via recognition of PAMPs by PRRs) would be difficult to reconcile with any formal identification of an ACAMP and evidence of strong structural identity between PAMPs and ACAMPs. Such results would, however, be consistent with an alternative hypothesis of immune recognition, the ‘Danger Model’ where the nature of the receptor is not the critical factor in deciding any resultant response but the presence or absence of ‘danger signals’ [5]. In the case of apoptotic cell clearance, there would be a predicted lack of such danger permitting “inflammatory” receptors, such as CD14, to mediate quiet removal of unwanted cell corpses. However, in the event of failed clearance of apoptotic cells at the site of inflammation, resultant necrotic cells could provide danger signals (e.g. HMGB-1) and subsequent immune stimulation [78, 79]. An addition to this is the idea (irrespective of whether ligation of PRRs is inherently inflammatory) that the reason for the quiet nature of apoptotic cell removal is in fact the presence of ‘calming influences’. Such immunomodulatory influences (e.g. the release of TGF-`1 and IL-10) have been noted from phagocytes clearing apoptotic cells and such immunosuppression appears powerful, even in the face of potent pro-inflammatory stimuli such as LPS [80, 81]. Furthermore, while such cytokine production promotes an anti-inflammatory environment, it also tailors phagocytes. IL-10 is known to direct macrophages towards an “alternatively activated” phenotype, so-called “M2” [82], which are notable for their preferential clearance of early apoptotic cells in a manner that is dependent upon CD14-mediated binding [83]. Taken together, these strands promote the idea that the appearance of apoptotic cells at a site (e.g. inflamed tissue) would promote an immunosuppressive milieu that is highly supportive of phagocytes for the clearance of apoptotic cells in a manner dependent upon component molecules of the innate immune system. The basis of any response to phagocytosis using PRRs is most likely defined in the constitution of the proposed phagocytic synapse [7, 84] that is assembled in response to ligation of pathogens or apoptotic cells. The net balance of responses to ligation of a range of receptors and signalling pathways will likely dictate the outcome. CD14, a GPI-anchored glycoprotein that lacks signalling capacity through a transmembrane domain, is an interesting case model. For responses to LPS, CD14 functions in association with TLR4 (to elicit inflammatory signals), whereas it seems likely that responses to apoptotic cells utilise other co-receptors (or alternatively CD14 acts as a simple tethering molecule). The basis of differing responses to CD14 ligation by LPS or apoptotic cells is yet to be fully characterised, but the discovery of TLR4 as an important molecule in responses to LPS may have partly answered the question. TLRs appear not to be involved in recognition of apoptotic cells and indeed may negatively regulate the degradation of engulfed apoptotic cells [85]. Furthermore, phagocytosis of bacteria but not apoptotic cells was inhibited by the absence of TLR signalling, supporting a lack of involvement of TLRs in apoptotic
49
Andrew Devitt and Christopher D. Gregory
cell clearance [86]. An alternative signalling partner for CD14 for AC clearance may yet be identified and candidate molecules include the `2 integrins [87].
Summary Removal of effete inflammatory cells in an immunologically quiet, controlled fashion is vital to efficient resolution of inflammation. The ultimate step in resolution is the recognition and removal of apoptotic cells by phagocytes via a process involving a range of components of the innate immune system functioning in non-inflammatory/anti-inflammatory mode. The involvement of PRR in both inflammatory defence and anti-inflammatory removal of apoptotic cells is a key issue for study in the field of apoptotic cell research and has led to suggestions that PRRs evolved initially for the removal of cell deaths during development [3, 5] and later evolved a role in defence following PRR subversion by pathogens. As such, it may now be surprising to identify innate immune components that are not involved in clearance of apoptotic cells.
References 1
2 3 4 5 6 7 8
9 10
50
Fadok VA, Bratton DL, Guthrie L, Henson PM (2001) Differential effects of apoptotic versus lysed cells on macrophage production of cytokines: role of proteases. J Immunol 166: 6847–6854 Janeway CA Jr (1989) Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 54: 1–13 Franc NC, White K, Ezekowitz RA (1999) Phagocytosis and development: Back to the future. Curr Opin Immunol 11: 47–52 Gregory CD (2000) CD14-dependent clearance of apoptotic cells: Relevance to the immune system. Curr Opin Immunol 12: 27–34 Matzinger P (2002) The danger model: A renewed sense of self. Science 296: 301–305 Gregory CD, Devitt A (2004) The macrophage and the apoptotic cell: An innate immune interaction viewed simplistically? Immunology 113: 1–14 Savill J, Dransfield I, Gregory C, Haslett C (2002) A blast from the past: Clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2: 965–975 Hart SP, Smith JR, Dransfield I (2004) Phagocytosis of opsonized apoptotic cells: Roles for ‘old-fashioned’ receptors for antibody and complement. Clin Exp Immunol 135: 181–185 Ferrero E, Goyert SM (1988) Nucleotide sequence of the gene encoding the monocyte differentiation antigen, CD14. Nucleic Acids Res 16: 4173 Simmons DL, Tan S, Tenen DG, Nicholson-Weller A, Seed B (1989) Monocyte antigen CD14 is a phospholipid anchored membrane protein. Blood 73: 284–289
Innate immune mechanisms in the resolution of inflammation
11
12 13
14
15
16 17
18
19
20
21
22
23 24 25
26
Haziot A, Chen S, Ferrero E, Low MG, Silber R, Goyert SM (1988) The monocyte differentiation antigen, CD14, is anchored to the cell membrane by a phosphatidylinositol linkage. J Immunol 141: 547–552 Gregory CD, Devitt A (2002) Innate immunity and apoptosis: CD14-dependent clearance of apoptotic cells. Wiley-VCH, Weinheim Ugolini V, Nunez G, Smith RG, Stastny P, Capra JD (1980) Initial characterization of monoclonal antibodies against human monocytes. Proc Natl Acad Sci USA 77: 6764– 6768 Flora PK, Gregory CD (1994) Recognition of apoptotic cells by human macrophages: Inhibition by a monocyte/macrophage-specific monoclonal antibody. Eur J Immunol 24: 2625–2632 Devitt A, Moffatt OD, Raykundalia C, Capra JD, Simmons DL, Gregory CD (1998) Human CD14 mediates recognition and phagocytosis of apoptotic cells. Nature 392: 505–509 Ulevitch RJ, Tobias PS (1995) Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu Rev Immunol 13: 437–457 Haziot A, Ferrero E, Kontgen F, Hijiya N, Yamamoto S, Silver J, Stewart CL, Goyert SM (1996) Resistance to endotoxin shock and reduced dissemination of Gram-negative bacteria in CD14-deficient mice. Immunity 4: 407–414 Ferrero E, Jiao D, Tsuberi BZ, Tesio L, Rong GW, Haziot A, Goyert SM (1993) Transgenic mice expressing human CD14 are hypersensitive to lipopolysaccharide. Proc Natl Acad Sci USA 90: 2380–2384 Devitt A, Parker KG, Ogden CA, Oldreive C, Clay MF, Melville LA, Bellamy CO, LacyHulbert A, Gangloff SC, Goyert SM et al (2004) Persistence of apoptotic cells without autoimmune disease or inflammation in CD14–/– mice. J Cell Biol 167: 1161–1170 Platt N, Suzuki H, Kodama T, Gordon S (2000) Apoptotic thymocyte clearance in scavenger receptor class A-deficient mice is apparently normal. J Immunol 164: 4861– 4867 Devitt A, Pierce S, Oldreive C, Shingler WH, Gregory CD (2003) CD14-dependent clearance of apoptotic cells by human macrophages: The role of phosphatidylserine. Cell Death Differ 10: 371–382 Savill J, Hogg N, Ren Y, Haslett C (1992) Thrombospondin cooperates with CD36 and the vitronectin receptor in macrophage recognition of neutrophils undergoing apoptosis. J Clin Invest 90: 1513–1522 Ren Y, Silverstein RL, Allen J, Savill J (1995) CD36 gene transfer confers capacity for phagocytosis of cells undergoing apoptosis. J Exp Med 181: 1857–1862 Savill J, Dransfield I, Hogg N, Haslett C (1990) Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature 343: 170–173 Oka K, Sawamura T, Kikuta K, Itokawa S, Kume N, Kita T, Masaki T (1998) Lectin-like oxidized low-density lipoprotein receptor 1 mediates phagocytosis of aged/apoptotic cells in endothelial cells. Proc Natl Acad Sci USA 95: 9535–9540 Murphy JE, Tacon D, Tedbury PR, Hadden JM, Knowling S, Sawamura T, Peckham
51
Andrew Devitt and Christopher D. Gregory
27
28
29
30
31
32
33
34
35
36
37
38
52
M, Phillips SE, Walker JH, Ponnambalam S (2006) LOX-1 scavenger receptor mediates calcium-dependent recognition of phosphatidylserine and apoptotic cells. Biochem J 393: 107–115 Platt N, Suzuki H, Kurihara Y, Kodama T, Gordon S (1996) Role for the class A macrophage scavenger receptor in the phagocytosis of apoptotic thymocytes in vitro. Proc Natl Acad Sci USA 93: 12456–12460 Terpstra V, Kondratenko N, Steinberg D (1997) Macrophages lacking scavenger receptor A show a decrease in binding and uptake of acetylated low-density lipoprotein and of apoptotic thymocytes, but not of oxidatively damaged red blood cells. Proc Natl Acad Sci USA 94: 8127–8131 Fukasawa M, Adachi H, Hirota K, Tsujimoto M, Arai H, Inoue K (1996) SRB1, a class B scavenger receptor, recognizes both negatively charged liposomes and apoptotic cells. Exp Cell Res 222: 246–250 Murao K, Terpstra V, Green SR, Kondratenko N, Steinberg D, Quehenberger O (1997) Characterization of CLA-1, a human homologue of rodent scavenger receptor BI, as a receptor for high density lipoprotein and apoptotic thymocytes. J Biol Chem 272: 17551–17557 Shiratsuchi A, Kawasaki Y, Ikemoto M, Arai H, Nakanishi Y (1999) Role of class B scavenger receptor type I in phagocytosis of apoptotic rat spermatogenic cells by Sertoli cells. J Biol Chem 274: 5901–5908 Imachi H, Murao K, Hiramine C, Sayo Y, Sato M, Hosokawa H, Ishida T, Kodama T, Quehenberger O, Steinberg D et al (2000) Human scavenger receptor B1 is involved in recognition of apoptotic thymocytes by thymic nurse cells. Lab Invest 80: 263–270 van den Eijnde SM, Boshart L, Baehrecke EH, De Zeeuw CI, Reutelingsperger CP, Vermeij-Keers C (1998) Cell surface exposure of phosphatidylserine during apoptosis is phylogenetically conserved. Apoptosis 3: 9–16 Komohara Y, Terasaki Y, Kaikita K, Suzuki H, Kodama T, Takeya M (2005) Clearance of apoptotic cells is not impaired in mouse embryos deficient in class A scavenger receptor types I and II (CD204). Dev Dyn 232: 67–74 Botto M, Dell’Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, Loos M, Pandolfi PP, Walport MJ (1998) Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 19: 56–59 Taylor PR, Carugati A, Fadok VA, Cook HT, Andrews M, Carroll MC, Savill JS, Henson PM, Botto M, Walport MJ (2000) A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med 192: 359–366 Ogden CA, deCathelineau A, Hoffmann PR, Bratton D, Ghebrehiwet B, Fadok VA, Henson PM (2001) C1q and mannose binding lectin engagement of cell surface calreticulin and CD91 initiates macropinocytosis and uptake of apoptotic cells. J Exp Med 194: 781–795 Nauta AJ, Trouw LA, Daha MR, Tijsma O, Nieuwland R, Schwaeble WJ, Gingras AR, Mantovani A, Hack EC, Roos A (2002) Direct binding of C1q to apoptotic cells and cell blebs induces complement activation. Eur J Immunol 32: 1726–1736
Innate immune mechanisms in the resolution of inflammation
39 40
41
42 43 44
45
46
47
48
49
50
51 52
Mevorach D, Mascarenhas JO, Gershov D, Elkon KB (1998) Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 188: 2313–2320 Quartier P, Potter PK, Ehrenstein MR, Walport MJ, Botto M (2004) Predominant role of IgM-dependent activation of the classical pathway in the clearance of dying cells by murine bone marrow-derived macrophages in vitro. Eur J Immunol 35: 252–260 Ogden CA, Kowalewski R, Peng Y, Montenegro V, Elkon KB (2005) IGM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity 38: 259–264 Takizawa F, Tsuji S, Nagasawa S (1996) Enhancement of macrophage phagocytosis upon iC3b deposition on apoptotic cells. FEBS Lett 397: 269–272 Peng Y, Kowalewski R, Kim S, Elkon KB (2005) The role of IgM antibodies in the recognition and clearance of apoptotic cells. Mol Immunol 42: 781–787 Chang MK, Bergmark C, Laurila A, Horkko S, Han KH, Friedman P, Dennis EA, Witztum JL (1999) Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: Evidence that oxidation-specific epitopes mediate macrophage recognition. Proc Natl Acad Sci USA 96: 6353–6358 Kim SJ, Gershov D, Ma X, Brot N, Elkon KB (2002) I-PLA(2) activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation. J Exp Med 196: 655–665 Gershov D, Kim S, Brot N, Elkon KB (2000) C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: Implications for systemic autoimmunity. J Exp Med 192: 1353–1364 Helmy KY, Katschke KJ Jr, Gorgani NN, Kljavin NM, Elliott JM, Diehl L, Scales SJ, Ghilardi N, van Lookeren Campagne M (2006) CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell 124: 915–927 Vandivier RW, Ogden CA, Fadok VA, Hoffmann PR, Brown KK, Botto M, Walport MJ, Fisher JH, Henson PM, Greene KE (2002) Role of surfactant proteins A, D, and C1q in the clearance of apoptotic cells in vivo and in vitro: calreticulin and CD91 as a common collectin receptor complex. J Immunol 169: 3978–3986 Nepomuceno RR, Ruiz S, Park M, Tenner AJ (1999) C1qRP is a heavily O-glycosylated cell surface protein involved in the regulation of phagocytic activity. J Immunol 162: 3583–3589 Norsworthy PJ, Fossati-Jimack L, Cortes-Hernandez J, Taylor PR, Bygrave AE, Thompson RD, Nourshargh S, Walport MJ, Botto M (2004) Murine CD93 (C1qRp) contributes to the removal of apoptotic cells in vivo but is not required for C1q-mediated enhancement of phagocytosis. J Immunol 172: 3406–3414 van de Wetering JK, van Golde LM, Batenburg JJ (2004) Collectins: Players of the innate immune system. Eur J Biochem 271: 1229–1249 Kishore U, Greenhough TJ, Waters P, Shrive AK, Ghai R, Kamran MF, Bernal AL, Reid
53
Andrew Devitt and Christopher D. Gregory
53 54 55
56
57
58
59 60
61
62
63
64
65
66
54
KB, Madan T, Chakraborty T (2006) Surfactant proteins SP-A and SP-D: structure, function and receptors. Mol Immunol 43: 1293–1315 Schagat TL, Wofford JA, Wright JR (2001) Surfactant protein A enhances alveolar macrophage phagocytosis of apoptotic neutrophils. J Immunol 166: 2727–2733 Clark H, Palaniyar N, Strong P, Edmondson J, Hawgood S, Reid KB (2002) Surfactant protein D reduces alveolar macrophage apoptosis in vivo. J Immunol 169: 2892–2899 Stuart LM, Takahashi K, Shi L, Savill J, Ezekowitz RA (2005) Mannose-binding lectindeficient mice display defective apoptotic cell clearance but no autoimmune phenotype. J Immunol 174: 3220–3226 Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, Bratton DL, Oldenborg PA, Michalak M, Henson PM (2005) Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123: 321–334 Gardai SJ, Xiao YQ, Dickinson M, Nick JA, Voelker DR, Greene KE, Henson PM (2003) By binding SIRPalpha or calreticulin/CD91, lung collectins act as dual function surveillance molecules to suppress or enhance inflammation. Cell 115: 13–23 Sano H, Sohma H, Muta T, Nomura S, Voelker DR, Kuroki Y (1999) Pulmonary surfactant protein A modulates the cellular response to smooth and rough lipopolysaccharides by interaction with CD14. J Immunol 163: 387–395 Sano H, Chiba H, Iwaki D, Sohma H, Voelker DR, Kuroki Y (2000) Surfactant proteins A and D bind CD14 by different mechanisms. J Biol Chem 275: 22442–22451 Chiba H, Sano H, Iwaki D, Murakami S, Mitsuzawa H, Takahashi T, Konishi M, Takahashi H, Kuroki Y (2001) Rat mannose-binding protein A binds CD14. Infect Immun 69: 1587–1592 Fraser DA, Bohlson SS, Jasinskiene N, Rawal N, Palmarini G, Ruiz S, Rochford R, Tenner AJ (2006) C1q and MBL, components of the innate immune system, influence monocyte cytokine expression. J Leukoc Biol 80: 107–116 Familian A, Zwart B, Huisman HG, Rensink I, Roem D, Hordijk PL, Aarden LA, Hack CE (2001) Chromatin-independent binding of serum amyloid P component to apoptotic cells. J Immunol 167: 647–654 Bijl M, Horst G, Bijzet J, Bootsma H, Limburg PC, Kallenberg CG (2003) Serum amyloid P component binds to late apoptotic cells and mediates their uptake by monocytederived macrophages. Arthritis Rheum 48: 248–254 Rovere P, Peri G, Fazzini F, Bottazzi B, Doni A, Bondanza A, Zimmermann VS, Garlanda C, Fascio U, Sabbadini MG et al (2000) The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood 96: 4300–4306 Baruah P, Dumitriu IE, Peri G, Russo V, Mantovani A, Manfredi AA, Rovere-Querini P (2006) The tissue pentraxin PTX3 limits C1q-mediated complement activation and phagocytosis of apoptotic cells by dendritic cells. J Leukoc Biol 80: 87–95 van Rossum AP, Fazzini F, Limburg PC, Manfredi AA, Rovere-Querini P, Mantovani A, Kallenberg CG (2004) The prototypic tissue pentraxin PTX3, in contrast to the short
Innate immune mechanisms in the resolution of inflammation
67
68
69
70 71 72 73 74
75
76
77
78 79
80 81
pentraxin serum amyloid P, inhibits phagocytosis of late apoptotic neutrophils by macrophages. Arthritis Rheum 50: 2667–2674 Jiang HX, Siegel JN, Gewurz H (1991) Binding and complement activation by C-reactive protein via the collagen-like region of C1q and inhibition of these reactions by monoclonal antibodies to C-reactive protein and C1q. J Immunol 146: 2324–2330 Nauta AJ, Bottazzi B, Mantovani A, Salvatori G, Kishore U, Schwaeble WJ, Gingras AR, Tzima S, Vivanco F, Egido J et al (2003) Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur J Immunol 33: 465–473 Ying SC, Gewurz AT, Jiang H, Gewurz H (1993) Human serum amyloid P component oligomers bind and activate the classical complement pathway via residues 14–26 and 76–92 of the A chain collagen-like region of C1q. J Immunol 150: 169–176 Pepys MB, Hirschfield GM (2003) C-reactive protein: a critical update. J Clin Invest 111: 1805–1812 Serhan CN, Savill J (2005) Resolution of inflammation: The beginning programs the end. Nat Immunol 6: 1191–1197 Marnell LL, Mold C, Volzer MA, Burlingame RW, Du Clos TW (1995) C-reactive protein binds to Fc gamma RI in transfected COS cells. J Immunol 155: 2185–2193 Bharadwaj D, Stein MP, Volzer M, Mold C, Du Clos TW (1999) The major receptor for C-reactive protein on leukocytes is Fcgamma receptor II. J Exp Med 190: 585–590 Mold C, Baca R, Du Clos TW (2002) Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through Fcgamma receptors. J Autoimmun 19: 147–154 Truman LA, Ogden CA, Howie SE, Gregory CD (2004) Macrophage chemotaxis to apoptotic Burkitt’s lymphoma cells in vitro: role of CD14 and CD36. Immunobiology 209: 21–30 Segundo C, Medina F, Rodriguez C, Martinez-Palencia R, Leyva-Cobian F, Brieva JA (1999) Surface molecule loss and bleb formation by human germinal center B cells undergoing apoptosis: role of apoptotic blebs in monocyte chemotaxis. Blood 94: 1012–1020 Lauber K, Bohn E, Krober SM, Xiao YJ, Blumenthal SG, Lindemann RK, Marini P, Wiedig C, Zobywalski A, Baksh S et al (2003) Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 113: 717– 730 Scaffidi P, Misteli T, Bianchi ME (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418: 191–195 Rovere-Querini P, Capobianco A, Scaffidi P, Valentinis B, Catalanotti F, Giazzon M, Dumitriu IE, Muller S, Iannacone M, Traversari C et al (2004) HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep 5: 825–830 Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I (1997) Immunosuppressive effects of apoptotic cells. Nature 390: 350–351 Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM (1998) Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine
55
Andrew Devitt and Christopher D. Gregory
82 83
84 85
86 87
56
production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 101: 890–898 Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3: 23–35 Xu W, Roos A, Schlagwein N, Woltman AM, Daha MR, van Kooten C (2006) IL-10producing macrophages preferentially clear early apoptotic cells. Blood 107: 4930– 4937 Fadok VA, Bratton DL, Henson PM (2001) Phagocyte receptors for apoptotic cells: recognition, uptake, and consequences. J Clin Invest 108: 957–962 Shiratsuchi A, Watanabe I, Takeuchi O, Akira S, Nakanishi Y (2004) Inhibitory effect of Toll-like receptor 4 on fusion between phagosomes and endosomes/lysosomes in macrophages. J Immunol 172: 2039–2047 Blander JM, Medzhitov R (2004) Regulation of phagosome maturation by signals from Toll-like receptors. Science 304: 1014–1018 Petty HR, Todd RF 3rd (1996) Integrins as promiscuous signal transduction devices. Immunol Today 17: 209–212
Cell surface molecular changes associated with apoptosis Ian Dransfield1, Sandra Franz2, Kim Wilkinson1, Aisleen McColl1, Martin Herrmann2 and Simon P. Hart1 1
MRC Centre for Inflammation Research, University of Edinburgh Medical School, Teviot Place, Edinburgh EH8 9AG, UK; 2Institute for Immunology, FAU Erlangen-Nuremberg, Glückstrasse 4a, 91054 Erlangen, Germany
Cell surface receptors Regulation of cellular responses to micro-environmental stimuli is achieved through cell surface receptors, which may assemble into complexes that permit the bi-directional transmission of information across the plasma membrane. It has been estimated that circulating lymphocytes may express several hundred different surface receptors [1], which may confer specificity for an equivalent number of extracellular cues. The expression and function of these critical portals of communication are thus extremely tightly regulated to ensure appropriate cellular responses, including altered adhesion and migration, activation and cellular proliferation. In this chapter we consider the changes in cell surface receptor profiles that are associated with programmed cell death or apoptosis, discussing the implications in terms of their influence upon cellular responses and upon processes that impact upon disease pathogenesis. Many studies of the process of apoptosis have been performed in vitro, using model systems in which cell death is initiated following chemical or radiation (e.g. ultraviolet) insult. Alternatively, apoptosis may be induced by ligation of death receptors leading to activation of the caspase cascade within the cell. Whether the changes observed in these in vitro systems mimic physiological death within tissues is uncertain, but for the purposes of this review, we assume that many of the changes that are initiated also occur on cells as they undergo apoptosis in situ.
Apoptosis As discussed elsewhere in this volume, apoptosis is a physiological form of cell death that initiates a defined series of biochemical changes within the cell leading to the destruction of proteins, DNA and carbohydrates through the activation of a variety of proteases, nucleases and glycosidases [2, 3]. These changes result in the disruption of the cytoskeleton [4], altering intracellular transport [5, 6] and, The Resolution of Inflammation, edited by Adriano G. Rossi and Deborah A. Sawatzky © 2008 Birkhäuser Verlag Basel/Switzerland
57
Ian Dransfield et al.
crucially for the molecular changes that occur on the plasma membrane, movement of vesicles within the cell [6]. It is now clear that, while these characteristics of apoptosis are broadly true, there may be some variation when apoptosis is specifically accelerated following interactions of cells with pathogens including viruses, bacteria and mycobacteria. Indeed, there are pathogen-specific alterations in gene expression profiles associated with apoptosis [7], which may alter surface molecular profiles. Importantly, apoptosis is usually associated with the rapid removal of cells from tissues either by neighbouring cells or by “professional” phagocytic cells [8]. In this way the potentially harmful intracellular contents of apoptotic cells are prevented from being released and are disposed of within the cell responsible for clearing it. This clearance process represents an important mechanism for the removal of large numbers of cells that undergo programmed cell death each day. Furthermore, it is now widely accepted that removal of dying cells is actually more than just a silent clearance pathway, leading to alteration of cellular behaviour in the phagocytic cell that are often considered anti-inflammatory through the suppression of pro-inflammatory cytokine production and induction of IL-10 and TGF-` release [9–11]. A large array of phagocyte receptors have been reported to contribute to the recognition process [12]. In addition, it has been reported that disablement of cell detachment may contribute to apoptotic cell uptake by phagocytes [13]. It is likely that the responses of phagocytes to apoptotic cell uptake will be determined by the repertoire of phagocyte receptors that are engaged during the binding and subsequent internalisation of apoptotic cells. Crucially, in the absence of phagocytic removal, cells that have undergone apoptosis are likely to progress to late apoptosis and ultimately to secondary necrosis. The balance between apoptotic, late apoptotic and necrotic cell death within tissues is therefore likely to impact on responses of cells within tissues and development of immune responses [14].
Membrane alterations associated with apoptosis One of the best-characterized surface molecular alterations associated with apoptosis in many different cell types is the exposure of the anionic phospholipid, phosphatidylserine (PS), on the outer leaflet of the plasma membrane [15]. On viable cells, anionic phospholipids are maintained on the inner leaflet of the plasma membrane through the action of specific phospholipid translocases. Exposure of PS upon the apoptotic cell membrane appears to represent a critical determinant of their immunosuppressive and anti-inflammatory effects of apoptotic cells upon neighbouring cell types. A number of specific adaptor proteins, including Gas6, `2-GPI, and MFG-E8 have been shown to bind to PS [16, 17] and, despite the problems with the definitive identification of the PS receptor [18, 19], it remains possible that phagocytes are capable of directly recognising PS. Interest-
58
Cell surface molecular changes associated with apoptosis
ingly, reported inhibition of phagocytosis of apoptotic cells by liposomes containing PS is seldom complete, implying involvement of other receptor pathways in the recognition process.
The neutrophil – Surface alterations associated with apoptosis In considering changes in the plasma membrane molecules that accompany apoptosis, the neutrophil is discussed here as a model cell type. The neutrophil granulocyte is the archaetypal inflammatory leukocyte that is the major subset (> 70% of circulating leukocytes) present in the peripheral blood and is the first cell type recruited in innate defences against invading pathogens [20]. In response to infection or tissue injury, neutrophils are rapidly (within minutes) recruited into tissues, binding and transmigrating across activated endothelial cells [21]. Specific recruitment of neutrophils is directed by the adhesion and chemokine receptors that neutrophil express. Once present within inflammatory sites, neutrophils are efficient phagocytes, capable of recognising a wide variety of pathogens via different opsonins. Neutrophils express a number of receptors for complement components and immunoglobulins that are able to bind to pathogens, targeting them for phagocytic destruction. Phagocytosed pathogens are subjected to attack from an extensive battery of destructive enzymes capable of breaking down protein, carbohydrate and lipids together with reactive oxygen species, which further compromises pathogen survival [22]. Following clearance of pathogens, neutrophils are thought to be removed from inflammatory sites through the induction of programmed cell death or apoptosis, which marks them for phagocytic removal [23]. The numbers of neutrophils present at inflammatory sites is thus determined by the balance between pro- and anti-apoptotic stimuli present in the local microenvironment [24]. The profile of membrane receptors that neutrophils express can be rapidly altered in response to external stimuli, either by mobilisation of intracellular azurophilic and specific granule compartments or through the rapid and specific proteolytic shedding of the ecto-domain of specific receptors [25–27]. Regulation of expression of receptors allows the generation of distinct receptor repertoires that directly influence neutrophil functional status. Neutrophils constitutively undergo apoptosis when cultured in vitro, a process that can be regulated by different exogenous factors, including growth factors (e.g. GM-CSF), cytokines (e.g. TNF-_) and inflammatory mediators (e.g. prostaglandin E2). Neutrophil apoptosis may also be regulated by ligation of death receptors (e.g. Fas, TNFR and TRAILR) [28] and other interactions with other cell types [29]. Interestingly, interactions of neutrophils with different pathogens may also influence engagement of apoptotic programmes [30, 31], providing a mechanism for ensuring that highly phagocytic neutrophils containing pathogenic organisms are functionally silenced. Membrane receptor alterations observed when neutrophils undergo apoptosis may therefore
59
Ian Dransfield et al.
Figure 1. Schematic representation of cell surface molecular changes associated with neutrophil apoptosis.
differ depending on the initiating apoptotic stimulus (see Fig. 1 for a schematic representation of changes). As discussed previously, one important consequence of the surface molecular alterations associated with the apoptotic programme is that phagocytes are able to specifically recognise and phagocytose apoptotic neutrophils [32], targeting them for clearance from resolving inflammatory lesions.
Apoptosis-induced surface receptor alterations In a series of studies relating to the effects of long-term treatment of neutrophils with cytokines, it was noticed that there were marked alterations to expression of the glycophosphatidylinositol-anchored IgG receptor, FcaRIII (CD16) [33, 34]. Two distinct subpopulations of in vitro cultured neutrophils could be defined in terms of levels of
60
Cell surface molecular changes associated with apoptosis
CD16 expression, correlating with the proportion of apoptotic neutrophils present. This observation implied that there may be specific alterations in membrane receptor expression that accompany the programme of morphological changes associated with apoptosis. Levels of receptor expression at the plasma membrane reflect the balance between production of new proteins from the endoplasmic reticulum, receptor shedding, together with receptor internalisation and recycling. Disruption of the endoplasmic reticulim (ER)-Golgi-plasma membrane transport represents an early event in the apoptotic process [5, 6], with the potential to profoundly influence the levels of expression of plasma membrane receptors. One possibility was that shutdown of the secretory pathway in apoptotic neutrophils led to the reduced expression of many surface receptors. However, this was found not to be the case [35]. Importantly, examination of the other GPI-linked molecules indicated that the nature of the membrane anchor was not responsible for the profound loss (>90% of surface receptors) of FcaRIII, as similar changes were not seen for CD58 for example. Further analysis of other receptors expressed on neutrophils cultured in vitro revealed that there was also a marked down-regulation of a restricted profile of receptors associated with neutrophil apoptosis [36]. Interestingly, these molecules [CD62L, CD44, CD43 and TNFRI (CD120a)] have the potential to be shed via the action of metalloproteases during neutrophil activation. Dual fluorescence labelling with annexin V to mark PS exposure indicated that there was a catastrophic loss of these receptors that correlated with PS exposure, as opposed to a gradual loss of receptors over time. One possibility was that the intense membrane re-organisation (blebbing) that correlates with exposure of PS during early apoptosis, is accompanied by the activation of surface-associated metalloproteases, resulting in specific receptor cleavage. This change, together with a shutdown in transport of newly synthesised receptors to the cell surface may account for the marked down-regulation of these target molecules observed. Our analysis also revealed that many different surface receptors exhibit a smaller reduction in surface expression (approximately 30% of the levels found on non-apoptotic neutrophils) [35]. Given that this downregulation occurs for apparently unrelated molecules, this observation may simply reflect the loss of plasma membrane and reduction in cell volume that occurs as a result of membrane blebbing events accompanying apoptosis. Early studies of the membrane alterations associated with apoptosis suggested that there may be net changes in the cell surface charge, possibly due to altered glycosylation patterns [37]. One possibility is that there may be altered activity of carbohydrate processing enzymes, e.g. sialidases [38], that accompany apoptosis. In addition, it is also possible that post-translational processing of proteins in the Golgi is inhibited prior to shutdown of Golgi-plasma membrane transport, allowing incompletely processed carbohydrate moieties to be present on proteins that are expressed on the plasma membrane. A panel of labelled lectins, each with a relative specificity for particular carbohydrate structures, were used to analyse the glycosylation status of the plasma membrane of neutrophils during apoptosis. The lectins derived from
61
Ian Dransfield et al.
Griffonia simplificolia II (GSL II), Narcissus pseudonarcissus (NPn), and Ulex europaeus I (UEA I) increased their binding to surfaces of apoptotic neutrophils [39]. The exposure of PS and the loss of cellular volume both preceded the increased lectin binding. Interestingly, these lectins recognize sugar structures (N-acetylglucosamine, polymannose, and fucose, respectively) predominantly found as terminal residues of immature glycoproteins during their processing in ER and Golgi. In non-apoptotic neutrophils the majority of these sugars are located intracellulary. In late apoptotic stages they get exposed at the cell surfaces, suggesting that the plasma membranes of apoptotic neutrophils contain incompletely processed proteins. The terminal residues of oligosaccharides of mature glycoproteins are typically formed by sialic acid residues. During neutrophil apoptosis mature glycostructures are lost from cell surfaces as detected by decreased binding of sialic acid recognising lectins derived from Maackia amurensis and Sambucus nigra [35] (Franz, unpublished data). Increased binding of the galactose binding lectin, peanut agglutinin, was not observed, implying that en masse desialylation caused by activated sialidases did not represent a major carbohydrate modification event accompanying apoptosis. More likely, plasma membranes containing sialic acid glycostructures get lost during the apoptotic blebbing process. In a recent study we analysed the plasma membrane composition of late apoptotic neutrophils that are reduced in size but have still maintained their plasma membrane impermeability for propidium iodide (Franz, unpublished data). We found the ER-resident protein calnexin to be exposed in the membranes of late apoptotic cells. Furthermore, the glycolipid GM1, which is lost from the surfaces of ageing neutrophils in the early stages of apoptosis [40], gets re-exposed from internal stores. The ER-derived proteins and lipids appear at the cell surface with the same time course as the immature glycoprotein epitopes, detected by GSL II, NPn, and UEA I. These findings indicate that internal membranes at least partially derived form the ER get translocated to the surface of late apoptotic neutrophils. Thereby, preformed internal target structures get access to the cell surface. This mechanism of membrane exchange may help to explain how apoptotic neutrophils rapidly alter their glycocalyx and receptor availability. An apoptotic cell soon shuts down its power production and must, therefore, deal parsimoniously with its ATP reservoir. From this point of view, the exposure of preformed internal structures that are sequestered inside viable cells is an economical method for the concomitant generation of several phagocyte recognition structures on surfaces of apoptotic neutrophils.
Receptor inactivation One of the key membrane changes associated with neutrophil apoptosis is the functional uncoupling of signalling receptors, acting to isolate the apoptotic cell from
62
Cell surface molecular changes associated with apoptosis
stimuli that normally trigger production of superoxide and degranulation [41]. The apoptosis-associated increase in activity of caspases and calpains is likely to disrupt the recruitment and subsequent assembly of signalling complexes that are required to translate receptor occupancy into a functional response [42]. Furthermore, disruption of cytoskeletal integrity [4, 42, 43] through proteolysis of actin or other actin-binding proteins such as gelsolin, ezrin, fodrin or band 4.1 would be likely to inhibit neutrophil adhesion, migration and degranulation. For apoptotic neutrophils, we reported specific loss of the capacity for `2 integrins to bind to ligand, even though levels of surface integrin expression remained similar on the surface of apoptotic neutrophils [36]. It is well established that `2 integrins exhibit regulated ligand binding function, through a process known as “inside-out” signalling [44]. Another possibility is that loss of integrin ligand binding activity reflects changes in integrin organisation within the membrane (avidity), together with loss of affinity regulation. However, examination of binding of antibody NKI-L16 to apoptotic cells revealed similar levels of expression on apoptotic and non-apoptotic cells (Dransfield and Figdor, unpublished data). Since NKI-L16 binding has been suggested to be linked with avidity regulation of LFA-1, this observation suggests that altered affinity regulation is the principal reason for loss of integrin activity on apoptotic neutrophils. One possibility is that there is dysregulation of key signalling pathways following apoptosis. Intriguingly, an active conformation of `2 integrins could not be forced even in the presence of the divalent cation Mn2+ [36], implying that the membrane lipid and cytoskeletal alterations associated with apoptosis may further restrict integrin activity and thereby ensure a lack of neutrophil response to environmental signals. The effects of apoptosis on plasma membrane organisation, including assembly and organisation of lipid rafts has not been well studied. In neutrophils, spontaneous apoptosis may be a consequence of recruitment of deathinducing signalling complex (DISC) components (FADD, pro-caspase-8 and -10 and c-FLIP) to lipid rafts, since disruption of raft organisation with nystatin delayed apoptosis [45]. However, Sherriff and co-workers [40] demonstrated that binding of the ganglioside GM-1 (thought to be a marker of lipid rafts) was specifically lost from apoptotic cells. This event appeared to be a very early change, preceding or accompanying exposure of PS, and thus might represent an early marker of cell death. Whether these changes influence the function of other receptors is not clear. One surface receptor that has been proposed to play an important role in the discrimination of viable and apoptotic cells is the immunoglobulin superfamily, molecule platelet-cell adhesion molecule-1 (PECAM-1) or CD31 [46]. This 130-kDa glycoprotein is expressed by endothelial cells, platelets, monocytes, neutrophils, naïve CD4+ cells and memory CD8+ cells. It has been reported that homotypic interaction of CD31 on neutrophils and CD31 on phagocytes is capable of mediating intercellular adhesion. However, whereas CD31 provides a signal leading to the active detachment of viable neutrophils, tethering of apoptotic neutrophils via CD31 may lead to subsequent engulfment [13]. For endothelial cells, CD31 was
63
Ian Dransfield et al.
found to be cleaved during apoptosis into a soluble 100-kDa fragment composed of the extracellular domain, which was shed into the culture medium, in addition to a 28-kDa truncated form, comprising a small extracellular region, the transmembrane section and the cytoplasmic domain. In preliminary studies, changes in expression of CD31 associated with apoptosis in neutrophils was found to be somewhat variable, but in some experiments was found to be reduced by approximately 50% (Dransfield, unpublished data) raising the possibility that proteolytic loss of CD31 expression during apoptosis may be a more general phenomenon. The truncated form was shown to differentially recruit `-catenin, a-catenin and SHP-2 when compared with full-length CD31, providing a potential mechanism for differential signalling leading to a failure to undergo detachment [47]. One possibility is that the truncated form of CD31 may assume a conformation similar to that of the phosphorylated form, and thus differentially recruit signalling molecules during apoptosis and thus CD31 ligation on apoptotic cells is unable to generate signals that promote cell detachment. Neutrophils also express CD47, the ligand for the immunoglobulin superfamily member SIRP_ [48]. For viable neutrophils, this interaction has been proposed to give rise to ‘don’t eat me’ signals and when this interaction was blocked by CD47 Fab’ fragments, viable cells were engulfed [49]. In terms of membrane distribution, CD47 was found to be spatially segregated from calreticulin and PS, putative counter-receptors for phagocyte recognition molecules, suggesting that regulatory molecules may act independently of putative recognition receptors to control phagocytic function.
Other changes associated with “late” apoptosis We have characterised a monoclonal antibody (BOB78) that binds to a subset of apoptotic neutrophils (annexin V positive) that exhibit distinct forward/side scatter properties [35]. We have found that the antigen recognised by BOB78 was normally expressed intracellularly in neutrophils and have described that this BOB78-positive population represents “late” apoptotic cells, with a distinctive morphological appearance, yet distinct from propidium iodide positive, necrotic cells. Preliminary data indicate that the BOB78 antigen may be a member of the heat-shock protein family (Ross, unpublished data), possibly implying that these chaperone proteins become “stranded” at the cell surface during the later stages of apoptosis. Heatshock proteins have been reported to be specifically expressed on the surface of neutrophils and other cells following stress or pathogen-induced cell death [50–52]. This finding may have particular relevance to the promotion of antigen presentation, as heat-shock proteins represent a potent stimulus of dendritic cell maturation. For neutrophils, progression from early apoptosis to this late apoptotic phenotype appears to be a relatively slow process. In contrast, many other cell types
64
Cell surface molecular changes associated with apoptosis
rapidly acquire the late apoptotic phenotype following induction of apoptosis. Interestingly, late apoptotic neutrophils have been shown to bind a number of plasma proteins that are importance in homeostatic regulation, e.g. binding of the matricellular protein thrombospondin [35], the pentraxin C-reactive protein [53], serum amyloid P [54] and also the complement component C1q [55]. Binding of these molecules does not appear to represent non-specific protein binding capacity since other proteins (e.g. labelled bovine serum albumin) do not bind to these cells. One implication is that certain antigens may become accessible during this phase of apoptosis and thus potentially alter phagocyte recognition of these cells. Of particular interest with respect to neutrophil apoptosis is the binding of anti-neutrophil cytoplasmic autoantibodies (ANCAs) to apoptotic neutrophils. These antibodies can be shown to have two major patterns of binding, reacting with cytoplasmic or perinuclear antigens. Electron microscopic analysis suggested that translocation of intracellular granules to the plasma membrane occurs late during the apoptotic process, exposing granule proteins such as myeloperoxidase and proteinase 3 [56]. Although the exposure of these antigens was reported to be independent of prior priming and activation of the neutrophils, other studies have suggested that ANCA fail to bind to apoptotic cells unless mobilised to the surface by isolation procedures [57]. As shown for the BOB78-positive cells, ANCA-positive neutrophils exhibit extensive nuclear degradation, although they remain able to exclude propidium iodide. It is possible that other major autoantigens such as nucleosomal DNA and small ribonucleoproteins, SS-A/Ro and SS-B/La become accessible during the later stages of apoptosis, prior to loss of membrane integrity. The opsonisation of cells with complement components also deserves consideration. C1q has been demonstrated to bind to blebs on apoptotic cells [58] and have a role in clearance of apoptotic cells both in vitro (apoptotic thymocytes) and in vivo associated with the development of glomerulonephritis in C1q-deficient animals [59, 60]; together with the well-defined association between C1q deficiency and incidence of systemic lupus erythematosus, the possibility is raised that defective apoptotic cell clearance predisposes affected individuals to development of autoimmune conditions. However, studies in other animals lacking phagocytic receptors, e.g. CD14 [61], have suggested that this association is not absolute. Studies from Kim and co-workers [62] suggested that C1q deposition on apoptotic cells was mediated in part through the binding of IgM antibodies to the cell surface during apoptosis. Binding of IgM could be increased by hydrolysis of membrane phospholipids with phospholipase A2, suggesting that lysophosphatidylcholine becomes exposed during the later stages of apoptotic cell death. Apoptotic cells have also been reported to become opsonised with C3 components [63]. Recognition of complement-opsonised apoptotic cells is then mediated by `2 integrins CD11b/CD18 and CD11c/CD18. However, opsonisation with some complement components may only occur later during the apoptotic pro-
65
Ian Dransfield et al.
cess [64]. Most cells express surface receptors that protect against complement activation, termed complement regulators [65]. CD46 and CD55 act to regulate C3 convertase activity and CD59 controls the assembly of the membrane attack complex. Interestingly, the expression of CD55 and CD59 are down-regulated on apoptotic neutrophils, potentially making these cells vulnerable to complementmediated attack [66]. In addition, deposition of C3 components may target these cells for phagocytic clearance via complement receptors, including CD11b/CD18 and CD35. It is clear that if these proteins that have been implicated in the recognition and subsequent phagocytic clearance of apoptotic cells are present at inflammatory sites, there may be profound consequences in terms of how these cells are subsequently cleared. From the published data relating to the potential for opsonisation of apoptotic cells, it seems likely that their clearance will differ both in terms of phagocyte recognition pathways engaged and also in the efficiency of internalisation. Mechanisms for clearing late apoptotic cells may represent a backup pathway for ensuring that failure to clear early apoptotic cells does not lead to release of intracellular contents [12]. Surprisingly, given the potential importance of apoptotic cell removal in so many diverse processes, there have been few studies that have compared molecular mechanisms and functional consequences of phagocyte clearance of cells at different stages of the apoptotic process.
Apoptosis-enabled receptors? There have been few reports of gain of function of cell surface receptors following induction of apoptosis. Interestingly, Moffatt and colleagues [67] reported that the binding profile of ICAM-3 was altered following apoptosis. Thus, while ICAM-3 on viable cells was able to bind to the counter-receptor LFA-1, on apoptotic cells this capacity was lost. Instead, ICAM-3 was suggested to be able to bind to CD14. Recently, we have described a novel mechanism whereby apoptotic neutrophils become opsonised by immune complexes [68]. This finding arose from the characterisation of a monoclonal antibody that exhibited a unique binding profile for neutrophils. After extensive characterisation, we found that this murine IgG1 antibody rapidly formed immune complexes in the presence of the antigen (the foetal calf serum protein fetuin) and bound to apoptotic neutrophils via an interaction of the Fc portion to FcaRII. Surprisingly, antibody-antigen complexes did not bind, or bound weakly to freshly isolated or cytokine/chemokine-activated neutrophils, despite abundant expression of FcaRII on these cells. We believe that this alteration in ligand binding activity is the first example of a molecule that shows reduced expression on apoptotic cells, yet exhibits enhanced function. It is possible that other, as-yet-unidentified, surface receptors may behave in a similar manner. The molecular mechanism(s) responsible for
66
Cell surface molecular changes associated with apoptosis
this effect remains to be defined and although the significance of opsonisation of apoptotic neutrophils by immune complexes during inflammation is not known, it is likely that subsequent phagocytic clearance will be affected [69].
Apoptosis and antigen presentation The surface molecular alterations associated with apoptosis may profoundly influence generation of effective immune responses to endogenous or tumour cell-associated antigens. Many different peptide epitopes derived from antigens expressed by tumours can be recognised by cytotoxic T lymphocytes in the context of MHC class I molecules [70]. However, endogenous expression of most tumour antigens may normally induce tolerance, with antigens containing cryptic epitopes capable of eliciting effective immune responses. It has been established that ex vivo immunisation of antigen-presenting cells (including dendritic cells and Langerhans cells) with tumour-derived material could provide effective anti-tumour therapy [71–73], particularly following acquisition of antigens from apoptotic cells [51]. Generation of antigen-presenting cells with high levels of expression of co-stimulatory molecules can also be influenced by the mode of cell death [50, 52, 74]. Thus, the mode of cell death likely represents a critical factor that determines the antigen-presentation capacity and thus the generation of effective immune responses.
Summary In conclusion, since the process of programmed cell death was first described in 1972 [75], there has been tremendous progress in defining the underlying regulatory mechanisms and the consequences in terms of gene expression patterns, functional activity and membrane receptor alterations. However, the issues relating to heterogeneity of the apoptotic cell phenotype discussed here have profound implications for future studies of phagocyte recognition, uptake and, crucially, phagocyte responses following phagocytosis of apoptotic cells. Delayed apoptotic cell clearance within tissues could potentially drive the progression to late apoptosis and secondary necrosis. Efficient clearance of apoptotic cells by macrophages may inhibit induction of specific immune responses, a finding of considerable importance in terms of potential tumour immunotherapy. The presence of late apoptotic or necrotic cells would be predicted to promote maturation of antigen-presenting cells to express co-stimulatory molecules that would maximally activate lymphocyte responses. In addition, masking of the PS on the apoptotic cell membrane would be predicted to interfere with suppression of pro-inflammatory signals and also with the generation of anti-inflammatory signals. Indeed, production of IL-1 and TNF-_ was augmented and TGF-` release was suppressed in macrophages challenged with
67
Ian Dransfield et al.
annexin V-coated irradiated tumour cells in vitro when compared with untreated irradiated cells [76], potentially overcoming tolerogenic responses to apoptotic cell uptake. Definition of the precise role of membrane receptor alterations associated with apoptosis upon phagocyte recognition of apoptotic cells and their influence upon subsequent phagocyte responses remains an important goal. Understanding the contribution that these changes make to development of inflammatory and autoimmune diseases represents a considerable challenge for future studies.
Acknowledgements This work was supported by the Medical Research Council (Clinician Scientist award to S.P.H.), the Arthritis Research Campaign (grant R0622) and the Wellcome Trust. We would especially like to thank Prof. Christopher Haslett, Prof. John Savill and Dr. Simon Brown for constructive discussion.
References 1 2
3
4 5
6
7
8 9
68
Barclay AN (2001) Biochemical analysis of the lymphocyte cell surface – From alloantisera to the role of membrane proteins. Immunol Rev 184: 69–81 Wyllie AH, Morris RG, Smith AL, Dunlop D (1984) Chromatin cleavage in apoptosis: Association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol 142: 67–77 Wyllie AH, Morris RG (1982) Hormone-induced cell death. Purification ad properties of thymocytes undergoing apoptosis after glucocorticoid treatment. Am J Pathol 109: 78–87 Brown, SB, Bailey K, Savill J (1997) Actin is cleaved during constitutive apoptosis. Biochem J 323: 233–237 Lane JD, Lucocq J, Pryde J, Barr FA, Woodman PG, Allan VJ, Lowe M (2002) Caspasemediated cleavage of the stacking protein GRASP65 is required for Golgi fragmentation during apoptosis. J Cell Biol 156: 495–509 Walker A, Ward C, Sheldrake TA, Dransfield I, Rossi AG, Pryde JG, Haslett C (2004) Golgi fragmentation during Fas-mediated apoptosis is associated with the rapid loss of GM130. Biochem Biophys Res Commun 316: 6–11 Kobayashi SD, Braughton KR, Whitney AR, Voyich JM, Schwan TG, Musser JM, DeLeo FR (2003) Bacterial pathogens modulate an apoptosis differentiation program in human neutrophils. Proc Natl Acad Sci USA 100: 10948–10953 Savill J, Fadok V, Henson P, Haslett C (1993) Phagocyte recognition of cells undergoing apoptosis. Immunol Today 14: 131–136 Meagher LC, Savill JS, Baker A, Fuller RW, Haslett C (1992) Phagocytosis of apoptotic neutrophils does not induce macrophage release of thromboxane B2. J Leukoc Biol 52: 269–273
Cell surface molecular changes associated with apoptosis
10 11
12 13
14 15
16 17
18
19
20 21
22 23
24
25
Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I (1997) Immunosuppressive effects of apoptotic cells. Nature 390: 350–351 Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM (1998) Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 101: 890–898 Savill J, Dransfield I, Gregory C, Haslett C (2002) A blast from the past: Clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2: 965–975 Brown S, Heinisch I, Ross E, Shaw K, Buckley CD, Savill J (2002) Apoptosis disables CD31-mediated cell detachment from phagocytes promoting binding and engulfment. Nature 418: 200–203 Lorenz HM, Herrmann M, Winkler T, Gaipl U, Kalden JR (2000) Role of apoptosis in autoimmunity. Apoptosis 5: 443–449 Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM (1992) Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 148: 2207–2216 Hanayama R, Tanaka M, Miwa K, Shinohara A, Iwamatsu A, Nagata S (2002) Identification of a factor that links apoptotic cells to phagocytes. Nature 417: 182–187 Manfredi AA, Rovere P, Galati G, Heltai S, Bozzolo E, Soldini L, Davoust J, Balestrieri G, Tincani A, Sabbadini AG (1998) Apoptotic cell clearance in systemic lupus erythematosus. I. Opsonization by antiphospholipid antibodies. Arthritis Rheum 41: 205–214 Fadok VA, Bratton DL, Rose DM, Pearson A, Ezekewitz RA, Henson PM (2000) A receptor for phosphatidylserine-specific clearance of apoptotic cells. Nature 405: 85–90 Bose J, Gruber AD, Helming L, Schiebe S, Wegener I, Hafner M , Beales M, Kontgen F, Lengeling A (2004) The phosphatidylserine receptor has essential functions during embryogenesis but not in apoptotic cell removal. J Biol 3: 15 Haslett C, Savill JS, Meagher L (1989) The neutrophil. Curr Opin Immunol 2: 10–18 Liu Y, Shaw SK, Ma S, Yang L, Luscinskas FW, Parkos CA (2004) Regulation of leukocyte transmigration: cell surface interactions and signaling events. J Immunol 172: 7–13 Borregaard N, Cowland JB (1997) Granules of the human neutrophilic polymorphonuclear leukocyte. Blood 89: 3503–3521 Savill JS, Wyllie AH, Henson JE, Walport MJ, Henson PM, Haslett C (1989) Macrophage phagocytosis of aging neutrophils in inflammation. Programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest 83: 865–875 Haslett C, Savill JS, Whyte MK, Stern M, Dransfield I, Meagher LC (1994) Granulocyte apoptosis and the control of inflammation. Philos Trans R Soc Lond B Biol Sci 345: 327–333 Borregaard N, Kjeldsen L, Sengelov H, Diamond MS, Springer TA, Anderson HC, Kishimoto TK, Bainton DF (1994) Changes in subcellular localization and surface
69
Ian Dransfield et al.
26
27
28
29 30 31
32 33
34
35
36 37 38
39
40
70
expression of L-selectin, alkaline phosphatase, and Mac-1 in human neutrophils during stimulation with inflammatory mediators. J Leukoc Biol 56: 80–87 Miller LJ, Bainton DF, Borregaard N, Springer TA (1987) Stimulated mobilization of monocyte Mac-1 and p150,95 adhesion proteins from an intracellular vesicular compartment to the cell surface. J Clin Invest 80: 535–544 Campanero MR, Pulido R, Alonso JL, Pivel JP, Pimentel-Muinos FX, Fresno M, Sanchez-Madrid F (1991) Down-regulation by tumor necrosis factor-alpha of neutrophil cell surface expression of the sialophorin CD43 and the hyaluronate receptor CD44 through a proteolytic mechanism. Eur J Immunol 21: 3045–3048 Renshaw SA, Parmar JS, Singleton V, Rowe SJ, Dockrell DH, Dower SK, Bingle CD, Chilvers ER, Whyte MK (2003) Acceleration of human neutrophil apoptosis by TRAIL. J Immunol 170: 1027–1033 Ginis I, Faller DV (1997) Protection from apoptosis in human neutrophils is determined by the surface of adhesion. Am J Physiol 272: C295-C309 Moulding DA, Walter C, Hart CA, Edwards SW (1999) Effects of staphylococcal enterotoxins on human neutrophil functions and apoptosis. Infect Immun 67: 2312–2318 Perskvist N, Long M, Stendahl O, Zheng L (2002) Mycobacterium tuberculosis promotes apoptosis in human neutrophils by activating caspase-3 and altering expression of Bax/Bcl-xL via an oxygen-dependent pathway. J Immunol 168: 6358–6365 Savill J, Fadok V (2000) Corpse clearance defines the meaning of cell death. Nature 407: 784–788 Dransfield I, Buckle AM, Savill JS, McDowall A, Haslett C, Hogg N (1994) Neutrophil apoptosis is associated with a reduction in CD16 (Fc gamma RIII) expression. J Immunol 153: 1254–1263 Moulding DA, Hart CA, Edwards SW (1999) Regulation of neutrophil FcgammaRIIIb (CD16) surface expression following delayed apoptosis in response to GM-CSF and sodium butyrate. J Leukoc Biol 65: 875–882 Hart SP, J. A. Ross JA, Ross K, Haslett C, Dransfield I (2000) Molecular characterization of the surface of apoptotic neutrophils: Implications for functional downregulation and recognition by phagocytes. Cell DeathDiffer 7: 493–503 Dransfield I, Stocks SC, Haslett C (1995) Regulation of cell adhesion molecule expression and function associated with neutrophil apoptosis. Blood 85: 3264–3273 Morris RG, Hargreaves AD, Duvall E, Wyllie AH (1984) Hormone-induced cell death. 2. Surface changes in thymocytes undergoing apoptosis. Am J Pathol 115: 426–436 Cross AS, Wright DG (1991) Mobilization of sialidase from intracellular stores to the surface of human neutrophils and its role in stimulated adhesion responses of these cells. J Clin Invest 88: 2067–2076 Franz S, Frey B, Sheriff A, Gaipl US, Beer A, Voll RE, Kalden JR, Herrmann M (2006) Lectins detect changes of the glycosylation status of plasma membrane constituents during late apoptosis. Cytometry A 69: 230–239 Sheriff A, Gaipl US, Franz S, Heyder P, Voll RE, Kalden JR, Herrmann M (2004) Loss
Cell surface molecular changes associated with apoptosis
41 42
43
44 45
46 47
48
49
50 51
52
53
54
of GM1 surface expression precedes annexin V-phycoerythrin binding of neutrophils undergoing spontaneous apoptosis during in vitro aging. Cytometry A 62: 75–80 Whyte MK, Meagher LC, MacDermot J, Haslett C (1993) Impairment of function in aging neutrophils is associated with apoptosis. J Immunol 150: 5124–5134 Knepper-Nicolai B, Savill J, Brown SB (1998) Constitutive apoptosis in human neutrophils requires synergy between calpains and the proteasome downstream of caspases. J Biol Chem 273: 30530–30536 Kothakota S, Azuma T, Reinhard C, Klippel A, Tang J, Chu K, McGarry TJ, Kirschner MW, Koths K, Kwiatkowski DJ, Williams LT (1997) Caspase-3-generated fragment of gelsolin: Effector of morphological change in apoptosis. Science 278: 294–298 Brown E, Hogg N (1996) Where the outside meets the inside: Integrins as activators and targets of signal transduction cascades. Immunol Lett 54: 189–193 Scheel-Toellner D, Wang K, Singh R, Majeed S, Raza K, Curnow SJ, Salmon M, Lord JM (2002) The death-inducing signalling complex is recruited to lipid rafts in Fasinduced apoptosis. Biochem Biophys Res Commun 297: 876–879 Ilan N, Madri JA (2003) PECAM-1: Old friend, new partners. Curr Opin Cell Biol 15: 515–524 Ilan N, Mohsenin A, Cheung L, Madri JA (2001) PECAM-1 shedding during apoptosis generates a membrane-anchored truncated molecule with unique signaling characteristics. FASEB J 15: 362–372 Vernon-Wilson EF, Kee WJ, Willis AC, Barclay, Simmons DL, Brown MH (2000) CD47 is a ligand for rat macrophage membrane signal regulatory protein SIRP (OX41) and human SIRPalpha 1. Eur J Immunol 30: 2130–2137 Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE, Bratton DL, Oldenborg PA, Michalak M, Henson PM (2005) Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 123: 321–334 Gallucci S, Lolkema M, Matzinger P (1999) Natural adjuvants: Endogenous activators of dendritic cells. Nat Med 5: 1249–1255 Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N (2000) Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 191: 423–434 Zheng L, He M, Long M, Blomgran R, Stendahl O (2004) Pathogen-induced apoptotic neutrophils express heat shock proteins and elicit activation of human macrophages. J Immunol 173: 6319–6326 Hart SP, Alexander KM, MacCall SM, Dransfield I (2005) C-reactive protein does not opsonize early apoptotic human neutrophils, but binds only membrane-permeable late apoptotic cells and has no effect on their phagocytosis by macrophages. J Inflamm (Lond) 2: 5 Familian A, Zwart B, Huisman HG, Rensink I, Roem D, Hordijk PL, Aarden LA, Hack
71
Ian Dransfield et al.
55
56
57
58
59
60
61
62
63 64
65 66
72
CE (2001) Chromatin-independent binding of serum amyloid P component to apoptotic cells. J Immunol 167: 647–654 Gaipl US, Kuenkele S, Voll RE, Beyer TD, Kolowos W, Heyder P, Kalden JR, Herrmann M (2001) Complement binding is an early feature of necrotic and a rather late event during apoptotic cell death. Cell Death Differ 8: 327–334 Gilligan HM, Bredy B, Brady HR, Hebert MJ, Slayter HS, Xu Y, Rauch J, Shia MA, Koh JS, Levine JS (1996) Antineutrophil cytoplasmic autoantibodies interact with primary granule constituents on the surface of apoptotic neutrophils in the absence of neutrophil priming. J Exp Med 184: 2231–2241 Yang JJ, Tuttle RH, Hogan SH, Taylor JG, Phillips BD, Falk RJ, Jennette JC (2000) Target antigens for anti-neutrophil cytoplasmic autoantibodies (ANCA) are on the surface of primed and apoptotic but not unstimulated neutrophils. Clin Exp Immunol 121: 165–172 Korb LC, Ahearn JM (1997) C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: Complement deficiency and systemic lupus erythematosus revisited. J Immunol 158: 4525–4528 Botto M, Dell’Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, Loos M, Pandolfi PP, Walport MJ (1998) Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 19: 56–59 Taylor PR, Carugati A, Fadok VA, Cook HT, Andrews M, Carroll MC, Savill JS, Henson PM, Botto M, Walport MJ (2000) A hierarchical role for classical pathway complement proteins in the clearance of apoptotic cells in vivo. J Exp Med 192: 359–366 Devitt A, Parker KG, Ogden CA, Oldreive C, Clay MF, Melville LA, Bellamy CO, Lacy-Hulbert A, Gangloff SC, Goyert SM, Gregory CD (2004) Persistence of apoptotic cells without autoimmune disease or inflammation in CD14–/– mice. J Cell Biol 167: 1161–1170 Kim SJ, Gershov D, Ma X, Brot N, Elkon KB (2002) I-PLA(2) activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation. J Exp Med 196: 655–665 Mevorach D, Mascarenhas JO, Gershov D, Elkon KB (1998) Complement-dependent clearance of apoptotic cells by human macrophages. J Exp Med 188: 2313–2320 Hart SP, Smith JR, Dransfield I (2004) Phagocytosis of opsonized apoptotic cells: roles for ‘old-fashioned’ receptors for antibody and complement. Clin Exp Immunol 135: 181–185 Morgan BP (1995) Complement regulatory molecules: Application to therapy and transplantation. Immunol Today 16: 257–259 Jones J, Morgan BP (1995) Apoptosis is associated with reduced expression of complement regulatory molecules, adhesion molecules and other receptors on polymorphonuclear leucocytes: Functional relevance and role in inflammation. Immunology 86: 651–660
Cell surface molecular changes associated with apoptosis
67 68
69
70 71
72
73 74
75 76
Moffatt OD, Devitt A, Bell ED, Simmons DL, Gregory CD (1999) Macrophage recognition of ICAM-3 on apoptotic leukocytes. J Immunol 162: 6800–6810 Hart SP, Jackson C, Kremmel LM, McNeill MS, Jersmann H, Alexander KM, Ross JA, Dransfield I (2003) Specific binding of an antigen-antibody complex to apoptotic human neutrophils. Am J Pathol 162: 1011–1018 Hart SP, Alexander KM, Dransfield I (2004) Immune complexes bind preferentially to FcgammaRIIA (CD32) on apoptotic neutrophils, leading to augmented phagocytosis by macrophages and release of proinflammatory cytokines. J Immunol 172: 1882–1887 Novellino L, Castelli C, Parmiani G (2005) A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54: 187–207 Pospisilova D, Borovickova J, Polouckova A, Spisek R, Sediva A, Hrusak O, Stary J, Bartunkova J (2002) Generation of functional dendritic cells for potential use in the treatment of acute lymphoblastic leukemia. Cancer Immunol Immunother 51: 72–78 Goldszmid RS, Idoyaga J, Bravo AI, Steinman R, Mordoh J, Wainstok R (2003) Dendritic cells charged with apoptotic tumor cells induce long-lived protective CD4+ and CD8+ T cell immunity against B16 melanoma. J Immunol 171: 5940–5947 Andersen MH, Becker JC, Straten P (2005) Regulators of apoptosis: suitable targets for immune therapy of cancer. Nat Rev Drug Discov 4: 399–409 Scheffer SR, Nave H, Korangy F, Schlote K, Pabst R, Jaffee EM, Manns MP, Greten TF (2003) Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer 103: 205–211 Kerr JF, Wyllie AH, Currie AR (1972) Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239–257 Bondanza A, Zimmermann VS, Rovere-Querini P, Turnay J, Dumitriu IE, Stach CM, Voll RE, Gaipl US, Bertling W, Poschl E, Kalden JR, Manfredi AA, Herrmann M (2004) Inhibition of phosphatidylserine recognition heightens the immunogenicity of irradiated lymphoma cells in vivo. J Exp Med 200: 1157–1165
73
Fate of macrophages once having ingested apoptotic cells: Lymphatic clearance or in situ apoptosis? Geoffrey J. Bellingan and Geoffrey J. Laurent Centre for Respiratory Research, University College London, Rayne Institute, London WC1E 6JJ, UK
Introduction Neutrophil and macrophage kinetics at the inflamed site differ markedly [1, 2]. Unlike neutrophils, many organs and tissues have a population of resident macrophages, hence these cells have a different baseline at the outset of inflammation. Resident macrophages are a key population in the initiation of local inflammation [3]. Neutrophils influx rapidly early in the acute inflammatory event, while resident tissue macrophages may actually decline in numbers due to a process known as the macrophage disappearance reaction (MDR) [4]. Like neutrophils, inflammatory monocytes migrate in from the blood stream, although this lags somewhat behind the insurgence of neutrophils. These monocytes mature locally into inflammatory macrophages, although their activation state may alter over the course of the inflammatory process [5, 6]. Neutrophil numbers peak earlier than macrophages. Their decline can be due to necrosis, apoptosis and subsequent phagocytosis, or progressing to secondary necrosis if phagocytosis of apoptotic cells fails [7]. Neutrophils may be able to efflux away from the inflamed site, for example back into the blood stream, or, with pulmonary inflammation for example, they can migrate into the airway lumen [8–10]. It appears, however, that their main fate is to undergo apoptosis locally as shown in a number of models and in vivo settings [7, 11]. In normally resolving inflammation, macrophages phagocytose the apoptotic neutrophils and their numbers then decline allowing the tissue to return to normal structure and function [12–14]. This chapter examines macrophage clearance in the resolution of inflammation. Macrophages are powerful scavengers and are the major cell involved in phagocytosis of apoptotic neutrophils. The fate of macrophages once they have ingested apoptotic neutrophils is open to much debate. There is good evidence that the macrophage, unlike both the neutrophil and the un-activated monocyte, is a long-lived cell [15, 16]. Despite working in a highly toxic environment, macrophages need to be robust cells and retain viability and functionality until they have facilitated clearance of the inciting pathogen(s). Macrophages are resistant to many apoptotic The Resolution of Inflammation, edited by Adriano G. Rossi and Deborah A. Sawatzky © 2008 Birkhäuser Verlag Basel/Switzerland
75
Geoffrey J. Bellingan and Geoffrey J. Laurent
stimuli including Fas and tumour necrosis factor (TNF)-_ death receptor ligation, ionising radiation, and multiple anti-neoplastic or cytotoxic agents [17–19]. This suggests that local apoptosis may not be the immediate fate for these cells and this is supported by several investigators who have shown that macrophages from inflamed sites can be found in the draining lymph nodes [20–22]. Experimental evidence, using the inflamed peritoneum as a model, demonstrated remarkably little local apoptosis or subsequent phagocytosis and confirmed emigration into the draining lymphatics was the major route for macrophage clearance [21, 23]. The situation is not so clear cut, however, as it is well established that macrophages, despite their inherent resistance to apoptosis, can undergo apoptotic cell death and a number of mechanisms are recognized to drive this process [24, 25]. Indeed macrophage apoptosis has been shown to occur in the presence of a range of infections such as that with Shigella [26]. More recently, we have learned that the perceived resistance of macrophages to apoptosis is not fixed and that these cells can, in certain circumstances, gain susceptibility to apoptosis in a potentially beneficial way for the hosts innate immune response [27]. Hence, both local apoptosis and emigration appear to be valid modes for macrophage clearance with the resolution of inflammation.
Macrophage apoptosis Macrophage resistance to apoptosis Macrophages produce a number of powerful effector molecules to kill pathogens; these include reactive oxygen and nitrogen species and histotoxic enzymes. To survive in such a local toxic environment macrophages have been shown to up-regulate enzymes including catalase and manganese and copper superoxide dismutase and buthionine sulfoximine which help in buffering intracellular redox systems providing a powerful mechanism through which cell survival is increased [28–30]. Along with protection through enhanced protection against free radical damage, there is also modulation of apoptosis through changes in a variety of intracellular pathways including activation of JNK but mainly by expression of the pro- and anti-apoptotic molecules of the Bcl-2 family [31, 32]. Raised Bcl-2 expression is associated with resistance to apoptosis, while Bax is associated with enhanced apoptosis and these have been found to have clinical relevance for example in tuberculous disease where caseating granumoma have increased macrophage apoptosis with a relative predominance of Bax over Bcl-2 [30, 32]. The phosphatidylinositol 3-kinase (PI3K) pathway appears to be important for macrophage survival as mice with abnormal regulation of this pathway have altered regulation of macrophage apoptosis, reduced viral clearance and increased inflammation [33, 34]. Akt-1 is a PI3K-regulated serine/threonine kinase that regulates survival through myeloid cell leukaemia
76
Fate of macrophages once having ingested apoptotic cells: Lymphatic clearance or in situ apoptosis?
sequence (Mcl)-1, a Bcl-2 family member, rather than through caspases, or NF-gB. Mcl-1 is up-regulated during macrophage differentiation and protects cells from apoptosis from a range of toxins including irradiation, drugs or through the withdrawal of growth factors. Importantly Mcl-1 has a relatively short half-life [27].
Macrophage apoptosis and infections Despite this resistance to apoptosis, it is clear that a number of pathogens can lead to macrophage apoptotic cell death. This was first shown for Shigella; however, the number of pathogens shown to lead to macrophage apoptosis is now large and includes Salmonella enterica serovar typhi, Bacillus anthracis, Yersinia, Mycobacterium tuberculosis, Streptococcus pneumoniae, Trichomonas vaginalis and Pneumocystis pneumonia infection [35–43]. The timing with which such infections lead to apoptosis is not clear. In certain circumstances macrophage apoptosis appears to be a response to an overwhelming infection with a virulent pathogen, suggesting the macrophage defences are simply overwhelmed. In these situations, macrophage apoptosis is usually part of the pathogenic process and the host does badly, e.g. if caspase-9 is inhibited, alveolar macrophage apoptosis is prevented in a rodent pneumocystis pneumonia model and survival is dramatically enhanced [43]. Similarly, the pathogenic Shigella strain induces macrophage cell death and has a high mortality, while the non-pathogenic strain is not associated with cell death or pathogenicity [35]. In other circumstances, apoptosis may follow as a consequence of bacterial phagocytosis. For example, macrophages infected with M. tuberculosis at low copy number are stimulated to undergo apoptosis in a TNF-dependent fashion and this appears to be a host-protective process as it leads to reduced mycobacterial viability [40]. Of interest, however, when infected with a high copy number, the pathogen induces macrophage apoptosis, now in a TNF-independent fashion that does not reduce viability of the mycobacterium and allows for its release and dissemination. Indeed, it appears that there may be a relationship between the intracellular live bacterial load and the degree of induction of macrophage apoptosis for other bacteria including the Pneumococcus [41]. As with mycobacterial-induced macrophage apoptosis, pneumococcal induced macrophage apoptosis is linked with bacterial killing. Marriott et al. [44] have shown that the phagocytosis of pneumococci leads to nitric oxide production in microvesicles adjacent to the lysosomes. This nitric oxide contributes to intracellular killing of the pneumococci but is also associated, later with increased apoptotic death of the macrophage itself. Interestingly, the pro-apoptotic effect of exogenous nitric oxide alone is far lower, suggesting other factors including bacterial load are crucial to this process. In the absence of nitric oxide, pneumococcal infection leads the macrophages to undergo necrosis. These experiments were performed in vitro; 20 h after infection up to a quarter of the
77
Geoffrey J. Bellingan and Geoffrey J. Laurent
macrophages had evidence of apoptotic features. It is not clear if all the macrophages phagocytose pneumococci and, if so, are some relatively protected from cell death or is apoptosis related to a population more involved in phagocytosis? Also of interest is the in vivo fate of those macrophages undergoing apoptosis; are they then phagocytosed by other macrophages and how are these then cleared? This raises the possibility that different macrophage populations exist with different propensities for bacterial clearance/killing vs for cell clearance and inflammatory resolution. This concept is not new: for example, alveolar and peritoneal macrophages have been shown to have different phagocytic ability for apoptotic cells. However, this may relate to the site more than the cell type as monocytes recruited to the lung also phagocytose apoptotic cells poorly [45, 46]. Macrophages can also exist in different activation states, depending on the local activation signals [5, 47], and the possibility of activation state altering apoptotic and emigration potential is, as yet, unexplored.
Macrophage apoptosis and non-infective challenges Non-infective causes of macrophage apoptosis are also well described, e.g. hydrogen peroxide induces cell death that can be ameliorated with nitric oxide [29]. Nitric oxide is also well known as a trigger for macrophage apoptosis [48]. Inflammation, as noted above, leads to inducible nitric oxide synthase (iNOS) synthesis and hence high levels of nitric oxide locally. Macrophages elaborate anti-inflammatory prostaglandins such as the cyclopentone 15dPGJ2, which could act to inhibit the synthesis of nitric oxide. Interestingly, however, although treatment with 15dPGJ2 inhibits the expression of iNOS, it results in an increase in the percentage of apoptotic cells, probably through preferential formation of peroxynitrite, in these conditions [49]. Serum deprivation can lead to apoptosis in most cells; this is also apparent for macrophages though at a much lower level. This has recently been shown to be mediated by interferon secretion [50]. Other mechanisms shown to induce macrophage apoptosis include engagement of Fas ligand [51]. There is now good evidence that macrophages can undergo apoptosis locally at the inflamed site even in sterile inflammation. Gilroy et al. [52] used an acute pleurisy model in which they demonstrated an early neutrophil predominance, which declined through apoptosis to be replaced by monocytes-derived inflammatory macrophages. In this model, inflammatory resolution was associated with programmed cell death in the macrophages and in both cases apoptosis was mediated by cyclooxygenase 2-derived 15deoxyDelta12-14PGJ2, expressed during the resolution phase. In atheroma models, cholesterol and oxidized LDL have also been shown to drive apoptosis. In addition, in atheromatous plaques, overexpression of TIMP-2 leads to a nearly 50% reduction in plaque and this was associated with a reduction in macrophage apoptosis [53].
78
Fate of macrophages once having ingested apoptotic cells: Lymphatic clearance or in situ apoptosis?
Differential regulation of macrophage resistance to apoptosis As discussed above, pathogens can promote macrophage apoptosis. They may also inhibit apoptosis, e.g. Tunbridge et al. [54] showed that Neisseria meningitides, which is known to inhibit apoptosis in other cells, prevents macrophage apoptosis via genes encoding nitric oxide detoxification and a porin. This may contribute to innate immunity. In a similar vein, Gross et al. [55] demonstrated that Brucella infection led to overexpression of the A1 gene, a member of the Bcl-2 family and prevented apoptosis. This ability of an intracellular pathogen to modulate apoptosis in the host‘s cells suggests this may be an advantageous strategy for Brucella to avoid its elimination. Interestingly, Mcl-1 offers a unique control point for macrophage sensitivity to apoptosis. A number of Mcl-1 splice variants exist and Marriott et al. [27] have shown that Mcl-1 is up-regulated in the early phase of inflammation, while macrophage functionality is well maintained, with the cells being viable and able to phagocytose bacteria. Later Mcl-1 is down-regulated, corresponding to emergence of a smaller splice variant and evidence of mitochondrial membrane permeabilisation and induction of apoptosis. This change has been shown to be of functional importance in a rodent model where overexpression of Mcl-1 resulted in delayed mitochondrial membrane permeability and reduced bacterial clearance both in vitro and in vivo. This suggests that the switch of Mcl-1 splice variants with associated enhanced susceptibility to apoptosis may, in certain circumstances, promote resolution. Such a change in sensitivity to apoptosis is not without precedent as similar findings have been observed for Bcl-2 and a shortened cleavage fragment Bcl-2/ Delta34 that lacks the ability to heterodimerise with Bax and hence the cleavage fragment lacks the anti-apoptotic effect of Bcl-2 [56]. Mogga et al. [57] also suggest that macrophage apoptosis is related to Bcl-2 expression and that overexpression of Bcl-2 can reduce macrophage apoptosis and may be associated with intracellular survival of tubercle bacilli.
Macrophage emigration Emigration is the other major mechanisms for macrophage exit. Our early work on this was stimulated by the concept that macrophages were indeed long-lived cells and thus the idea that local apoptosis was the route for clearance was questioned. We used in vivo fluorescence labelling to track macrophages during the resolution of sterile inflammatory challenges. These were either short (starch: 2–4 days), medium (thioglycolate: 5–10 days) or longer term models (heat-killed Corynebacterium parvum: 2 weeks or more). Interestingly, we found that with resolving peritonitis, fluorescence-labelled macrophages increasingly accumulated in the draining lymph nodes as resolution proceeded, suggesting emigration was a
79
Geoffrey J. Bellingan and Geoffrey J. Laurent
feature of resolution. These experiments could not account for the possibility that macrophages were dying locally and being phagocytosed, and the labelled cells we were finding in the lymph nodes had in fact gained the label by ingesting apoptotic labelled macrophages. To examine this, red fluorescently labelled inflammatory macrophages from H-2k/d mice were transferred into the peritoneal cavity of H-2k mice at the start of the resolution of thioglycolate peritonitis. The number of transferred macrophages within the peritoneum declined rapidly over the next 4 days. Dual-colour flow cytometry permitted discrimination among donor cells, recipient cells, and donor cells that had been phagocytosed by recipient macrophages and this showed that there was little evidence of any significant local phagocytosis of transferred macrophages [21]. Importantly labelled, non-phagocytosed macrophages were detected with increasing frequency in the draining lymph nodes, but not in a variety of other tissues. These data suggest that inflammatory macrophages normally emigrate rapidly from the peritoneal cavity during the resolution of inflammation. In conjunction with this, we examined the clearance of resident peritoneal macrophages and found that they too were capable of emigrating to the local lymph nodes but, unlike the rapid emigration of inflammatory macrophages, the resident cells could persist in the non-inflamed peritoneum for weeks. This major difference in kinetics suggested that the process of emigration was regulated. To investigate this further we compared the clearance of live and formalin-fixed adoptively transferred macrophages and found that clearance of the formalin-fixed cells was slower than that of the live cells and that the formalin-fixed cells were only found in the draining lymph nodes after they had been phagocytosed by live macrophages. This confirmed that emigration was an active process. Our work was in line with that of others, e.g. Rosen and Gordon [58], also using adoptive transfer of fluorescent macrophages, showing that they were able to migrate to specialized lymphoid organs. Reviewing the lymphatic drainage system of the peritoneum we see that the greater omental lymphoid organ and the subdiaphragmatic surface of the diaphragm are the main sites for the origin of the draining lymphatics. This drainage occurs through stomata called milky spots. The peritoneum is lined with flattened mesothelial cells; however, at the milky spots these cells gain a cuboid morphology with microvilli. They surround a small opening that connects the peritoneal cavity with an underlying lymph vessel. Along with a lymph duct there is a prominent vascular supply. In addition, leukocytes are commonly found adherent to the overlying mesothelial cells. These structures appear to contribute to the influx of leukocytes into the peritoneum during the onset of inflammation. The small 5–8-mm opening can also allow macrophage emigration, although this would require these cells to adhere and squeeze through. When we looked at ex vivo tissue from resolving thioglycolate peritonitis we could clearly see fluorescently labelled macrophages adhering to milky spots and, looking at lymphatics in the diaphragm, could then see labelled macrophages in draining lymphatic vessels tracking away to the draining nodes Figure 1.
80
Fate of macrophages once having ingested apoptotic cells: Lymphatic clearance or in situ apoptosis?
Figure 1. Fluorescence-labelled macrophages in the draining parathymic lymph nodes.
To address the question of how this macrophage emigration is regulated, we focused on the adhesion interaction between macrophages and the mesothelial cells. Using ex vivo tissue we were able to demonstrate that macrophages did indeed adhere to the mesothelial lining of the peritoneum and that this adhesion was calcium and magnesium dependent, such that more than 70% of adhesion could be abolished in the absence of these divalent cations. Despite the powerful importance of the `2 integrins to macrophage function, inhibiting these molecules alone made no difference to macrophage-mesothelial cells interactions. Using RGD peptides, however, we could demonstrate a significant inhibition of adhesion and this was borne out by using blocking antibodies to very late antigen-4 (VLA-4) and VLA-5. When the `1 integrins were blocked, the addition of blocking `2 integrin antibodies exposed a further inhibitory effect on macrophage-mesothelial cell adhesion. The relevance of this ex vivo work was confirmed when blocking `1 integrins or RGD peptides was shown to significantly delay macrophage clearance from the inflamed peritoneum and reduce macrophage accumulation at the parathymic lymph nodes Figure 2 [23]. In a similar set of investigations, Cao et al. [59] confirmed that inflammatory macrophages do not die locally but migrate across the peritoneum into the lym-
81
Geoffrey J. Bellingan and Geoffrey J. Laurent
Figure 2. Protocol for adoptive transfer of fluorescence-labelled macrophages, ensuring donor macrophages are at the same stage in the inflammatory process as the recipient mouse and are labelled and coated in blocking antibody.
phatics to the regional lymph nodes. They again showed that activation increased the rate of emigration; however, their work demonstrated that upon further activation it was the `2 integrin, Mac-1, that was a critical regulator of emigration. This is in keeping with our finding of an additional `2 integrin activity when `1 integrins were blocked. Moreover, unlike the findings published by Hotchkiss et al. [60] where the introduction of apoptotic cells prior to the induction of sepsis was harmful, it has recently been shown that the rate of inflammatory macrophage clearance from the inflamed site with resolution can be enhanced by phagocytosis of apoptotic cells [61]. This enhanced emigration again occurred though `1 integrin-mediated mechanisms [62]. It must be emphasized that local apoptosis and emigration are not necessarily mutually exclusive. We do not know what happens to those macrophages that undergo apoptosis after ingesting bacteria; are they then engulfed by other macrophage populations that then emigrate themselves? This leads us to recognize a situation in which macrophages could undergo apoptosis early in the inflammatory process through a toxicity-driven process that
82
Fate of macrophages once having ingested apoptotic cells: Lymphatic clearance or in situ apoptosis?
typically is associated with increased morbidity, while, in the presence of other intracellular pathogens such as M. tuberculosis, the macrophage could undergo altruistic apoptosis to facilitate pathogen clearance [63]. Generally, however, the macrophage aims to resist being driven into apoptosis and instead to facilitate pathogen clearance and then inflammatory resolution. Having phagocytosed apoptotic neutrophils they can then leave by emigration.
Macrophage disappearance reaction Another situation in which macrophages have been shown to enter the lymphatics is via the MDR. This is a response of peritoneal macrophages (and probably other resident macrophage populations) to a variety of stimuli in which many of the resident cells disappear and are not able to be lavaged or recovered from the peritoneum [4]. Using fluorescent labelling, Melnicoff et al. [1] showed that some of these cells are recoverable after a period of days, suggesting either firm adherence to the surrounding parietal peritoneum or a process of recirculation. Many cells do not reappear. We have examined this process in more detail and see that peritoneal macrophages adhere to the greater omental lymphoid organ and subdiaphragmatic surface of the peritoneum, sites representing the highest concentrations of milky spots. Moreover, the instillation and ingestion of apoptotic cells is a powerful stimulus for the very rapid “disappearance” of both apoptotic cells and resident macrophages that are found co-localised in great numbers adherent to the greater omental lymphoid organ in particular. Instillation of live cells is not associated with ingestion or with an MDR. A good number of these adherent macrophages are found then to migrate into the draining lymphatics. This work supports the concept that ingestion of apoptotic cells is a key signal for macrophage adherence and emigration into local lymphatics and efflux to the draining lymph nodes.
Site-specific clearance Most work examining macrophage emigration has been done in the peritoneum. Other serosal-lined cavities such as the pleura and pericardium also have milky spots and resident macrophages and probably have similar mechanisms for clearance. Both peritoneal and pleural macrophages have also been shown to undergo local apoptosis but this has been in response to a pathogenic stimulus rather than to ingestion of apoptotic cells. Macrophages are known to emigrate to the draining lymphatics from solid organ inflammation; this has certainly been shown for the kidney and the lung [20, 22]. Again, the impact of apoptotic cell ingestion on this process is not clear. Indeed even Kupffer cells, long believed to be tissue-fixed macrophages, have been shown to migrate using high resolution video microscopy,
83
Geoffrey J. Bellingan and Geoffrey J. Laurent
although this is more restricted migration along sinusoid walls with or against blood flow rather than into the lymphatics [64]. There is also increasing evidence that macrophages actually contribute to lymphangiogenesis in inflammation and this may further increase cell clearance and reduce the consequences of inflammation [65, 66].
Summary of emigration Hence, in summary, the emigration process is regulated by adhesion molecules and, more importantly, by the ingestion of apoptotic cells. This occurs both for inflammatory macrophages with the resolution of inflammation and for resident macrophages as part of the MDR. Such an emigration process has much to commend it teleologically. It makes sense not to have macrophage clearance before resolution of the neutrophillic phase of inflammation as these cells are required to clear the burden of polymorphonuclear leukocytes. Moreover, it is also sensible for the process of engulfment of apoptotic cells to drive the clearance of the engulfing macrophage. This phagocytosis signals that the cell has performed its key final local role of cell clearance and it is now time for these macrophages to be removed, themselves, from the inflamed site. It would appear logical for the macrophage to travel to the draining lymph nodes where it could then interact with the lymphocytes there; impacting on the immune response. Macrophages are not the only cells that migrate to the draining lymph nodes. Lymphocytes can be cleared by both apoptosis and emigration and mature lymphocytes participate in a similarly complex pattern of trafficking, passing from sites of inflammation into the lymph ducts to the regional lymph nodes. This T cell emigration is under specific chemokine control as CCR7 is required for T cell exit [67]. Interestingly, this same chemokine is induced on dendritic cells after interaction with apoptotic cells [68]. Dendritic cells also undertake such a journey as, early on in the inflammatory response, they rapidly emigrate to the draining lymph nodes where they present antigen and promote clonal lymphocyte proliferation and an immune response to the inciting antigen. Apoptotic cell ingestion can even modulate maturation of dendritic cells [69, 70]. Importantly, it has been demonstrated that macrophages actually have an immune down-modulating effect on lymphocyte proliferation, suggesting that their arrival in the lymph nodes could further act to silence the immune/inflammatory response [71]. Despite this logical set of processes, however, we have seen that the picture is not so clear-cut as macrophage apoptosis is also well described. Much work also needs to be done to understand these processes. If emigration is the main mechanism for clearance after ingestion of apoptotic cells, what signals lead to altered adhesion? Are these processes similar for both solid organs and for serosal cavity inflammation? Is regulation of this process only at the level of adhesion or are there chemokine/cytokine signals at play that either wane allowing clearance
84
Fate of macrophages once having ingested apoptotic cells: Lymphatic clearance or in situ apoptosis?
or act as lymphatic-specific chemotactic signals? What is the importance of the hyaluronan receptor LYVE-1 and lymphatic trafficking, in addition to its role in lymphangiogenesis [72]?
Phagocytosis and clearance Many factors can alter macrophage–neutrophil interaction and phagocytosis. Clearance of apoptotic cells depends on effective phagocytosis and this can be defective, for example in the NOD mouse, with consequent potential effects on autoimmune disorders [73]. Other factors are now increasingly recognized as important in this phagocytic interaction, such as the role of the lipoxins [74]. The study by Amano et al. [75] suggests that altering neutrophil clearance has an effect on resolution of inflammation, in this case on lung injury. They demonstrated that levels of monocyte chemoattractant protein (MCP-1) were increased before macrophage ingestion of neutrophils, and the administration of blocking-MCP-1 antibodies reduced macrophage clearance of neutrophils and potentiated lung tissue injury. Conversely, the administration of MCP-1 itself increased neutrophil ingestion by macrophages and reduced lung tissue injury. One wonders if the noted effect of cigarette smoke on reducing macrophage phagocytosis of apoptotic cells contributes to the persisting inflammation seen in the lungs of many smokers [76]. Data from Asada et al. [77] suggest that peroxisome proliferator-activated receptor gamma (PPARa), expressed by alveolar macrophages, plays an anti-inflammatory role through inhibiting cytokine production, increasing CD36 expression and enhancing phagocytosis of apoptotic neutrophils, although the relevance directly to inflammation in vivo and macrophage clearance of apoptotic cells has not been established. Also the local chemical environment can directly alter the ability of macrophages to ingest apoptotic cells, for example the presence of steroids augments this while interferongamma prevents this augmentation. [78, 79]. Finally, the ingestion of apoptotic cells may down-regulate any future ability of macrophages to ingest other apoptotic cells [80]. This provides the macrophage with a complex life cycle where, as a monocyte, it is rescued from early apoptotic death by the onset of inflammation. These cells, which may be derived from a distinct subpopulation of monocytes to those that spawn resident macrophages, migrate into the inflamed site and adopt a pro-inflammatory phenotype where, along with the resident macrophages, they are vital in the phagocytosis and killing of pathogens and the orchestration of the pro-inflammatory response through their cytokine and chemokine elaboration. Induction of iNOS and nitric oxide are critically important in this, certainly for live bacterial challenges. Indeed, such pathogenic insults may overwhelm the macrophages defences, despite their inherent resistance to apoptosis and longevity, and lead to death locally, either by necrosis or by apoptosis. With the waning of the inflammatory response, macro-
85
Geoffrey J. Bellingan and Geoffrey J. Laurent
phages adopt different roles; they can, depending on regulation of their own sensitivity, undergo apoptosis locally. They may also undergo alternative activation and contribute to wound healing and, as we have seen, clear apoptotic cells which then drives their emigration to the draining lymph nodes. Here they may present antigen and thus further regulate the immune response and may act to suppress this.
References 1 2 3
4 5 6
7
8 9
10
11
12 13
14
86
Melnicoff MJ, Horan PK, Morahan PS (1989) Kinetics of changes in peritoneal cell populations following acute inflammation. Cell Immunol 118: 178–191 Bellingan G (1999) Inflammatory cell activation in sepsis. Br Med Bull 55: 12–29 Cailhier JF, Partolina M, Vuthoori S, Wu S, Ko K, Watson S, Savill J, Hughes J, Lang RA (2005) Conditional macrophage ablation demonstrates that resident macrophages initiate acute peritoneal inflammation. J Immunol 174: 2336–2342 Barth MW, Hendrzak JA, Melnicoff MJ, Morahan PS (1995) Review of the macrophage disappearance reaction. J Leukoc Biol 57: 361–367 Riches DW (1995) Signalling heterogeneity as a contributing factor in macrophage functional diversity. Semin Cell Biol 6: 377–384 Porcheray F, Viaud S, Rimaniol AC, Leone C, Samah B, Dereuddre-Bosquet N, Dormont D, Gras G (2005) Macrophage activation switching: An asset for the resolution of inflammation. Clin Exp Immunol 142: 481–489 Brazil TJ, Dagleish MP, McGorum BC, Dixon PM, Haslett C, Chilvers ER (2005) Kinetics of pulmonary neutrophil recruitment and clearance in a natural and spontaneously resolving model of airway inflammation. Clin Exp Allergy 35: 854–865 Rydell-Tormanen K, Uller L, Erjefalt JS (2006) Direct evidence of secondary necrosis of neutrophils during intense lung inflammation. Eur Respir J 28: 268–274 Hughes J, Johnson RJ, Mooney A, Hugo C, Gordon K, Savill J (1997) Neutrophil fate in experimental glomerular capillary injury in the rat. Emigration exceeds in situ clearance by apoptosis. Am J Pathol 150: 223–234 Erjefalt J (2005) Transepithelial migration, necrosis and apoptosis as silent and proinflammatory fates of airway granulocytes. Curr Drug Targets Inflamm Allergy 4: 425–431 Rysanek D, Sladek Z (2006) The image of exocytosis during neutrophils and macrophages phagocytic activities in inflammation of mammary gland triggered by experimental Staphylococcus aureus infection. Anat Histol Embryol 35: 171–177 Haslett C (1999) Granulocyte apoptosis and its role in the resolution and control of lung inflammation. Am J Respir Crit Care Med 160: S5–11 Savill JS, Wyllie AH, Henson JE, Walport MJ, Henson PM, Haslett C (1989) Macrophage phagocytosis of aging PMNs in inflammation. Programmed cell death in the PMN leads to its recognition by macrophages. J Clin Invest 83: 865–875 Savill J, Hogg N, Ren Y, Haslett C (1992) Thrombospondin cooperates with CD36 and
Fate of macrophages once having ingested apoptotic cells: Lymphatic clearance or in situ apoptosis?
15
16
17
18
19
20
21
22 23
24 25
26 27
the vitronectin receptor in macrophage recognition of PMNs undergoing apoptosis. J Clin Invest 90: 1513–1522 Mangan DF, Wahl SM (1991) Differential regulation of human monocyte programmed cell death (apoptosis) by chemotactic factors and pro-inflammatory cytokines. J Immunol 147: 3408–3412 Perera LP, Waldmann TA (1998) Activation of human monocytes induces differential resistance to apoptosis with rapid down regulation of caspase-8/FLICE. Proc Natl Acad Sci USA 95: 14308–14313 Perlman H, Pagliari LJ, Georganas C, Mano T, Walsh K, Pope RM (1999) FLICEinhibitory protein expression during macrophage differentiation confers resistance to Fas-mediated apoptosis. J Exp Med 190: 1679–1688 Kiener PA, Davis PM, Starling GC, Mehlin C, Klebanoff SJ, Ledbetter JA, Liles WC (1997) Differential induction of apoptosis by Fas–Fas ligand interactions in human monocytes and macrophages. J Exp Med 185: 1511–1516 Munn DH, Beall AC, Song D, Wrenn RW, Throckmorton DC (1995) Activationinduced apoptosis in human macrophages: developmental regulation of a novel cell death pathway by macrophage colony-stimulating factor and interferon. J Exp Med 181: 127–136 Lan HY, Nikolic-Paterson DJ, Atkins RC (1993) Trafficking of inflammatory macrophages from the kidney to draining lymph nodes during experimental glomerulonephritis. Clin Exp Immunol 92: 336–341 Bellingan GJ, Caldwell H, Howie SE Dransfield I, Haslett C (1996) In vivo fate of the inflammatory macrophage during the resolution of inflammation: Inflammatory macrophages do not die locally, but emigrate to the draining lymph nodes. J Immunol 157: 2577–2585 Harmsen AG, Muggenburg BA, Snipes MB, Bice DE (1985) The role of macrophages in particle translocation from lungs to lymph nodes. Science 230: 1277–1280 Bellingan GJ, Xu P, Cooksley H, Cauldwell H, Shock A, Bottoms S, Haslett C, Mutsaers SE, Laurent GJ (2002) Adhesion molecule-dependent mechanisms regulate the rate of macrophage clearance during the resolution of peritoneal inflammation. J Exp Med 196: 1515–1521 Grage-Griebenow E, Durrbaum-Landmann I, Pryjma J, Loppnow H, Flad HD, Ernst M (1998) Apoptosis in monocytes. Eur Cytokine Netw 9: 699–700 Malyshev IY, Shnyra A (2003) Controlled modulation of inflammatory, stress and apoptotic responses in macrophages. Curr Drug Targets Immune Endocr Metab Disord 3: 1–22 Hilbi H, Zychlinsky A, Sansonetti PJ (1997) Macrophage apoptosis in microbial infections. Parasitology 115 (Suppl): S79–87 Marriott HM, Bingle CD, Read RC, Braley KE, Kroemer G, Hellewell PG, Craig RW, Whyte MK, Dockrell DH (2005) Dynamic changes in Mcl-1 expression regulate macrophage viability or commitment to apoptosis during bacterial clearance. J Clin Invest 115: 359–368
87
Geoffrey J. Bellingan and Geoffrey J. Laurent
28
29
30 31 32
33
34
35 36 37
38
39
40
41
88
Komuro I, Yasuda T, Iwamoto A, Akagawa KS (2005) Catalase plays a critical role in the CSF-independent survival of human macrophages via regulation of the expression of BCL-2 family. J Biol Chem 280: 41137–41145 Yoshioka Y, Kitao T, Kishino T, Yamamuro A, Maeda S (2006) Nitric oxide protects macrophages from hydrogen peroxide-induced apoptosis by inducing the formation of catalase. J Immunol 176: 4675–4681 Ferret PJ, Soum E, Negre O, Fradelizi D (2002) Auto-protective redox buffering systems in stimulated macrophages. BMC Immunol 3: 3 Himes SR, Sester DP, Ravasi T, Cronau SL, Sasmono T, Hume DA (2006) The JNK are important for development and survival of macrophages. J Immunol 176: 2219–2228 Fayyazi A, Eichmeyer B, Soruri A, Schweyer S, Herms J, Schwarz P, Radzun HJ (2000) Apoptosis of macrophages and T cells in tuberculosis associated caseous necrosis. J Pathol 191: 417–425 Tyner JW, Uchida O, Kajiwara N, Kim EY, Patel AC, O’Sullivan MP, Walter MJ, Schwendener RA, Cook DN, Danoff TM, Holtzman MJ (2005) CCL5-CCR5 interaction provides antiapoptotic signals for macrophage survival during viral infection. Nat Med 11: 1180–1187 Francois S, El Benna J, Dang PM, Pedruzzi E, Gougerot-Pocidalo MA, Elbim C (2005) Inhibition of neutrophil apoptosis by TLR agonists in whole blood: Involvement of the phosphoinositide 3-kinase/Akt and NF-kappaB signaling pathways, leading to increased levels of Mcl-1, A1, and phosphorylated Bad. J Immunol 174: 3633–3642 Zychlinsky A, Prevost MC, Sansonetti PJ (1992) Shigella flexneri induces apoptosis in infected macrophages. Nature 358: 167–169 Hueffer K, Galan JE (2004) Salmonella-induced macrophage death: Multiple mechanisms, different outcomes. Cell Microbiol 6: 1019–1025 Hsu LC, Park JM, Zhang K, Luo JL, Maeda S, Kaufman RJ, Eckmann L, Guiney DG, Karin M (2004) The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature 428: 341–345 Zauberman A, Cohen S, Mamroud E, Flashner Y, Tidhar A, Ber R, Elhanany E, Shafferman A, Velan B (2006) Interaction of Yersinia pestis with macrophages: Limitations in YopJ-dependent apoptosis. Infect Immun 74: 3239–3250 Rios-Barrera VA, Campos-Pena V, Aguilar-Leon D, Lascurain LR, Meraz-Rios MA, Moreno J, Figueroa-Granados V, Hernandez-Pando R (2006) Macrophage and T lymphocyte apoptosis during experimental pulmonary tuberculosis: Their relationship to mycobacterial virulence. Eur J Immunol 36: 345–353 Lee J, Remold HG, Ieong MH, Kornfeld H (2006) Macrophage apoptosis in response to high intracellular burden of Mycobacterium tuberculosis is mediated by a novel caspaseindependent pathway. J Immunol 176: 4267–4274 Ali F, Lee ME, Iannelli F, Pozzi G, Mitchell TJ, Read RC, Dockrell DH (2003) Streptococcus pneumoniae-associated human macrophage apoptosis after bacterial internalization via complement and Fcgamma receptors correlates with intracellular bacterial load. J Infect Dis 188: 1119–1131
Fate of macrophages once having ingested apoptotic cells: Lymphatic clearance or in situ apoptosis?
42
43
44
45
46
47
48 49
50 51
52
53
54
55
Chang JH, Kim SK, Choi IH, Lee SK, Morio T, Chang EJ (2006) Apoptosis of macrophages induced by Trichomonas vaginalis through the phosphorylation of p38 mitogenactivated protein kinase that locates at downstream of mitochondria-dependent caspase activation. Int J Biochem Cell Biol 38: 638–647 Lasbury ME, Durant PJ, Ray CA, Tschang D, Schwendener R, Lee CH (2006) Suppression of alveolar macrophage apoptosis prolongs survival of rats and mice with pneumocystis pneumonia. J Immunol 176: 6443–6453 Marriott H, Ali F, Read, RC, Mitchell, TJ, Whyte MKB, Dockrell DH (2004) Nitric oxide levels regulate macrophage commitment to apoptosis or necrosis during pneumococcal infection. FASEB J 18: 1126–1128 Hu B, Sonstein J, Christensen PJ, Punturieri A, Curtis JL (2000) Deficient in vitro and in vivo phagocytosis of apoptotic T cells by resident murine alveolar macrophages. J Immunol 165: 2124–2133 Jennings JH, Linderman DJ, Hu B, Sonstein J, Curtis JL (2005) Monocytes recruited to the lungs of mice during immune inflammation ingest apoptotic cells poorly. Am J Respir Cell Mol Biol 32: 108–117 Lake FR, Noble PW, Henson PM, Riches DW (1994) Functional switching of macrophage responses to tumor necrosis factor-alpha (TNF alpha) by interferons. Implications for the pleiotropic activities of TNF alpha. J Clin Invest 93: 1661–1669 Albina JE, Cui S, Mateo RB, Reichner JS (1993) Nitric oxide-mediated apoptosis in murine peritoneal macrophages. J Immunol 150: 5080–5085 Hortelano S, Castrillo A, Alvarez AM, Bosca L (2000) Contribution of cyclopentenone prostaglandins to the resolution of inflammation through the potentiation of apoptosis in activated macrophages. J Immunol 165: 6525–6531 Wei J, Sun Z, Chen Q, Gu J (2006) Serum deprivation induced apoptosis in macrophage is mediated by autocrine secretion of type I IFNs. Apoptosis 11: 545–554 Hohlbaum AM, Gregory MS, Ju ST, Marshak-Rothstein A (2001) Fas ligand engagement of resident peritoneal macrophages in vivo induces apoptosis and the production of neutrophil chemotactic factors. J Immunol 167: 6217–6224 Gilroy DW, Colville-Nash PR, McMaster S, Sawatzky DA, Willoughby DA, Lawrence T (2003) Inducible cyclooxygenase-derived 15-deoxy(Delta)12-14PGJ2 brings about acute inflammatory resolution in rat pleurisy by inducing neutrophil and macrophage apoptosis. FASEB J 17: 2269–2271 Johnson JL, Baker AH, Oka K, Chan L, Newby AC, Jackson CL, George SJ (2006) Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase-2: Involvement of macrophage migration and apoptosis. Circulation 113: 2435–2444 Tunbridge AJ, Stevanin TM, Lee M, Marriott HM, Moir JW, Read RC, Dockrell DH (2006) Inhibition of macrophage apoptosis by Neisseria meningitidis requires nitric oxide detoxification mechanisms. Infect Immun 74: 729–733 Gross A, Terraza A, Ouahrani-Bettache S, Liautard JP, Dornand J (2000) In vitro Bru-
89
Geoffrey J. Bellingan and Geoffrey J. Laurent
56
57
58
59 60
61
62
63
64 65
66
67
68
90
cella suis infection prevents the programmed cell death of human monocytic cells. Infect Immun 68: 342–351 Lin H, Zhang XM, Chen C, Chen BD (2000) Apoptosis of Mo7e leukemia cells is associated with the cleavage of Bcl-2 into a shortened fragment that is not functional for heterodimerization with Bcl-2 and Bax. Exp Cell Res 261: 180–186 Mogga SJ, Mustafa T, Sviland L, Nilsen R (2002) Increased Bcl-2 and reduced Bax expression in infected macrophages in slowly progressive primary murine Mycobacterium tuberculosis infection. Scand J Immunol 56: 383–391 Rosen H, Gordon S (1990) Adoptive transfer of fluorescence-labeled cells shows that resident peritoneal macrophages are able to migrate into specialized lymphoid organs and inflammatory sites in the mouse. Eur J Immunol 20: 1251–1258 Cao C, Lawrence DA, Strickland DK, Zhang L (2005) A specific role of integrin Mac-1 in accelerated macrophage efflux to the lymphatics. Blood 106: 3234–3241 Hotchkiss RS, Chang KC, Grayson MH, Tinsley KW, Dunne BS, Davis CG, Osborne DF, Karl IE (2003) Adoptive transfer of apoptotic splenocytes worsens survival, whereas adoptive transfer of necrotic splenocytes improves survival in sepsis. Proc Natl Acad Sci USA 100: 6724–6729 Huynh ML, Fadok VA, Henson PM (2002) Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation. J Clin Invest 109: 41–50 Bellingan G, Bottoms S, Xu P, Shock T, Laurent G (2004) Apoptotic cells promote inflammatory macrophage clearance through a `1 integrin dependent mechanism. Am J Respir Crit Care Med May 25: A502 Molloy A, Laochumroonvorapong P, Kaplan G (2004) Apoptosis, but not necrosis, of infected monocytes is coupled with killing of intracellular bacillus Calmette-Guerin. J Exp Med 180: 1499–1509 MacPhee PJ, Schmidt EE Groom AC (1992) Evidence for Kuppfer cell migration along liver sinusoids from high resolution in vivo microscopy. Am J Physiol 263: G17–23 Maruyama K, Ii M, Cursiefen C, Jackson DG, Keino H, Tomita M, Van Rooijen N, Takenaka H, D’Amore PA, Stein-Streilein J, Losordo DW, Streilein JW (2005) Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages. J Clin Invest 115: 2363–2372 Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, Jeltsch M, Petrova TV, Pytowski B, Stacker SA et al (2005) Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest 115: 247–257 Debes GF, Arnold CN, Young AJ, Krautwald S, Lipp M, Hay JB, Butcher EC (2004) Chemokine receptor CCR7 required for T lymphocyte exit from peripheral tissues Nat Immunol 6: 889–894 Hirao M, Onai N, Hiroishi K, Watkins SC, Matsushima K, Robbins PD, Lotze MT, Tahara H (2000) CC chemokine receptor-7 on dendritic cells is induced after interaction with apoptotic tumor cells: Critical role in migration from the tumor site to draining lymph nodes. Cancer Res 60: 2209–2217
Fate of macrophages once having ingested apoptotic cells: Lymphatic clearance or in situ apoptosis?
69
70 71
72 73
74
75
76
77
78
79
80
Stuart LM, Lucas M, Simpson C, Lamb J, Savill J, Lacy-Hulbert A (2002) Inhibitory effects of apoptotic cell ingestion upon endotoxin-driven myeloid dendritic cell maturation. J Immunol 168: 1627–1635 Chung EY, Kim SJ, Ma XJ (2006) Regulation of cytokine production during phagocytosis of apoptotic cells. Cell Res 16: 154–161 van Vugt E, Arkema JM, Verdaasdonk MA, Beelen RH, Kamperdijk EW (1991) Morphological and functional characteristics of rat steady state peritoneal dendritic cells. Immunobiology 184: 14–24 Jackson DG (2004) Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis. APMIS 112: 526–538 O’Brien BA, Geng X, Orteu CH, Huang Y, Ghoreishi M, Zhang Y, Bush JA, Li G, Finegood DT, Dutz JP (2006) A deficiency in the in vivo clearance of apoptotic cells is a feature of the NOD mouse. J Autoimmun 26: 104–115 Reville K, Crean JK, Vivers S, Dransfield I, Godson C (2006) Lipoxin A4 redistributes myosin IIA and Cdc42 in macrophages: implications for phagocytosis of apoptotic leukocytes J Immunol 176: 1878–1888 Amano H, Morimoto K, Senba M, Wang H, Ishida Y, Kumatori A, Yoshimine H, Oishi K, Mukaida N, Nagatake T (2004) Essential contribution of monocyte chemoattractant protein-1/C-C chemokine ligand-2 to resolution and repair processes in acute bacterial pneumonia. J Immunol 172: 398–409 Kirkham PA, Spooner G, Rahman I, Rossi AG (2004) Macrophage phagocytosis of apoptotic neutrophils is compromised by matrix proteins modified by cigarette smoke and lipid peroxidation products. Biochem Biophys Res Commun 318: 32–37 Asada K, Sasaki S, Suda T, Chida K, Nakamura H (2004) Anti-inflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages. Am J Respir Crit Care Med 169: 195–200 Liu Y, Cousin JM, Hughes J, Van Damme J, Seckl JR, Haslett C, Dransfield I, Savill J, Rossi AG (1999) Glucocorticoids promote nonphlogistic phagocytosis of apoptotic leukocytes. J Immunol 162: 3639–3646 Heasman SJ, Giles KM, Rossi AG, Allen JE, Haslett C, Dransfield I (2004) Interferon gamma suppresses glucocorticoid augmentation of macrophage clearance of apoptotic cells. Eur J Immunol 34: 1752–1761 Erwig LP, Gordon S, Walsh GM, Rees AJ (1999) Previous uptake of apoptotic PMNs or ligation of integrin receptors downmodulates the ability of macrophages to ingest apoptotic PMNs. Blood 93: 1406–1412
91
Novel lipid mediators in resolution and their aspirin triggered epimers: Lipoxins, resolvins, and protectins Charles N. Serhan Center for Experimental Therapeutics and Reperfusion Injury, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital and Department of Oral Medicine, Infection, and Immunity, Harvard School of Dental Medicine and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
Introduction In The Doctor’s Dilemma (1906) by the popular writer George Bernard Shaw, the character Sir Bloomfield Bonnington stated: Drugs can only repress symptoms: they cannot eradicate disease. The true remedy for all diseases is Nature’s remedy. Nature and Science are at one, Sir Patrick, believe me; though you were taught differently. Nature has provided, in the white corpuscles as you call them – in the phagocytes as we call them – a natural means of devouring and destroying all disease germs. There is at bottom only one genuinely scientific treatment for all diseases, and that is to stimulate the phagocytes. Stimulate the phagocytes. In view of our current appreciation of resolution of inflammation, reviewed in this chapter, these lines from The Doctor’s Dilemma take on new meaning, namely, resolution as an active biochemical and cellular process in controlled molecular terms by specialised mediators that function in resolution and can give rise to new approaches to therapeutics. Efforts taken in the author’s laboratory focus on gaining a molecular understanding of the natural means by which the body controls phagocytes, both positive and negative physiological signals. In this context, the eicosanoids generated from arachidonic acid are mediators of special interest, given their prominent and well-appreciated role(s) as pro-inflammatory mediators [1]. Our interest in endogenous control mechanisms in inflammation led us to recognise the lipoxins (LXs) as the first local mediators possessing both anti-inflammatory and pro-resolving actions (recently reviewed in [2]). The connection and role of omega-3 polyunsaturated fatty acids (t-3 PUFA) was unknown as precursors to novel mediators operative in resolution. These first pathways in resolution are now described and overviewed here. The essential roles of dietary t-3 PUFA were uncovered in the late 1920s [3] and their importance observed in many studies to date [4–7]. Inflammation has emerged The Resolution of Inflammation, edited by Adriano G. Rossi and Deborah A. Sawatzky © 2008 Birkhäuser Verlag Basel/Switzerland
93
Charles N. Serhan
Figure 1A. Lipid-derived mediators in programmed resolution of acute inflammation. Precursors of lipid mediators. Arachidonic acid is the precursor to eicosanoids that have distinct roles as proinflammatory mediators. The prostaglandins (PGs) and leukotrienes (LTs) each play specific actions pivotal to the progression of inflammation. Arachidonic acidderived epoxyeicosatetraenoic acids (EETs) produced via P450 [93, 94] and t-3 polyunsaturated fatty acids (PUFA) P450 epoxides may also play roles [68, 95]. Cell-cell interactions, exemplified by platelets-leukocytes within blood vessels and/or polymorphonuclear leukocytes (PMN)-mucosal interactions, enhance generation of lipoxins that serve as endogenous anti-inflammatory mediators self-limiting the course of inflammation [26]. The essential t-3 fatty acids eicosapentaenoic acid (EPA, C20:5) and docosahexaenoic acid (DHA, C22:6) are converted to two novel families of lipid mediators, resolvins (Rv) and protectins, that play pivotal roles in promoting resolution. Resolvin E series are generated from EPA, e.g. RvE1, and resolvins of the D series, e.g. RvD1, are generated from DHA as well as the protectins such as neuroprotectin D1 (see text for details).
today as a central component contributing to many prevalent diseases in Western civilisation that were previously not known to involve inflammation, including Alzheimer’s disease, cardiovascular disease [8] and cancer [9]. These now add to the list of diseases associated with uncontrolled inflammation such as arthritis and periodontal disease [10, 11]. In an effort to determine a link between t-3 fatty acids and endogenous anti-inflammation, the author and colleagues identified previously unknown pathways for enzymatic oxygenated products that were biosynthesised from the two main t-3 PUFA, eicosapentaenoic acid (EPA) and docosahexaenoic acid (C22:6, DHA). The isolated compounds proved to possess potent actions
94
Novel lipid mediators in resolution and their aspirin triggered epimers: Lipoxins, resolvins, and protectins
Figure 1B. Aspirin triggering of lipid mediators. Aspirin impacts the formation of lipoxins and resolvin by acetylating cyclooxygenase 2 (COX-2), for example in human vascular endothelial cells that stereoselectively can generate in the case of RvE1 biosynthesis to generate 18R-HPEPE that is picked up via transcellular cell-cell interactions by leukocytes and converted in a lipoxygenase-like mechanism to RvE1. The complete stereochemistry of RvE1 and one of its receptors were established ([46] and see Fig. 2). Of interest, biosynthesis of RvE1 can also be initiated by P450-like enzymes in microbes [18]. Aspirin also influences the biosynthesis of D-series resolvins. Aspirin catalytically switches COX-2 to a 17R-lipoxygenase-like mechanism that generates 17R-containing series of resolvin D and protectins, for example, neuroprotectin D1/protectin D1 (see text).
within resolving inflammatory exudates. Hence, they were coined resolvins (Rv) or resolution phase interaction products, and protectins. In this chapter, an overview of these new compounds and pathways that carry potent biological actions is given as well as the impact of aspirin in these biosynthetic routes.
Specialised lipid mediators in the resolution of inflammation Given that many, if not most, of the mediators generated from arachidonic acid are pro-inflammatory [1, 12], it was unexpected to find that specific products, i.e. LXs, produced from arachidonic acid during cell-cell interactions via transcellular biosynthesis (Fig. 1) carry potent anti-inflammatory and pro-resolving actions [2]. The resolvins of the E series and those derived from DHA, resolvins of the D series,
95
Charles N. Serhan
as well as bioactive members from DHA that carry conjugated triene structures (docosatrienes) termed protectins, are also both anti-inflammatory [13, 14] and neuroprotective mediators [15, 16]. When generated from neural tissues, these DHA products are denoted neuroprotectins (NPD1) [16] and, in other tissues, protectins [17]. It is important to point out that other compounds identified earlier from t-3 fatty acids are prostaglandin (PG)- and leukotriene (LT)-like structures (i.e., PGE3 or LT5 series), but were less potent and/or devoid of bioactivity in inflammation. This sharply contrasts the resolvins and protectins that each evoke potent actions in vivo [13–18]. The LXs, resolvins, and protectins are three structurally distinct families of chemical mediators that are separated in their biosynthesis in space and time in experimental inflammation and resolution. Specific members of each family carry potent agonist properties in endogenous anti-inflammation and pro-resolving circuits in vivo in animal models (see Tabs 1 and 2 and below). Whether they counter and can stop the progression to chronic diseases in humans is of interest, as deficiencies in these resolving pathways might underlie disease pathology not previously recognised.
The resolution program: An active biochemical progression at the tissue level The signs of inflammation (oedema, redness, heat) were known to early civilisations. Egyptian hieroglyphics, Greek and Chinese ancient medical texts taught of the flame of inflammation, mistakenly, as a disease unto itself [19]. In 1794, Scottish surgeon John Hunter wrote that “Inflammation in itself is not to be considered as a disease, but as a salutary operation consequent to some